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ABSTRACT OF DISSERTATION
A LIFE SPAN APPROACH TO THE RELATIONSHIP BETWEEN CHOLESTEROL, LATE
ONSET ALZHEIMER’S DISEASE, AND COGNITIVE FUNCTIONING
AMONG OLDER ADULTS
There is evidence that cholesterol presents an important risk factor for Alzheimer’s disease (AD),
but the direction of this relationship is modified by age. High cholesterol during midlife and low
cholesterol during late life are both associated with an increased risk for AD. This dissertation
research engaged a life span approach to study the relationship between cholesterol, AD and
cognitive functioning among older adults. The purpose of this research was to determine if
trajectories of cholesterol from midlife through late life differ according to AD status and if these
trajectories are associated with cognitive functioning during old age.
This research employed a secondary analysis of cognitive, phenotypic and genetic data collected
from subjects of the Framingham Heart Study (FHS) Original and Offspring Cohorts. Aim One
involved creating three summary scores of the FHS neuropsychological battery. ROC analysis
was used to determine which score best differentiated between cognitively normal, impaired and
dementia subjects. Aim Two used generalized additive mixed models to examine trajectories of
total, HDL and total/HDL cholesterol ratio according to AD status in the Original Cohort. Aim
Three used mixed-effects models to examine the relationship between subject-specific trajectories
of total cholesterol and cognition during old age.
Aim One determined that a summary score that provided equal weight to each assessment in the
FHS neuropsychological battery best differentiates between subjects classified as cognitively
normal, cognitively impaired and dementia. The findings from Aim Two indicated that there are
subtle differences in the longitudinal trajectories of total, HDL and total/HDL ratio according to
AD status. The findings from Aim Three provide limited evidence for a relationship between
subject-specific trajectories of total cholesterol and cognitive functioning later in life. Older
adults in the highest quartile for cognitive functioning had lower total cholesterol at
approximately 55 years of age, but there were no differences in the mean trajectories of total
cholesterol according to cognitive functioning later in life.
The findings from this research suggest that older adults with high cognitive functioning have
lower total cholesterol during midlife, but life span cholesterol trajectories do not appear to be
associated with AD status or cognitive function.
KEYWORDS: Life span, Cholesterol, Alzheimer’s Disease, Cognition, Older Adults
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Chapter One: Introduction and Background
On November 25, 1901, a 51-year-old woman named Auguste D was admitted to a
German hospital with symptoms of impaired comprehension, memory, language and
psychosocial skills, along with unpredictable behavior, paranoia and hallucinations (Maurer,
Volk, & Gerbaldo, 1997). An autopsy following her death in 1906 revealed that her brain was
filled with abnormal proteins that had aggregated into plaques and tangles. Auguste D’s
physician from 1901 until her death was Dr. Alois Alzheimer, a psychiatrist and neuropathologist
who documented the progression of her disease and, postmortem, observed the plaques and
tangles in her brain.
Over a century has passed since Alois Alzheimer first described the clinical and
neuropathological characteristics of what would become known as Alzheimer’s disease (AD).
Alzheimer’s initial reports, at first, attracted limited interest within the scientific community, but
the past fifty years have included landmark discoveries on the biological underpinnings of AD,
clinical and neuropathological characteristics of the disease, potential treatments, and genetic and
environmental risk factors for AD. These discoveries coincided with population aging and
influential social and political events, such as the National Alzheimer’s Project Act (United States
National Plan to Address Alzheimer's Disease, 2012), which have collectively contributed to
increased public awareness of AD.
Alzheimer’s disease is a complex disease with genetic, physiological, behavioral, social,
and cultural factors all apparently contributing to the onset and progression of the disease.
Declines in memory and difficulty recalling recently learned information are among the earliest
observable symptoms of AD (Perry & Hodges, 1999). However, biomarkers that signal changes
in biological processes that likely play a causal role in the development of AD begin to deviate
from normal many years before the onset of cognitive symptoms (Jack et al., 2013). The declines
in memory and other cognitive domains, such as language and decision making, are followed by
declines in physical functioning and behavioral changes (Mega, Cummings, Fiorello, &
1

Gornbein, 1996) that substantially reduce a person’s quality of life. Older adults in the advanced
stages of AD require assistance from family members or professional caregivers to perform
routine activities such as bathing, eating, and dressing. The increasing dependence on caregivers
as the disease progresses has a substantial impact on the health of the individual who is providing
care, and family caregivers are at an increased risk for depression (Pinquart & Sorensen, 2003),
anxiety (Mahoney, Regan, Katona, & Livingston, 2005) and chronic stress (Russo, Vitaliano,
Brewer, Katon, & Becker, 1995). Alzheimer’s disease also has a significant impact at the societal
level. The estimated financial value of care provided by family members in 2010 for the U.S.
was $202.6 billion (Thies & Bleiler, 2011) and the estimated total health care costs in 2010 for
persons diagnosed with AD was between $157 billion and $215 billion (Hurd, Martorell,
Delavande, Mullen, & Langa, 2013).
The overall poor health of middle aged adults in the United States has received
considerable media attention because the resources that are required to treat and manage chronic
conditions, such as diabetes, hypertension and high cholesterol, have placed considerable strain
on our healthcare system. Medical advances have increased the life expectancy of people with
chronic vascular conditions, but this may have significant implications during old age because
poor vascular health during middle age has been linked with an increased risk for AD (Duron &
Hanon, 2008). Cholesterol is a marker and risk indicator for cardiovascular disease (Anderson,
Odell, Wilson, & Kannel, 1991; Castelli et al., 1986), but cholesterol may also be an important
risk factor for AD. There is increasing evidence that supports the hypothesis that cholesterol is an
important risk factor for AD. Observational studies indicate that high cholesterol during midlife 1
increases the risk for AD (Kivipelto et al., 2001; Solomon, Kivipelto, Wolozin, Zhou, &
Whitmer, 2009) and several genes involved in cholesterol transport and metabolism are

1

Midlife is typically defined as between the ages of 35 and 55 and late life is often defined as
older than 65 years of age, but these definitions vary slightly from study to study. The definitions
of midlife and late life that will be used in the dissertation research are described in more detail in
chapter three.
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associated with AD, most notably the apolipoprotein E (APOE) gene (Corder et al., 1993; Crean
et al., 2011; Olgiati, Politis, Papadimitriou, De Ronchi, & Serretti, 2011). However, low
cholesterol during late life and a decline in cholesterol from midlife to late life are both associated
with an increased risk for AD (Reitz, Tang, Luchsinger, & Mayeux, 2004; Siest et al., 2000;
Stewart, White, Xue, & Launer, 2007). These seemingly conflicting findings suggest an age
dependent relationship between cholesterol and AD. This relationship can be further explored by
examining longitudinal trajectories of cholesterol from midlife through late life.
The remainder of this chapter first presents a broad overview of the modern history of
AD research. This review is meant to provide readers who are not familiar with AD research
with sufficient background knowledge to appreciate the purpose and significance of this
dissertation research. This review includes a summary of landmark scientific discoveries that
have shaped the current scientific understanding of AD, important social and political events that
have increased the public awareness of AD, as well as research on the etiology, treatment and
prevention of AD. This chapter then introduces the life span research perspective, which served
as the conceptual framework for the dissertation research, and summarizes the dissertation
research by outlining the organization of the subsequent chapters of this dissertation.
Alzheimer’s Disease Research: A Brief Historical Review
By the start of the 20th century, the term dementia was fairly well established in the
scientific literature and several case reports of patients with the cognitive, behavioral, and
neuropathological characteristics associated with dementia had been described (Berrios, 1990).
The term Alzheimer’s disease, first used by Alois Alzheimer’s mentor Emil Kraepelin, would
suggest that Alois Alzheimer had discovered a new disease. However, Alzheimer did not make
this claim and there is debate as to if Kraepelin chose the term for purely scientific reasons and
believed Alzheimer’s had in fact identified a new disease or if there were personal motivations
behind his decision [see Berrios (1990)] for a historical review of Kraepelin’s potential
motivations for crediting Alois Alzheimer with discovering a new disease). What made Auguste
3

D a unique case were the combination of clinical and neuropathological characteristics and the
unusually young age of onset (Berrios, 1990).
Alzheimer’s disease has been subdivided into early and late onset based on the age of
diagnosis. Early onset AD refers to cases that are diagnosed before 65 years of age, whereas late
onset AD refers to cases that are diagnosed after 65 years of age or older. Mutations in the APP
(Nilsberth et al., 2001), PSEN1 (Uttner et al., 2010), and PSEN2 (Marchani et al., 2010) genes are
known causes of early onset AD. These genetic mutations are rare and early onset AD accounts
for less than 5% of all cases of AD (Hebert, Scherr, Bienias, Bennett, & Evans, 2003). Unlike
early onset AD, there is no single gene or set of genes that ensures a person will develop late
onset AD, but the APOE e4 allele is a genetic risk factor that has consistently been observed to
increase the risk for AD (Bertram, McQueen, Mullin, Blacker, & Tanzi, 2007). Auguste D’s
young age of onset makes it likely that she had early onset AD, but there is no definitive evidence
that Auguste D carried a genetic mutation for early onset AD. In 2010, Yu et al. (2010) identified
a modern-day German family residing in the Hesse region of Germany, the same region that
Auguste D lived, with a family history of early onset AD and who carried a mutation in the
PSEN2 gene. This circumstantial evidence, along with the cognitive and neuropathological
characteristics and the relatively young age in which her symptoms were observed, make it
possible that Auguste D had early onset AD.
Relatively little research on AD was conducted in the decades following the initial
discoveries by Alois Alzheimer in the early 1900s. This was due largely in part to the limited
funding for AD research and a lack of scientific interest in AD and aging research in general prior
to the 1970s (Hodges, 2006; Morley, 2004). The 1970s and 1980s marked a significant change in
the scientific interest and public awareness of AD in possible response to the founding of the
National Institute on Aging (NIA), the Alzheimer’s Association, and Alzheimer’s Disease
Centers (ADC) at select academic institutions in the United States. The NIA was founded in
1974 with the purpose of studying the biological mechanisms of aging and aging related diseases
4

(Morley, 2004). Soon after, in 1980, the Alzheimer’s Association was founded with support from
the NIA. The Alzheimer’s Association was started in an effort to compliment the mission of the
NIA by focusing research on AD, educating the public about AD and giving support to families
who were providing care for someone with AD. Finally, in 1984 the NIA granted funding to
Harvard University, Johns Hopkins University, Mount Sinai Medical School, the University of
California San Diego and the University of Southern California to allow each institute to start an
ADC. One year later, five more institutions, which included Duke University, the University of
Kentucky, Washington University at St. Louis, the University of Pittsburgh, and the University of
Washington, were provided funding for ADCs. There are currently twenty-nine ADCs in the
United States and these Centers conduct focused research on understanding the etiology,
progression, prevention and treatment of AD and other neurodegenerative diseases. These
Centers also make significant contributions to their respective communities by providing patients
and their families with educational resources about dementia, family and patient support groups,
and other resources (additional information can be accessed at the Alzheimer’s Disease Education
and Referral Center http://www.nia.nih.gov/alzheimers).
The substantial increase in funding for research brought on by the founding of the NIA,
Alzheimer’s Association, and ADCs, as well as an expected increase in dementia prevalence
(Plum, 1979), all contributed to significant scientific discoveries in the 1970s and 1980s that have
advanced scientific understanding of the biological underpinnings of AD. Extensive research in
the 1980s focused on determining the biological processes that allow humans to form new
memories, and how these processes may be altered in older adults diagnosed with AD. One of
the most significant discoveries was reported in 1974 by Drachman & Levit, who determined that
a chemical in the brain called acetylcholine plays an important role in the formation and retrieval
of memories (Drachman & Leavitt, 1974). In their study, Drachman & Leavitt examined healthy
adults to determine if blocking acetylcholine in the brain impairs a person’s ability to form and
retrieve recently learned information. Healthy adults who received a drug that blocked
5

acetylcholine performed worse on a series of memory tests compared to those who did not
receive the drug. Furthermore, the memory performance of subjects who received the drug were
consistent with the memory performance of older adults who received the same series of memory
tests (Drachman & Leavitt, 1974). These findings provided strong evidence that acetylcholine
plays a crucial role in the formation and retrieval of memories and that a decrease in acetylcholine
may contribute to the decline in memory that is observed to occur with age (Bartus, Dean, Beer,
& Lippa, 1982). Subsequent research revealed that the brains of older adults diagnosed with AD
have significantly fewer neurons that produce and release acetylcholine compared to older adults
without dementia (Lehericy et al., 1993; Whitehouse et al., 1982; Wright, Geula, & Mesulam,
1993). Collectively, these findings made acetylcholine an early target for drugs designed to treat
patients with AD. Early therapeutic treatments for AD were designed to target the decrease in
acetylcholine by inhibiting the activity of the enzyme acetylcholinesterase, which breaks down
acetylcholine (Soreq & Seidman, 2001). Drugs that target this enzyme are called
acetylcholinesterase inhibitors (AChEI). This class of drugs makes up the majority of therapeutic
treatments for AD that are currently approved by the Food and Drug Administration (FDA). An
example of an AChEI is tacrine, which was the first AD drug to enter large scale clinical trials in
the United States (Summers, Majovski, Marsh, Tachiki, & Kling, 1986) and was the first
pharmaceutical treatment to be approved by the FDA for the symptomatic treatment of mild to
moderate AD (Summers, 2006). There are currently five medications approved by the FDA that
treat the symptoms of AD (Table 1.1). Four of these medications (donepezil, galantamine,
rivastigmine, and tacrine) are acetylcholinesterase inhibitors.
The medication memantine targets a different chemical in the brain called glutamate.
Glutamate plays an integral role in learning and memory (Riedel, Platt, & Micheau, 2003), but
the presence of too much glutamate is harmful to neurons (Choi, 1992). Under normal
physiological conditions, glutamate and another chemical in the brain called glycine open a
structure called an ion channel by binding to specific receptors on the channel. Once the ion
6

channel has been opened, calcium and sodium are able to enter into the neuron. The flow of
sodium and calcium into the neuron is stopped once glycine and glutamate are removed from
their receptors on the ion channel (Figure 1.1). Neurons may become damaged in the presence of
too much glutamate because the ion channels remain open for an extended period of time, which
allows for calcium and sodium to over-stimulate the neuron. This over-stimulation increases
activity of specialized enzymes that breakdown structural proteins within a neuron and production
of free radicals that break down the cell membrane, which ultimately leads to early death of
neurons (Choi, 1988). Memantine limits the amount of calcium and sodium that enters into the
neuron by creating a physical barrier inside the ion channel (Figure 1.2). Memantine has been
shown to temporarily improve physical and cognitive functioning of patients diagnosed with
severe AD (Reisberg et al., 2003; Winblad & Poritis, 1999). Until recently, memantine was the
only FDA approved medication for older adults in the advanced stages of AD (Cosman, Boyle, &
Porsteinsson, 2007), but high doses of donepezil and rivastigmine have both shown efficacy for
severe AD (Farlow, Grossberg, Sadowsky, Meng, & Somogyi, 2013; Farlow et al., 2010).
Understanding Plaques and Tangles
Alois Alzheimer described the characteristic plaques and tangles in 1906, but it was not
until eighty years later that scientists were able to determine the composition of these two
hallmark pathologies of AD. In 1984, Glenner & Wong reported that they were able to
successfully isolate and identify the amyloid beta (Aβ) protein, which aggregates to form neuritic
plaques in the brain (Glenner & Wong, 1984). Insoluble Aβ 2 is produced when the amyloid
precursor protein (APP) is cut sequentially by the enzymes β-secretase and γ-secretase (Pike et
al., 2007). In AD, there is an increase in β-secretase activity, which leads to an over production
of insoluble Aβ in the brain. These proteins stick together to form neuritic plaque (Sinha et al.,
1999), which is hypothesized to play a direct role in the decline in cognitive functioning

2

A soluble form of Aβ that does not aggregate into neuritic plaques is produced when APP is cut
by α-secretase and γ-secretase.
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consistent with AD because the build up of neuritic plaque disrupts neuronal function and leads,
ultimately, to cell death (Geula et al., 1998).
Soon after it was determined that neuritic plaques form from the aggregation of Aβ,
scientists successfully identified the protein that makes up neurofibrillary tangles. Several
research groups published findings between 1986 and 1989 that indicated neurofibrillary tangles
as comprised mostly of the protein tau (Grundke-Iqbal et al., 1986; Kosik, Joachim, & Selkoe,
1986; J. G. Wood, Mirra, Pollock, & Binder, 1986). Tau is an important protein that maintains
the structural integrity of microtubules (Weingarten, Lockwood, Hwo, & Kirschner, 1975). In
AD, tau becomes saturated with the chemical phosphate in a process called phosphorylation
(Goode, Drubin, & Barnes, 2000). This causes tau to dissociate from microtubules (Ballatore,
Lee, & Trojanowski, 2007) and bind together to form neurofibrillary tangles inside of neurons
(Santa-Maria et al., 2012). Microtubules are involved in the transportation of nutrients,
molecules, and other materials within neurons (Goode et al., 2000) and neurons are unable to
maintain normal physiological functioning once microtubules lose their structural integrity.
Do Plaques and Tangles Cause Alzheimer’s Disease?
Neuritic plaques and neurofibrillary tangles must both be present along with cognitive
impairment to warrant a diagnosis of AD (Murayama & Saito, 2004). However, there is debate
among scientists as to if an abnormality in Aβ or tau is the primary cause of AD. The amyloid
cascade hypothesis proposes that changes in the processing of APP triggers the initial deposition
of neuritic plaques and subsequent deposition of neurofibrillary tangles that both contribute to the
loss of neurons in the brain and, ultimately, cognitive decline (Hardy & Higgins, 1992). There is
a large body of research that has produced evidence supporting the amyloid cascade hypothesis.
First, mutations in genes that regulate the processing of APP are associated with early onset AD
(Nilsberth et al., 2001; Rogaev et al., 1995; Sherrington et al., 1995). Second, changes in the
processing of APP and the accumulation of Aβ both occur before tau becomes phosphorylated
and forms neurofibrillary tangles (Jack, Vemuri, et al., 2011; Jack et al., 2012). Finally, there is
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evidence that the presence of Aβ in the brain directly contributes to the phosphorylation of tau
and subsequent formation of neurofibrillary tangles (Gotz, Schild, Hoerndli, & Pennanen, 2004;
M. E. King et al., 2006), but the biological mechanisms that drive this relationship are not well
understood (Armstrong, 2011; Ittner & Gotz, 2011). The evidence for the amyloid cascade
hypothesis has made Aβ and neuritic plaque a primary target of pharmaceutical treatments and
preventions.
Despite the strong support for the amyloid cascade hypothesis, there are important
limitations that suggest the accumulation of Aβ may not be the primary cause of AD. First, the
severity of neuritic plaque accumulation in the brain is not a strong predictor of the degree of
cognitive impairment among older adults diagnosed with AD (Giannakopoulos et al., 2003).
Furthermore, it has been reported that in some instances older adults who exhibit normal
cognitive functioning have Aβ accumulation in the brain consistent with AD (Bennett et al.,
2006; Knopman et al., 2003), while other investigators have reported severe cognitive impairment
despite relatively low plaque accumulation among the oldest old 3 (Haroutunian et al., 2008). The
second major limitation of the amyloid cascade hypothesis is that several therapies meant to
decrease the amount of Aβ produced in the brain and prevent neuritic plaques from forming have
not been shown to reverse or halt the progression of AD symptoms (Green et al., 2009; Siemers et
al., 2010; Wilcock et al., 2008).
An alternative explanation to the amyloid cascade hypothesis is that structural changes to
tau and subsequent formation of neurofibrillary tangles is the primary cause of AD (Parihar &
Hemnani, 2004). This hypothesis has been referred to as the tau and tangle hypothesis (Mudher
& Lovestone, 2002). The tau and tangle hypothesis has received considerably less support from
the scientific community compared to the amyloid cascade hypothesis, but tau plays an important
role in the development of AD. During the early stages of AD, neurofibrillary tangles begin to
accumulate in regions of the brain involved in memory (Arriagada, Growdon, Hedley-Whyte, &
3

Oldest old was defined by Haroutunian et al. (2008) as subjects greater than 90 years of age.
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Hyman, 1992; E. Braak, Braak, & Mandelkow, 1994) and spread to other regions of the brain as
the disease progresses (H. Braak & Braak, 1991, 1995). One of the strongest pieces of evidence
for the tau and tangle hypothesis is there is a much stronger relationship between the severity of
cognitive impairment and accumulation of neurofibrillary tangles compared to the amount of
neuritic plaque in the brain (Arriagada et al., 1992; Ghoshal et al., 2002; Guillozet, Weintraub,
Mash, & Mesulam, 2003; Mitchell et al., 2002; Nagy et al., 1995). The tau and tangle hypothesis
is not without its limitations; most notably that genetic mutations to the tau protein do not lead to
AD. Instead, genetic mutations in tau are known to cause frontotemporal dementia, which is
characterized by damage to the frontal and temporal lobes of the brain and severe changes to
personality, behavior, and language (McKhann et al., 2001).
Causal relationships between the accumulation of neuritic plaques and neurofibrillary
tangles and onset of cognitive and behavioral symptoms of AD have been difficult to establish
and disappointing findings from clinical studies that have employed therapies that remove
neuritic plaques and neurofibrillary tangles among older adults who are in the mild to moderate
stages of AD have motivated criticism towards some AD hypotheses. The collective strengths
and limitations of both the amyloid cascade and tau and tangle hypothesis suggest that changes in
an unknown biological pathway or pathways cause both the increased production of Aβ and
phosphorylation of tau (Small & Duff, 2008). The next steps for scientists are to identify
biological pathways that when altered lead to an increased production of both Aβ and
phosphorylated tau, and then determine if these biological pathways are potential therapeutic
targets. Current research is also focused on the pre-clinical stages of AD and investigating if
administering disease modifying therapies to older adults who may be in the pre-clinical stages of
AD have efficacy in delaying or preventing progression of AD.
An Increase in Public Awareness of Alzheimer’s Disease
Biomedical research attention along with growing federal funding targeting AD came at a
time when population aging was becoming increasingly recognized as a social issue. Retirement
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migration was having profound impacts on the age structure of such places as Florida and
Arizona (Bohland & Rowles, 1988; Litwak & Longino, 1987; A. Rogers & Watkins, 1987), and
even the local population aging as a result of labor outmigration (Wiseman & Roseman, 1979)
attracted public attention. An increase in fertility following World War II, along with public
health advances that dramatically affected mortality and life expectancy, brought elders into the
public spotlight. This lead to elders becoming a larger part of what the population saw each day
and their unique needs also became more visible, and more contentious, to the American public.
By the 1990’s, demographic changes in the United States had brought significant
attention to the social implications of AD and the anticipated increase in AD prevalence during
the coming decades was alarming to scientists and the general public. A significant event in the
public awareness of AD occurred on November 4, 1994 when President Ronald Reagan wrote a
letter to the American public that announced he had been diagnosed with AD. Even before his
announcement, President Reagan had worked hard to increase awareness of AD. In 1982 he,
along with the Alzheimer’s Association, established the week of Thanksgiving as National
Alzheimer’s Disease Awareness Week. While President Reagan’s announcement immediately
increased the awareness of AD among the general public, the disease was already widely
recognized as a significant public health concern within the scientific community due to the
anticipated increase in the prevalence 4 of AD as the baby boomer generation advanced towards
old age.
In 1980, an estimated 2.88 million adults 65 years of age or older were living with AD
(D. A. Evans, 1990). This was approximately 11.3% of adults who were 65 years of age and
over, but only 3.9% of adults between 65 and 74 years of age were estimated to have AD,
whereas 16.4% of adults between the ages of 75 and 84, and 47.6% of adults 85+ were estimated

4

Prevalence is a measure that indicates the total number of people in a population with a specific
disease.
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to have AD. Several studies that examined secular trends in the prevalence and incidence rate 5 of
dementia during the 1980’s, 1990’s and early 2000’s have provided evidence for a decline in
dementia during this time period. In one of the first studies to examine trends in AD incidence
rate over time, Kokmen et al., (1993) observed a U shaped trend in the age and sex adjusted five
year cumulative incidence 6 of AD over a twenty-five year period beginning in 1960. In this
study, Kokmen and colleges observed that the cumulative incidence rate of AD from 1960-64
was 74.8 cases per 100,000 people, which declined from 1965-69 to 59.6 cases/100,000 people.
The decline in the cumulative incidence was followed by a steady increase from 1970-74 (75.2
cases/100,000 people), 1975-79 (87.4 cases/100,000 people), which continued from 1980-84
(94.8 cases/100,000 people). A follow-up analysis conducted by Rocca et al., (2011), which
included data collected from 1985-94 detected a small but statistically significant 3% decline per
year in the cumulative incidence of AD during this period. These findings (Rocca et al., 2011)
are consistent with an earlier study conducted by Manton, Gu, and Ukraintseva (2005) in which
the estimated prevalence of dementia in the U.S. decreased from 5.7% in 1982 to 2.9% in 1999.
Finally, there is also evidence for a decreasing trend in the prevalence of mild cognitive
impairment (MCI), which is often described as a transitional stage between normal cognitive
aging and AD (Petersen, 2000, 2004), in the United States during the 1990’s and early 2000’s.
Utilizing data from the Health and Retirement Study, Langa et al. (2008) observed that the
prevalence of MCI from 1993 to 2002 among two different cohorts of adults 70 years of age and
older declined from 5.2% (1993 cohort) to 3.5% (2002 cohort), and that the prevalence of older
adults with cognitive impairment consistent with dementia declined from 7.0% (1993 cohort) to
5.2% (2002 cohort). Collectively, the decreasing trends for dementia, AD and cognitive

5

An incidence rate reflects the number of new cases of a disease per person in the at risk
population over a specified period of time, typically ranging from days to a year.
6
Cumulative incidence accounts for the number of new cases of a disease (i.e. incidence)
reported in the at-risk population over a rather long period of time compared to the common
incidence rate. Whereas the incidence rate allows examination of immediate disease trends, the
cumulative incidence addresses overall impact of a disease and its spread.
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impairment from 1980 to 2000 have been attributed to a greater proportion of older adults with
high educational attainment, improved vascular health, increased physical activity and greater
access to medical resources (Langa et al., 2008; Manton et al., 2005; Rocca et al., 2011). The
number of adults 65 years of age and older living with AD in the U.S. has increased during the
past decade from approximately 4.5 million in 2000 (Hebert et al., 2003) to 4.7 million in 2010
(Hebert, Weuve, Scherr, & Evans, 2013). The increase in the number of older adults with AD is
due largely in part to the growing segment of the population that is living well into old age.
According to the U.S. Census, the number of adults 65 years of age and older increased from 35
million in 2000 (Meyer, 2001) to 40 million in 2010 (Werner, 2011). When the 2000 and 2010
estimates for the number of AD cases reported by Hebert et al. are divided by the number of older
adults living in the U.S. in 2000 and 2010, the percentage of adults 65 years of age and older with
AD actually decreased slightly from 12.9% in 2000 to 11.8% in 2010.
Since AD risk increases with advancing age, the aging of the baby boomers all but
guarantees that the number of older adults diagnosed with AD will increase in the coming
decades. Many studies that have projected the future prevalence of AD estimate the number of
older adults living with AD by 2050 will approach or exceed 10 million people (Brookmeyer,
Gray, & Kawas, 1998; D. A. Evans et al., 1989; Hebert et al., 2003; Hebert et al., 2013).
However, it is important to take into account changes in the secular trends of AD risk factors and
how these changes may influence the future prevalence and incidence of AD. Compared to
previous generations, there is higher prevalence for obesity, diabetes and hypertension among
baby boomers (D. E. King, Matheson, Chirina, Shankar, & Broman-Fulks, 2013), but the higher
educational attainment (Day & Bauman, 2000), decreased prevalence of smoking (D. E. King et
al., 2013) and better access to medical care (Freid & Bernstein, 2010) may make baby boomers
less susceptible to AD. There is concern, however, that the continued increase in obesity (Wang
& Beydoun, 2007), diabetes (Mokdad et al., 2001) and hypertension (Ford, Giles, & Mokdad,
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2004) among young and middle aged adults may lead to an increase in the future prevalence and
incidence of AD (Larson, Yaffe, & Langa, 2013).
The Future of Alzheimer’s Disease Research
Memantine and other FDA approved medications are designed to lessen the severity of
AD symptoms but do not change the progression of the disease because these medications do not
target the biological mechanisms believed to cause AD (Golde, Schneider, & Koo, 2011; Huang
& Mucke, 2012). Several disease-modifying therapies for AD that target Aβ or phosphorylated
tau are currently in development (Table 1.2). The majority of these therapies target Aβ by either:
(1) altering the function of the enzymes that cut APP (Best et al., 2005; Eriksen et al., 2003); (2)
preventing Aβ from aggregating into neuritic plaques (Gervais et al., 2007; McLaurin et al.,
2006); or (3) removing Aβ from the brain (Bard et al., 2000; DeMattos et al., 2001; Escribano et
al., 2010). There are other disease-modifying therapies that focus on other biological
mechanisms that are believed to cause AD. Two of these therapies are designed to target the tau
protein. The first prevents tau from becoming phosphorylated (Hong, Chen, Klein, & Lee, 1997)
and the second prevents phosphorylated tau from aggregating into neurofibrillary tangles
(Wischik, Edwards, Lai, Roth, & Harrington, 1996). A third therapy is designed to maintain
mitochondrial function in neurons (S. Zhang, Hedskog, Petersen, Winblad, & Ankarcrona, 2010).
Mitochondria are structures found inside of cells that produce the main energy source used by
cells (Freeman, 2008). It has been hypothesized that a decrease in mitochondrial functioning with
age contributes to the onset of AD and that maintaining mitochondrial functioning may prevent
the cascade of biological events that culminate in AD (Swerdlow, Burns, & Khan, 2010;
Swerdlow & Khan, 2004).
A limited number of studies have reported that disease-modifying therapies improve
cognitive functioning among patients diagnosed with mild to moderate AD. Encouraging results
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from animal models 7 of AD for treatments that inhibit the aggregation of phosphorylated tau have
been reported (Deiana, Harrington, Wischik, & Riedel, 2009) and a Phase II clinical trial
demonstrated that patients with moderate AD who received the treatment had slower disease
progression compared to patients who were given a placebo (Gura, 2008). The findings from a
randomized clinical trial of the drug nilvadipine, which is designed to modify the processing of
APP and remove Aβ (Paris et al., 2011), indicated that mild AD patients in the treatment group
exhibited less declines in overall cognitive functioning and executive functioning 8 compared to
AD patients who received a placebo (Kennelly et al., 2012). A point must be made that this was
an open-label study, which means that both the study investigators and participants were aware of
which participants were in the control group and which were in the treatment group (Kennelly et
al., 2012). Finally, a Phase II 9 clinical trial of the drug dimebon, which is designed to maintain
mitochondrial function, indicated that treatment was associated with improved cognitive
performance over a 26-week period among participants diagnosed mild to moderate AD relative
to those who received a placebo (Doody et al., 2008). While initial reports for the benefits of
dimebon were promising, later clinical trials did not support these findings and dimebon did not
move past phase III clinical trials.
Despite the encouraging results from some clinical trials and animal models of AD, the
majority of Phase III clinical trials 10 have produced discouraging results, with little to no
observable benefits for cognitive functioning or overall quality of life (Extance, 2010; Gold et al.,
2010; Hampel et al., 2009; Salloway et al., 2009; Salloway et al., 2011; Siemers et al., 2010).

7

Scientists often use animals, such as mice or rats, when conducting research on biological
mechanisms of disease or when developing new therapies. These animals mimic the symptoms
or pathologies of a particular disease and are used to eliminate the risk of harming human
subjects.
8
Executive functioning is the ability to manage several different cognitive tasks, such as memory,
judgment, and decision-making.
9
Phase II clinical trials include a large sample of patients to determine the effectiveness of the
treatment and identify harmful side effects.
10
Phase III clinical trials include a large sample of patients to confirm the effectiveness of the
treatment and further identify harmful side effects.
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The limited benefit of disease modifying therapies may be due to therapies being administered
too late in the disease process when irreversible damage to the brain has already occurred (Roh &
Holtzman, 2012). Such results from drug trials suggest an urgency to develop methods to
accurately identify older adults who may be in the preclinical stages of AD. Identifying older
adults in the pre-clinical stages of AD may increase the effectiveness of pharmaceutical
interventions, and allow a longer time period for people to engage in behavioral changes and to
begin planning for potential care needs. But there are significant ethical implications that need to
be considered. An argument can be made that disclosing information to a person that they may
be in the pre-clinical stages of AD could cause more harm than good because of the anxiety and
fear brought on by the knowledge they will develop a disease that has no known cure. Therefore,
employing biomarkers to identify older adults with pre-clinical AD has valuable implications in
research settings, but is unlikely to have significant clinical value until a cure for AD, or therapy
that significantly slows or delays AD progression, is developed.
There are five established biomarkers for AD that reflect AD pathology in the brain (Jack
et al., 2010). The accumulation of Aβ in the brain is indicated by a decrease of Aβ in
cerebrospinal fluid (CSF; Andreasen et al., 1999) and detection of Aβ in the brain using imaging
techniques (Klunk et al., 2004). The loss of neurons in the brain is indicated by an increase in
total and phosphorylated tau in the CSF (Andreasen, Vanmechelen, Vanderstichele, Davidsson, &
Blennow, 2003), a decrease in glucose metabolism in the brain (Lowe et al., 2009), and cerebral
atrophy (Dickerson et al., 2011). These biomarkers accurately discriminate between older adults
who may be in the preclinical stages of AD and older adults who maintain normal cognitive
function (Shaw et al., 2009), but cost and physical discomfort are potential barriers to collecting
these biomarkers. These limitations have motivated research into detecting other biomarkers that
may identify older adults who are in the preclinical stages of AD. In a recent study (Mapstone et
al., 2014), older adults who transitioned from normal cognition to impaired memory during a
five-year period had lower concentrations for ten different phospholipids compared to older
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adults who maintained normal cognition. When an independent sample of older adults was
examined, this biomarker profile was highly accurate in identifying older adults who went on to
convert from normal cognition to impaired memory over a five-year period. These results
suggest that a biomarker profile obtained through a simple blood draw may be able to identify
older adults who develop memory impairment before any cognitive impairment is observed. The
full implications of these findings will not become clear until additional research is conducted,
but these findings are an important step forward in developing a blood test that accurately
identifies older adults who may be in the preclinical stages of AD.
Purpose and Objectives of Dissertation Research
There is a clinical need for a marker that can be collected quickly and is relatively noninvasive, such as a blood draw, that can be used to assess a person’s risk for AD long before
cognitive symptoms are observed. Mounting evidence for a relationship between cholesterol and
AD strongly suggest that continued research in this area is warranted because cholesterol is
routinely measured in clinical settings. This dissertation research utilized data from the
Framingham Heart Study (FHS) Original and Offspring Cohorts and engaged a life span
approach to study how cholesterol trajectories relate to both AD diagnosis and cognitive
functioning. The purpose of this research was to determine if longitudinal trajectories of
cholesterol from midlife through late life differ between older adults diagnosed with AD and
those without dementia and, further, if these cholesterol trajectories are associated with cognitive
functioning among older adults without dementia. Participants in the FHS have received a
comprehensive neuropsychological battery comprised of twelve cognitive assessments. The
ability of three different summary scores of the FHS neuropsychological battery to differentiate
between subjects classified as having normal cognition, impaired cognition, and dementia was
therefore investigated.
The life span research approach emphasizes human development as an ongoing process
from birth until death (Baltes, 1987). The dissertation research focused on examining continuous
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changes in cholesterol with age as opposed to treating midlife and late life as discrete life stages
as has been frequently done in previous studies. This allowed for potentially important changes
in the trajectories of total cholesterol, HDL cholesterol and total/HDL ratio to be detected. The
FHS is a multigenerational study and this research utilized data from the Original and Offspring
Cohorts. The Offspring Cohort is comprised of subjects, and their spouses, who had at least one
parent who participated in the Original Cohort. Subjects recruited to participate in the FHS
Original Cohort were between 28 and 74 years of age during the first clinical examination. The
FHS Offspring Cohort does include subjects who were as young as five years of age during the
first clinical exam, but this Cohort has not been followed for a long enough period of time to
allow for these subjects to reach what would be considered an old age. Therefore, this research is
limited in that only a segment of the life span can be studied at the individual level and potentially
significant factors prior to middle age are unable to be examined. This limitation needs to be
acknowledged because childhood, adolescence and young adulthood are potentially important life
stages that may influence AD risk and cognitive functioning later in life. An analysis of
biographies written by Catholic Nuns during their early 20’s conducted by Snowdon et al. (1996),
for example, revealed that low idea density and low grammatical complexity were both associated
with poor cognitive functioning nearly 60 years later. Idea density and grammatical complexity
were both positively correlated with educational attainment (Snowdon et al., 1996), which makes
it plausible that educational experiences during childhood and adolescence may influence
cognitive functioning during old age. This explanation is supported by the findings from other
studies that have identified low socioeconomic status during childhood to be associated with poor
cognitive functioning during old age (Moceri et al., 2001; R. S. Wilson et al., 2005). Childhood
and adolescence play a significant role in health outcomes among middle-aged adults, and these
early life stages may have lasting consequences for cognitive functioning during old age.
Subsequent research is necessary to examine how genetic, physiological, behavioral and social
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factors during childhood and young adulthood influence cholesterol during adulthood and if these
early life factors modify the relationship between cholesterol and AD.
Cholesterol is a vital molecule for healthy brain function (Mauch et al., 2001; Pfrieger,
2003), but excess cholesterol has been hypothesized to be harmful to the brain by altering APP
processing and increasing production of insoluble Aβ (Frears, Stephens, Walters, Davies, &
Austen, 1999). Furthermore, variations in genes that regulate cholesterol balance in the brain,
such as CYP46A1 (Combarros, Infante, Llorca, & Berciano, 2004), ABCA1 (Katzov et al., 2004)
and APOE (Corder et al., 1994; Corder et al., 1993) have all been observed to modify the risk for
AD. The blood brain barrier effectively prevents the exchange of cholesterol between the brain
and the periphery (Bjorkhem & Meaney, 2004), which makes it unlikely that peripheral
cholesterol (i.e. cholesterol outside of the brain) directly contributes to AD neuropathology.
While clear biological mechanisms that explain the apparent relationship between peripheral
cholesterol and AD remain unknown, there are several reasons why it is important to conduct
research on longitudinal trajectories of cholesterol, AD and cognitive functioning. First, the
anticipated findings from the dissertation research may generate evidence that patterns of change
in cholesterol from midlife to late life differ according to AD status and cognitive functioning
later in life. Second, the anticipated findings of the dissertation research may provide insight into
the approximate age in which physiological changes associated with AD begin to occur. Finally,
the anticipated findings may open new avenues of research to determine if longitudinal
trajectories of cholesterol can be used to identify individuals who are at an increased risk for AD
before symptoms are observed.
This dissertation is comprised of six chapters. Chapter Two offers a comprehensive
literature review from areas of research that influenced the dissertation research. This literature
review is meant to establish the background knowledge on the relationship between cholesterol
and AD to establish necessary context for this study’s specific aims. Chapter Three describes the
life span as a conceptual research framework and how this framework was engaged in the
19

dissertation research. Chapter Four describes in detail the methods utilized for each of the three
specific aims, and Chapter Five presents the results of each specific aim. Finally, Chapter Six
summarizes the results generated by the dissertation research and discusses these findings within
the context of previous research. This chapter also describes the life course perspective and how
applying this perspective to the study of AD and cognitive functioning later in life can contribute
to future research.
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Table 1.1: FDA Approved Symptomatic Treatments for Alzheimer’s Disease
Therapy
Donepezil
(Aricept™).

Galantamine
(Reminyl™)

Rivastigmine
(Exelon™)

Tacrine
(Cognex™)

Memantine
(Ebixa™,
Namenda™)

Mechanism
Cholinesterase
inhibitor

Strengths
Evidence that treatment
slows the progression of
cognitive impairment and
physical decline for up to
a year or more.
Cholinesterase
Evidence that treatment
inhibitor
maintains/improves
behavioral changes
associated with AD,
which contributes to a
decrease in self-reported
caregiver burden.
Cholinesterase
Treatment has been
inhibitor
shown to be effective in
moderately severe cases
of AD.
Cholinesterase
Treatment has been
inhibitor
shown to be beneficial for
cognitive functioning,
ability to perform ADL
and overall quality of life.
Prevents NMDA Treatment is able to
receptors from
delay/slow progression of
functioning
cognitive decline,
behavioral changes, and
loss of ability to perform
ADL.
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Limitations
Increased occurrences of adverse events,
such as falls, urinary tract infection,
pneumonia, and aggression, among
patients who received 23 mg/d dose
versus standard 10 mg/d dose.
Treatment does not appear to be more
effective for mild to moderate AD
compared to previously FDA approved
cholinesterase inhibitors (Mintzer &
Kershaw, 2003).

Side effects such as nausea and vomiting
can be severe in some patients (Mimica
& Presecki, 2009).
Treatment can be harmful to the liver
(Watkins et al. 1994) due to multiple
daily doses being required (BentueFerrer, Tribut, Polard, & Allain, 2003).
Side effects include incontinence,
diarrhea, difficulty sleeping, and
agitation.

Table 1.2: Disease Modifying Therapies for Alzheimer’s Disease
Drug
Rosiglitazone

Mechanism
Increases removal
of Aβ from the
brain.

Semagacestat

Decreases γsecretase activity.

Tarenflurbil
(Flurizan™)

Decreases γsecretase activity.

Tramiprosate
(Alzhemed™)

Prevents Aβ from
forming neuritic
plaques.

Scyllo-inositol

Prevents Aβ from
forming neuritic
plaques.

Bapineuzumab

Increases removal
of Aβ from the
brain.

Solanezumab

Increases removal
of Aβ from the
brain.

Results
Evidence for a decline of Aβ in specific regions of the
brain of mouse models of AD. Effectiveness of
treatment in humans may depend upon APOE
genotype. Improvement in cognitive functioning
among APOE e4- AD patients, but no observable
benefits for APOE e4+ AD patients.
Evidence that treatment significantly decreases Aβ
production among patients with AD. However, Elli
Lilly halted the development of semagacestat because
of significantly worse cognitive performance among
AD patients compared to AD patients who received
placebo.
Limited to no evidence that treatment is able to delay
or slow cognitive decline among patients with mild to
moderate AD.
Evidence that treatment has short-term benefits for
cognition, but treatment was not successful in a Phase
III clinical trial. Evidence that treatment may increase
the deposition of phosphorylated tau in the brain.
Findings from a Phase II clinical did not support that
Scyllo-inositol had a significant benefit for cognition
compared to placebo in patients diagnosed with mild
to moderate AD. The two highest doses of Scylloinositol were terminated due to an increased risk of
death in the treatment group.
Evidence for a slower rate of cognitive decline among
patients with mild to moderate AD who were APOE
e4-, but not for patients who were APOE e4+. Two
Phase II clinical trials did not find bapineuzumab to be
effective for patients with mild to moderate
Alzheimer’s disease.
No observed benefit for cognitive functioning among
patients with mild to moderate Alzheimer’s disease.
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Figure 1.1: Flow of Calcium and Sodium Through an Ion Channel

Charged particles pass through the lipid bilayer via protein structures called ion channels.
Calcium and sodium cannot pass through the lipid bilayer when an ion channel is closed (1). An
ion channel opens when glutamate and glycine bind to specialized receptors (2). Once the
magnesium “cork” leaves the ion channel, calcium and sodium are able to enter the neuron (3).
Eventually, glutamate and glycine are removed from their binding sites on the ion channel and the
flow of calcium and sodium into the neuron is stopped (4).
Figure 1.2: Effects of Memantine on Flow of Calcium and Sodium Through Ion Channels

During Alzheimer’s disease, it is hypothesized that excess glutamate causes the ion channel to
remain open for too long. This leads to an increase in the amount of sodium and calcium that
enters into the neuron, which causes the neuron to become damaged or destroyed due to over
stimulation. Memantine prevents neurons from becoming damaged from over stimulation by
blocking sodium and calcium from passing through an ion channel and into the neuron. Sodium
and calcium are able to pass through the ion channel once glycine and glutamate bind to their
receptors on the ion channel (1). However, memantine blocks sodium and calcium from entering
into the neuron by creating a physical barrier in the ion channel (2).
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Chapter Two: Review of the Literature
This chapter comprehensively reviews literature from the areas of scholarship that
contributed to this dissertation research. Chapter Two is divided into three major sections.
Section one is a broad overview of the exogenous and endogenous sources of cholesterol, how the
body uses cholesterol, how the body maintains cholesterol homeostasis, age related changes to
cholesterol, and the detrimental effects of abnormal levels of cholesterol on health. It is not
feasible to review all of these areas of research in detail, and section one is designed to provide
only the necessary background knowledge for subsequent sections of this chapter and the
dissertation research. Section two is a literature review of epidemiological studies that have
examined the relationship between cholesterol and AD. This includes reviews of midlife and late
life measures of total, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein
(HDL) cholesterol and the change in these cholesterol measures with increasing age. Section
three is an overall summary of the literature presented in section two and describes how this
research will contribute to the current scientific understanding of the relationship between
cholesterol and AD, as well as cholesterol and cognitive functioning.
Background
There is a negative connotation associated with cholesterol among the general public due
to the established relationship between high cholesterol and adverse health events, such as heart
attack and stroke (Pancioli et al., 1998). This perception is somewhat misguided because
cholesterol is an essential molecule for healthy functioning of the human body. The liver is the
primary source of cholesterol for the body (van der Wulp, Verkade, & Groen, 2013), but animal
based food products such as meat, eggs, and cheese are also significant sources of cholesterol
(Ford & Capewell, 2013). Cholesterol is necessary for maintaining the structural integrity of cell
membranes (de Meyer & Smit, 2009) and is a precursor for several molecules that have important
biological functions (Rezen, Rozman, Pascussi, & Monostory, 2011), including testosterone and
estrogen, vitamin D, and bile salts, which aid in digestion.
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Types of Cholesterol
Cholesterol is transported in the bloodstream by combining with specialized proteins to
form lipoproteins. The efficiency in which a lipoprotein travels through the bloodstream depends
on the proportion of protein to cholesterol that comprises the lipoprotein. There are three
different lipoproteins that are commonly found in the body. Lipoproteins that contain less protein
in relation to cholesterol have a low density and do not travel through the bloodstream very
efficiently. These lipoproteins are commonly referred to as “bad” cholesterol because it can
accumulate on the walls of blood vessels. The primary function of LDL is to transport
cholesterol from the liver through the bloodstream to be used by cells throughout the body
(Goldstein & Brown, 2009). Conversely, lipoproteins that contain more protein than cholesterol
have a high density and travel more efficiently through the bloodstream than LDL. These
lipoproteins are commonly referred to as “good” cholesterol because they carry excess cholesterol
in the bloodstream back to the liver where it is secreted into bile and eventually delivered to the
intestine (C. J. Fielding & Fielding, 1995). HDL and LDL are the two main lipoproteins that
transport cholesterol to and from the liver, but a third lipoprotein called very-low density
lipoprotein (VLDL) transports triglycerides along with cholesterol to cells where they are used
for energy (Hussain, 2000). Once VLDL has transported the triglycerides to a cell, it is converted
to LDL (Havel, 1984). Total cholesterol is the sum of HDL, LDL, and VLDL cholesterol that is
found in the bloodstream.
Maintaining Cholesterol Homeostasis
Homeostasis is the constant internal state that is maintained by adjusting chemical,
biological, and physiological processes in response to changes in the environment. The body
maintains cholesterol homeostasis by tightly regulating how much cholesterol the liver produces
based on how much dietary cholesterol is consumed, how much cholesterol is removed from the
bloodstream, and how much cholesterol is excreted from the body. Cholesterol levels fall out of
homeostasis if the biological mechanisms that regulate cholesterol synthesis, removal, or
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excretion become disrupted or do not function properly. Normative physiological changes in
liver function and cholesterol absorption that occur with age contribute to disruption in
cholesterol homeostasis (Schatz et al., 2001; Silbernagel et al., 2010; Strandberg, Gylling, Tilvis,
& Miettinen, 2010; Tilvis, Valvanne, Strandberg, & Miettinen, 2011)
Effects of Diet on Cholesterol Homeostasis: There is not strong evidence that consuming
a high cholesterol diet substantially increases the concentration of cholesterol in the bloodstream
(Harman, Leeds, & Griffin, 2008; Katz et al., 2005; Mutungi et al., 2008). This is because
complex biological mechanisms regulate cholesterol synthesis and the liver increases or decreases
the amount of cholesterol that is produced based on how much cholesterol is consumed in the diet
(Brown & Goldstein, 1997). For example, a person whose typical diet contains a lot of animal
products will synthesize less cholesterol because the body is able to utilize dietary cholesterol,
whereas a person whose typical diet contains a lot of plant based products, which do not contain
cholesterol, will synthesize more cholesterol to meet the body’s needs (P. J. Jones et al., 1996;
Sundram, French, & Clandinin, 2003). Foods that are high in fat, specifically trans fat and
saturated fat, such as red meat, fried and processed foods, and baked goods have a much greater
impact on cholesterol levels in the bloodstream (Mensink & Katan, 1990; Mensink, Zock, Kester,
& Katan, 2003). Consuming foods that are high in fat increase LDL cholesterol and decrease
HDL cholesterol (Mozaffarian, Katan, Ascherio, Stampfer, & Willett, 2006). This means that
there is more cholesterol being transported from the liver to cells throughout the body in the form
of LDL cholesterol and less cholesterol being transported back to the liver in the form of HDL
cholesterol resulting in a net increase in cholesterol.
Absorption and Excretion of Cholesterol: The small intestines play an important role in
maintaining cholesterol homeostasis because they regulate cholesterol absorption and excretion
from the body. Cholesterol that is consumed in the diet is first absorbed by the intestines and is
then transported to the liver where it is either used to make bile salts (J. Y. Chiang, 2004) or is
distributed throughout the body as VLDL, which is subsequently converted into LDL cholesterol
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(Havel, 1984). There is considerable variability among humans in the percentage of dietary
cholesterol that is absorbed by the intestines, which can range between 20 and 80 percent
(Bosner, Lange, Stenson, & Ostlund, 1999; Sehayek et al., 1998; Sudhop et al., 2002). Research
suggests that genetics accounts for largest source of variability in cholesterol absorption (Berge et
al., 2002; Gylling & Miettinen, 2002; Kesaniemi, Ehnholm, & Miettinen, 1987), but age related
changes in cholesterol synthesis and absorption and the use of cholesterol-lowering medications
also influence how much dietary cholesterol the intestines absorb. These factors are summarized
in subsequent sections of this chapter. Cholesterol is removed from the body in feces either in its
original form as cholesterol or in its modified form as bile salts (van der Wulp et al., 2013).
Genetic Contributions to Cholesterol Homeostasis: Several genes play an important role
in the absorption, transport, and excretion of cholesterol (Bjorkhem & Eggertsen, 2001; Chawla,
Repa, Evans, & Mangelsdorf, 2001; Keller et al., 2013). The most pertinent of these genes to the
dissertation research is apolipoprotein E (APOE). APOE is located on chromosome 19 (Olaisen,
Teisberg, & Gedde-Dahl, 1982) and encodes the apoE protein. APOE includes three different
variations or alleles, e2, e3, and e4. All people inherit one allele from each parent resulting in one
of six possible genotypes (e2/e2, e2/e3, e2/e4, e3/e3, e3/e4, and e4/e4). Among Caucasians an
estimated 78% of the APOE alleles are the e3 allele, whereas 15% are the e4 allele and the
remaining 7% are the e2 allele (Plassman & Breitner, 1996). The apoE protein is one of several
proteins that transport dietary cholesterol and triglycerides through the bloodstream as VLDL and
is also involved in the conversion of VLDL to LDL cholesterol and the absorption of dietary
cholesterol by the small intestines (Hauser, Narayanaswami, & Ryan, 2011). The apoE protein
plays an important role in cholesterol homeostasis as indicated by the differences in cholesterol
concentrations according to APOE genotypes. Adults with the e3/e3 genotype tend to have lower
cholesterol than adults with either the e3/e4 or e4/e4 genotypes, but higher cholesterol compared
to adults with either the e2/e4, e2/e3 or e2/e2 genotypes (Boerwinkle & Utermann, 1988;
Ehnholm, Lukka, Kuusi, Nikkila, & Utermann, 1986; C. E. Tan et al., 2003). When
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environmental factors such as high body mass index, high calorie diet and high blood sugar are
also present, adults with the APOE e2/e2 genotype often develop type III hyperlipidemia (de Beer
et al., 2002; Mahley, Huang, & Rall, 1999); a rare condition that is characterized by abnormally
high concentrations of chylomicrons in the bloodstream, which are another lipoprotein that
transports triglycerides to cells (Hussain, 2000).
The relationship between the gene APOE and cholesterol is important to the dissertation
research because the APOE e4 allele is the most widely recognized genetic risk factor for late
onset AD. The APOE e4 allele was first reported to be linked to AD by Pericak-Vance et al.
(1988). Subsequent research conducted by Saunders et al., (1993) and Strittmatter et al. (1993)
indicated that the APOE e4 allele frequency was significantly higher in AD cases compared to
controls. Finally, Corder et al. (1993) reported that compared to subjects with no APOE e4
alleles, those who carried one APOE e4 allele were nearly three times as likely to develop AD
and subjects with two APOE e4 alleles were eight times as likely to develop AD. Also, the
average age of AD diagnosis decreased with the presence of each APOE e4 allele. The average
age of diagnosis for subjects with no APOE e4 alleles was 85 years, those with one APOE e4
allele was 75 years, and subjects with two APOE e4 alleles was 68 years (Corder et al., 1993).
Cholesterol-Lowering Medications: There are several different cholesterol-lowering
medications that are commonly prescribed for the treatment of high cholesterol (Table 2.1). The
most well known class of these medications is HMG-CoA reductase inhibitors, more commonly
known as statins. Statins lower the concentration of cholesterol in the bloodstream by decreasing
the amount of cholesterol produced by the liver. Cholesterol is synthesized by the liver through a
series of complex steps regulated by the enzyme HMG-CoA reductase (Goldstein & Brown,
1984). Statins lower the concentration of cholesterol in the bloodstream by limiting the function
of HMG-CoA reductase to decrease cholesterol synthesis by the liver (Istvan & Deisenhofer,
2001). Statins are an effective therapy for lowering high LDL cholesterol and high triglycerides
(P. Jones, Kafonek, Laurora, & Hunninghake, 1998). However, statins are not able to lower
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cholesterol to a healthy level in all adults with high cholesterol. In these instances a physician
may prescribe another cholesterol lowering medication in addition to a statin and dietary changes,
the combination of which is an effective method to lower cholesterol.
Other classes of cholesterol-lowering medications include niacin, resins, fibrates, and
selective cholesterol absorption inhibitors. The benefits of niacin for cholesterol levels were first
reported in 1955 (Altschul, Hoffer, & Stephen, 1955). Niacin, also known as nicotinic acid, is a
type of B vitamin that effectively increases the amount of HDL cholesterol in the bloodstream by
decreasing the uptake of HDL cholesterol by the liver (L. H. Zhang, Kamanna, Zhang, &
Kashyap, 2008). Resins are a second class of cholesterol lowering medication that increases the
synthesis of HDL cholesterol, but also decreases LDL cholesterol (Davidson et al., 1999; Insull et
al., 2001). Resins improve LDL cholesterol levels by decreasing the amount of bile that is
reabsorbed by the small intestines during the digestive process. This requires the liver to increase
the amount of cholesterol that is converted into bile salts (Sheng, Otani, Brown, & Goldstein,
1995). The fourth class of cholesterol lowering medications is fibrates. These therapies lower
triglycerides and increase HDL cholesterol (Rubins et al., 1999) by decreasing the liver’s
synthesis of triglycerides while increasing HDL synthesis (Staels et al., 1998). The final class of
cholesterol lowering medications is selective cholesterol absorption inhibitors. These therapies
lower LDL cholesterol by decreasing the amount of dietary cholesterol that is absorbed by the
small intestines (Altmann et al., 2004; Ballantyne et al., 2003; Kastelein et al., 2008). All five
classes of cholesterol lowering medications are generally well tolerated by patients and common
side effects include flushing of the skin, headache, constipation, and dizziness (Beltowski,
Wojcicka, & Jamroz-Wisniewska, 2009; Bissonnette et al., 2006; Davidson et al., 1999; Goldberg
et al., 2000; Jeng et al., 1997). However, rhabdomyolysis, which is severe muscle inflammation,
is a rare but serious side effect of statins (P. H. Jones & Davidson, 2005).
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Age Related Changes to Cholesterol
Longitudinal studies indicate that total, HDL, and LDL cholesterol all tend to increase
with age among young and middle age adults and decline with age later in life (Carroll et al.,
2005; Ferrara, Barrett-Connor, & Shan, 1997; P. W. Wilson, Anderson, Harris, Kannel, &
Castelli, 1994). There are several factors that contribute to the age related changes in cholesterol.
The most consistent predictors for an increase in total and LDL cholesterol among young and
middle aged adults are consuming a high fat diet (Johansson et al., 2012) and weight gain (Ferrara
et al., 1997). The decline in cholesterol among older adults coincides with weight loss, a decrease
in body fat, and the use of statins and other cholesterol lowering medications (Carroll et al.,
2005). Previous studies have reported that the effect of age on cholesterol among older adults
remains significant even after adjusting for changes in diet, physical activity and the use of statins
and other lipid lowering medications (P. W. Wilson et al., 1994). This indicates that additional
factors influence the decline in cholesterol among older adults. One such factor is hormone
differences between men and women. Young and middle-aged women tend to have higher HDL
cholesterol and lower total and LDL cholesterol compared to men but these differences become
less apparent with increasing age (Jousilahti, Vartiainen, Tuomilehto, & Puska, 1999). Women
have a more desirable lipid profile earlier in life because the hormone estrogen regulates
cholesterol levels (Lundeen, Carver, McKean, & Winneker, 1997). As women age, total and
LDL cholesterol tend to increase and HDL cholesterol decreases due to a decline in estrogen
production preceding menopause (Matthews et al., 2009; Stevenson, Crook, & Godsland, 1993).
Postmenopausal women with other risk factors for cardiovascular disease may begin estrogen
replacement therapy (ERT) to improve their cholesterol levels and decrease their risk for
cardiovascular disease (Stampfer et al., 1991). Estrogen replacement therapy may be prescribed
for men diagnosed with prostate cancer (Ho, Lee, Lam, & Leung, 2011) but ERT is not used to
control high cholesterol among men. There is evidence from comparable studies examining the
relationship between testosterone and cholesterol levels among men that a decline in testosterone
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with advancing age coincides with an increase in triglycerides and decrease in HDL cholesterol
(Barrett-Connor, 1995; Zmuda et al., 1997). Supplementation of endogenous testosterone,
however, has not been consistently observed to improve the lipid profile among men (Meriggiola,
Marcovina, Paulsen, & Bremner, 1995; Zgliczynski et al., 1996).
The decline in cholesterol with increasing age among older adults observed in
longitudinal studies may be the result of a survivor effect in which subjects at an increased risk
for mortality due to diseases caused by elevated cholesterol die and subjects with healthy
cholesterol levels remain in a study into old age (Bilheimer, 1991). While this certainly needs to
be taken into consideration, the decline in cholesterol synthesis by the liver and decline in the
amount of dietary cholesterol absorbed by the intestines plays a significant part in the decline of
cholesterol later in life. This was demonstrated in a study conducted by Tilvis et al. (2011) in
which older adults exhibited a decline in the concentrations of lathosterol, which reflects
cholesterol synthesis (Kempen, Glatz, Gevers Leuven, van der Voort, & Katan, 1988) and
sitosterol, which reflects cholesterol absorption (Miettinen, Tilvis, & Kesaniemi, 1990) along
with a decline in total cholesterol with increasing age. These findings replicate those from earlier
studies (Schatz et al., 2001; Silbernagel et al., 2010; Strandberg et al., 2010) and may reflect an
overall decline in biological functioning with age that decreases the body’s ability to maintain
cholesterol homeostasis.
Cholesterol and Cardiovascular Health
A lipid profile test is often included as part of a routine medical exam and involves taking
a blood sample to estimate how much total cholesterol, HDL cholesterol, LDL cholesterol, and
triglycerides are in the blood. Current guidelines recommend that a lipid profile test be
performed after an eight to twelve hour fast (Grundy et al., 2004) because the concentration of
triglycerides in the blood increases after consuming a high fat meal (B. A. Fielding et al., 1996).
A physician is able to use the results from a lipid profile test along with additional health
information, such as age and family health history, to estimate a person’s risk for different
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cardiovascular diseases. According to the National Cholesterol Education Program's Adult
Treatment Panel III guidelines, total cholesterol should not exceed 200 mg/dl, LDL cholesterol
should not exceed 100 mg/dl, and HDL cholesterol should not be below 40 mg/dl for men and 50
mg/dl for women (Grundy et al., 2004). Triglyceride levels should not exceed 150 mg/dl
(Grundy et al., 2004). Based on data from the National Health and Nutrition Examination Survey
(NHANES), the percentage of adults between the ages of 40 and 74 with high LDL cholesterol
has declined from 59% between 1976-1980 to 27% between 2007-2010 (Kuklina, Carroll, Shaw,
& Hirsch, 2013). This decline is due largely to the increasing trend in the number of Americans
who have been prescribed cholesterol-lowering medications during the same time period
(Kuklina et al., 2013). Maintaining healthy levels of cholesterol is still a significant public health
concern because adults with high LDL cholesterol or low HDL cholesterol are at a substantial
risk for atherosclerosis (Assmann, Cullen, & Schulte, 2002), condition described by a hardening
and narrowing of arteries due to accumulation of fatty deposits inside the arterial wall (Berliner et
al., 1995). If left untreated the fatty deposits will increase in size and substantially restrict blood
flow, which may lead to a heart attack or stroke (Lloyd-Jones et al., 2009). Maintaining healthy
levels of HDL cholesterol decreases the risk for atherosclerosis because HDL is able to remove
cholesterol from fatty deposits and bring it back to the liver (von Eckardstein, Nofer, & Assmann,
2001).
Cholesterol and the Brain
The brain is a cholesterol rich organ and contains up to 30 percent of all the cholesterol
found in the human body (Reitz, 2013). Dietary cholesterol and cholesterol that is synthesized by
the liver does not contribute to the cholesterol that is found in the brain because the blood-brain
barrier prevents the exchange of cholesterol between the bloodstream and the brain (Dietschy &
Turley, 2001). Instead, specialized cells in the brain called oligodendrocytes and astrocytes are
responsible for synthesizing nearly all of the cholesterol found in the brain (Bjorkhem & Meaney,
2004). Neurons are also capable of synthesizing cholesterol, but in much smaller amounts
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(Funfschilling, Saher, Xiao, Mobius, & Nave, 2007). Oligodendrocytes need to synthesize large
amounts of cholesterol because they use cholesterol to produce myelin (Jurevics & Morell, 1995),
which is essential for the normal functioning of the brain and other parts of the nervous system.
Myelin insulates the axons of certain nerve cells similar to the insulating cover that surrounds a
wire and allows for electrical impulses to travel quickly along a nerve cell (Sherman & Brophy,
2005). The cholesterol that is synthesized by astrocytes is transported to neurons where it is then
incorporated into the cell membrane (Bjorkhem, 2006).
Oligodendrocytes and astrocytes synthesize cholesterol using the same biological
pathway as the liver (Maioli et al., 2013). Oligodendrocytes synthesize a limited amount of
cholesterol in utero because very little myelination occurs in the brain during the fetal stage of
development (Dietschy & Turley, 2004) 11. The rate of cholesterol synthesis in the brain increases
following birth and remains high up until young adulthood at which point the rate of synthesis
begins to decline as the brain becomes fully developed (Dietschy & Turley, 2004). While the
brain needs to synthesize cholesterol to maintain normal physiological functioning, it is important
that excess cholesterol is removed from the brain. The brain maintains cholesterol homeostasis
by modifying the structure of cholesterol into a form that is able to pass through the blood brain
barrier (Lutjohann et al., 1996). The inability to adequately modify the structure of cholesterol
and remove it from the brain is linked to several neurodegenerative diseases, including AD
(Casserly & Topol, 2004), Parkinson’s disease (Vance, 2012), and Huntington’s disease
(Karasinska & Hayden, 2011).

11

Children who do not synthesize an adequate amount of cholesterol by the liver and the brain in
utero and during the first few years of life exhibit developmental, physical, and neurological
abnormalities. Smith–Lemli–Opitz syndrome (SLOS) is a genetically inherited cholesterol
deficiency syndrome that is caused by a defect in the enzyme that converts 7-dehydrocholesterol
into cholesterol during the final step of the cholesterol synthesis pathway (Fitzky et al., 1998).
The number of live births that are diagnosed with SLOS is estimated to be between 1 in 2,100 and
1 in 19,000 (Battaile, Battaile, Merkens, Maslen, & Steiner, 2001). Children diagnosed with
SLOS may be born with physical abnormalities, such as a cleft-pallet and small head
circumference and exhibit delayed growth and intellectual delays (Tint et al., 1994).
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There are many different biological mechanisms proposed to explain the relationship
between high total cholesterol during midlife and AD. One potential mechanism is the link
between high cholesterol and atherosclerosis. The Circle of Willis is a collection of arteries that
supplies blood to the brain and atherosclerosis in these arteries is more prevalent among older
adults diagnosed with AD (Roher et al., 2011). The blood-brain barrier significantly limits the
exchange of cholesterol between the circulatory system and the brain (Dietschy & Turley, 2001)
making it unlikely that cholesterol directly contributes to Aβ production in the brain. While
cholesterol may not directly cause AD neuropathology, targeting high cholesterol may disrupt the
biological chain of events that triggers the deposition of Aβ and tau pathologies that ultimately
lead to neurodegeneration, cognitive decline, and AD. High cholesterol causes inflammation of
the brain (Thirumangalakudi et al., 2008) and to the small blood vessels that surround the brain
(Granger, Rodrigues, Yildirim, & Senchenkova, 2010). This inflammation has been linked to an
increase in Aβ generation (Lee et al., 2008). The accumulation of Aβ in the brain contributes to
the deposition of hyperphosphorylated tau (Busciglio, Lorenzo, Yeh, & Yankner, 1995;
Takahashi, Capetillo-Zarate, Lin, Milner, & Gouras, 2010), but the biological mechanisms
driving this relationship are not fully understood (Armstrong, 2011).
Epidemiology of Cholesterol and Alzheimer’s Disease
Epidemiologists primarily study how a disease or other health outcome is distributed
within a population and the factors that protect or predispose a population to that disease or
outcome. There is increasing evidence from epidemiological studies that indicate concentrations
of total, LDL, and HDL cholesterol in the bloodstream modify the risk for AD. This section
addresses literature that examines how the relationship between cholesterol and AD varies
according to the type of cholesterol that is measured (total, LDL, or HDL cholesterol), the age
that cholesterol is measured (midlife versus late life) and the change in cholesterol with age.
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Midlife Total, LDL, and HDL Cholesterol
Studies that examine the relationship between midlife measures of cholesterol and AD
are summarized in Table 2.2. In general, the findings from these studies indicate that high total
cholesterol during midlife is associated with an increased risk for AD during old age. There were
no studies identified by the literature review that assessed HDL or LDL cholesterol during
midlife. The findings of the three studies that reported a significant relationship between midlife
total cholesterol and AD suggest that the concentration of total cholesterol must surpass a specific
threshold before the risk for AD is increased. All three of these studies reported that an increased
risk for AD was only observed for subjects with total cholesterol that was >240 mg/dl whereas
subjects with borderline high cholesterol (200 mg/dl - <240 mg/dl) were not at an increased risk
compared to subjects with normal total cholesterol (<200 mg/dl). Mielke et al., (2010) did not
observe that high midlife total cholesterol increased AD risk but this may have been due to only
being able to examine women. None of the other four studies tested for an interaction between
total cholesterol and sex, so the potential interactive effects of sex on the relationship between
cholesterol and AD could not be determined based on the evidence from the literature review.
The age cut-off used to define midlife may also modify the relationship between total cholesterol
and AD. Of the three studies that detected a significant relationship, two restricted their sample
population to include subjects between 40 and 60 years of age (Kivipelto, Helkala, & Hallikainen,
2000; Notkola et al., 1998) and the third limited their sample to include subjects between 40 and
45 years of age (Solomon, Kivipelto, et al., 2009). C. J. Chiang et al. (2007) excluded subjects
who were younger than 30 years of age upon enrollment into the study, but this was the only
study identified in the literature to not specify if an upper limit was placed on age. Age was
treated as a continuous variable in all four of these studies.
Late Life Total, LDL, and HDL Cholesterol
Studies that examined the relationship between late life measures of cholesterol and AD
are summarized in Table 2.3. All of these studies assessed total cholesterol, whereas a limited
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number of studies included measures of LDL cholesterol or HDL cholesterol. The relationship
between cholesterol measures during late life and AD appears to vary according to total, LDL, or
HDL cholesterol. Based on evidence from the available literature, low total cholesterol during
late life appears to be a risk factor for AD. Nine studies detected a significant relationship
between total cholesterol and AD. Three of these studies reported that total cholesterol was
significantly lower in AD cases compared to controls (Lepara, Valjevac, Alajbegovic, Zaciragic,
& Nakas-Icindic, 2009; Merched, Xia, Visvikis, Serot, & Siest, 2000; Siest et al., 2000) and four
studies observed that higher total cholesterol decreased the risk for AD (R. M. Evans et al., 2000;
Kuusisto et al., 1997; Mielke et al., 2005; Reitz et al., 2004). Furthermore, Hayden et al., (2006)
reported that older adults with a history of high total cholesterol after the age of 65 had a
decreased risk of developing AD three years later. However, Lesser et al. reported that AD cases
had significantly higher total cholesterol compared to controls. Two of the seven studies that
examined LDL cholesterol found a significant association with AD. Lepara et al., (2009)
reported that AD cases had significantly lower LDL cholesterol during late life compared to
controls, whereas Lesser et al., (2001) observed that AD cases had higher LDL cholesterol
compared to controls. Finally, of the eleven studies that examined late life HDL cholesterol, only
three detected a significant association between HDL cholesterol and AD. Merched et al., (2000)
reported that AD cases had lower HDL cholesterol during late life compared to non-demented
controls. This is consistent with the findings reported by Reitz et al., (2004) in which high HDL
cholesterol during late life was protective against AD, but this finding was not replicated when
the data were examined using a prospective study design. However, Kalman et al., (1999)
observed that older adults diagnosed with AD had higher HDL cholesterol compared to controls.
Close examination of these studies suggests that the age cut-offs to define late life
influences the relationship between total cholesterol during late life and AD. Eleven of the
seventeen studies that assessed cholesterol during late life reported if the final sample was
restricted according to age and the majority of these studies removed subjects who were younger
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than 65 years of age. The results of studies that excluded subjects who were not 65 years of age
or older were much more consistent and seven of the ten studies reported that low total
cholesterol was associated with AD. The only study to contradict the above findings was
conducted by Lesser et al. (2001). In this study, Lesser et al. reported that AD cases had
significantly higher total cholesterol compared to controls (210.0 mg/dl vs. 194.0 mg/dl P<0.05).
There are several explanations as to why the results from this study contradict those reported by
the majority of studies. First, the sample population studied by Lesser et al. (2001) was
considerably older than the sample populations of the other studies. The median age of the final
sample of the Lesser et al. study was 89 years and only twelve of the 106 participants were
younger than 80 years of age. This is due to Lesser et al. only including participants in the final
sample who had received a postmortem autopsy of the brain to definitively diagnose AD.
Second, the control group consisted of subjects who had received a diagnosis of dementia while
living but did not meet the neuropathological criteria for possible, probable or definitive AD
based on a brain autopsy. The advantage of selecting a control group that consists of subjects
who exhibit the outward symptoms of a disease but do not actually have the disease is it can
decrease sampling bias. However, this is only the case if the exposure is not related to the
observed symptoms (Wacholder, Silverman, McLaughlin, & Mandel, 1992). Lesser et al. may
have violated this assumption because there is evidence that low cholesterol during late life is
associated with impaired cognitive functioning among non-demented older adults (Solomon,
Kareholt, et al., 2009; J. Zhang, McKeown, & Hajjar, 2005). These characteristics of the study
by Lesser et al. need to be considered when comparing their findings with those of other studies.
There is little evidence to suggest that there is a significant relationship between late life
LDL and HDL cholesterol and AD. Furthermore, the findings from the few studies that detected
a significant relationship between LDL, HDL, and AD are inconsistent. Two of the seven studies
that examined LDL cholesterol found a significant association with AD. Lepara et al., (2009)
reported that AD cases had significantly lower LDL cholesterol during late life compared to
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controls (3.51 mmol/L vs. 4.08 mmol/L P<0.05), whereas Lesser et al., (2001) observed that AD
cases had higher LDL cholesterol compared to controls (132.5 mg/dl vs. 119.5 mg/dl P<0.05).
Eleven studies examined late life HDL cholesterol, but only three studies detected a significant
association between HDL cholesterol and AD. Merched et al., (2000) reported that AD cases had
lower HDL cholesterol during late life compared to non-demented controls. This is consistent
with the findings reported by Reitz et al., (2004) in which high HDL cholesterol during late life
was protective against AD, but this finding was not replicated when the data was examined using
a prospective study design. However, Kalman et al., (1999) observed that older adults diagnosed
with AD had higher HDL cholesterol compared to controls. This conflicting finding may be due
to Reitz et al., (2004) and Merched et al., (2000) using fasting measures of HDL cholesterol
whereas Kalman et al. did not specify if fasting or non-fasting measures of HDL cholesterol were
used in the analysis.
Change in Total, LDL, and HDL Cholesterol
A summary of the four studies that examined the change in cholesterol and AD risk is
provided in Table 2.4. All four of these studies assessed total cholesterol, but none examined
changes in LDL or HDL cholesterol. Notkola et al. (1998) collected a total of six measures of
cholesterol over a thirty-year period beginning in 1959 from 444 Finish men. According to the
results from repeated measures ANOVA, men diagnosed with AD had higher total cholesterol on
average from 1959-1974 and a greater decrease in total cholesterol from 1974 to 1989 compared
to men without AD. In a more recent study, Mielke et al. (2010) used Cox proportional hazards
regression models to examine the time-dependent change in cholesterol and the onset of dementia
and AD among 1,462 Swedish women. Cholesterol change was defined by Mielke et al. (2010)
as the difference in cholesterol between consecutive examinations and was analyzed as quartiles.
Women in the quartile of greatest decrease in cholesterol (difference > -0.5 mmol/L between
examinations) were at an increased risk for all-cause dementia compared to women in the middle
two quartiles (cholesterol change of -0.5 mmol/L to 0.75 mmol/L between examinations). When
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only cases of AD were examined, women in the quartile of greatest decrease in cholesterol were
at a greater risk for AD compared to women in the middle two quartiles, but these results were
not statistically significant (Mielke et al., 2010). Tan et al., (2003) calculated the change in total
cholesterol using data that had been collected during two observation periods, but did not observe
that a greater decrease in cholesterol increased the risk for AD Finally, there is limited evidence
to suggest that subjects who develop AD exhibit a different trajectory of cholesterol over time
compared to subjects without dementia. In a study conducted by Stewart et al. (2007), randomeffects models were used to estimate the trajectories of cholesterol among Japanese American
men over a twenty-six year period. Stewart et al. (2007) did not observe any differences in total
cholesterol according to dementia status during the baseline examination, but men who developed
AD exhibited a greater non-linear decline in cholesterol with age compared to men who did not
develop dementia.
Summary
Many studies in this literature review did not detect a significant relationship between
late life cholesterol, midlife cholesterol, or changes in cholesterol and AD. There are several
explanations for the inconsistent findings between studies. First, results differed according to
study design. For example, Reitz et al., (2004) examined data from two cohorts (1992 – 1994,
1999 – 2002) of the Washington Heights-Inwood Columbia Aging Project to perform crosssectional and prospective analyses on the relationship between cholesterol and AD. When data
from both cohorts were combined and examined cross-sectionally, high HDL cholesterol was
associated with lower odds for AD but no significant association between total cholesterol and
AD was observed. When a prospective analysis using data from the 1992 cohort was performed,
high total cholesterol during late life was associated with a reduced risk for AD and the finding
for HDL cholesterol was not replicated. Reitz et al. (2004) did not specify if the 1992 and 1999
cohorts differed according to age, gender, education, statin use or other factors, and the
inconsistent findings may be an artifact of differences between the 1992 and 1999 cohorts.
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Differences in findings according to study design may also be due to the cross-sectional analysis
including prevalent cases of AD, whereas the prospective design examines incident cases of AD.
The disadvantage of utilizing a cross-sectional design is that some subjects with low cognitive
performance not due to disease (e.g. low educational attainment) may have been incorrectly
classified as having AD, which would potentially weaken the relationship between AD and
cholesterol. The potential for misclassification is reduced in a prospective study design that
includes incident cases of AD because all subjects entered into the study non-demented and a
diagnosis of AD is made based on cognitive performance over a number of years.
Another potential explanation for the inconsistent findings is the wide range in the
sample sizes examined by different studies. The sample sizes of the studies included in the
review ranged from N=39 (Kalman et al., 1999) to N=848505 (Kimm et al., 2011), and it is likely
that several studies were either under or over powered. Power is the likelihood that a statistical
test will reject the null hypothesis given a specified level of significance (often α<0.05), the
strength of the relationship between independent and dependent variables (i.e. effect size), and
sample size (J. Cohen, 1992). Studies that include a large number of participants are likely to
detect a significant relationship between cholesterol and AD even when the effect size is small,
whereas studies with small sample sizes will be less likely to detect a significant relationship
unless the effect size is very large.
A third explanation for inconsistent findings is that some studies did not control for the
effects of potentially important covariates in either the design stage or analysis stage of the study.
Covariates are independent variables that may influence the outcome of interest and whose effect
needs to be controlled for in the study. Common covariates included in studies that examine the
relationship between cholesterol and AD include age, sex, and APOE e4 allele status. A
summary of the covariates included in the review is provided in Table 2.5. Surprisingly, several
studies did not include what would seem to be potentially important covariates when performing
multivariable analyses, and two studies (C. J. Chiang et al., 2007; Wieringa, Burlinson, Rafferty,
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Gowland, & Burns, 1997) did not control for the effects of any covariates. Sixteen studies
controlled for age and sex, and eight studies included age, sex and education as covariates when
performing multivariable analyses. Six studies included history of statin use and seven studies
included APOE e4 allele status as covariates in multivariable analyses, and only ten studies
specified that they used fasting measures of cholesterol. Including additional variables such as
age or sex is important to avoid confounding, which occurs when a third variable is related to
both the independent variable and dependent variable, but is not in the causal pathway of the
disease. Potentially confounding variables can most often be detected by conducting a thorough
literature review and by comparing results of unadjusted and adjusted analyses. Not accounting
for the effect of a confounding variable will falsely increase or decrease the strength of the
association between independent and dependent variables (McNamee, 2003). For example,
statins are effective treatments for lowering high cholesterol, but there is evidence that patients
who have a history of taking a statin are less likely to develop AD later in life (Jick, Zornberg,
Jick, Seshadri, & Drachman, 2000; Wolozin, Kellman, Ruosseau, Celesia, & Siegel, 2000).
Therefore, if the effect of statin use is not accounted for in the study, then a relationship between
low cholesterol and decreased risk for AD may actually be due to the confounding effect of statin
use.
The effects of a confounding variable can be controlled for in the design phase or
analysis phase of a study. Confounding can be controlled for in the design phase several ways.
The first is randomization in which subjects are randomly assigned into a study group or control
group. Randomization controls for confounding by making the treatment and control groups
similar for known characteristics, such as age, gender, education, and unknown characteristics
that may also be confounders. An investigator can ensure that the randomization was effective by
comparing the characteristics of the treatment and control groups to make sure that there are no
significant differences between the groups. Randomization is well suited for clinical trials where
participants are randomly assigned to receive a placebo or the treatment, but is not possible in
42

observational studies. For example, it is not ethical to randomly assign a large group of people to
consume a high fat diet so that they develop high cholesterol and then examine if they are at an
increased risk for AD later in life. A second way to control for confounding is to restrict study
recruitment according to a specific characteristic. For example, if an investigator is concerned
that sex is a potential confounder then the sample population may only include men or women.
While this approach is very straightforward, there are several limitations. Restriction makes it
difficult to generalize the findings of the study to an entire population, may reduce the size of the
final sample, and makes it impossible to examine the effect the factor that subjects were restricted
against has on the outcome (e.g. cannot examine potential differences in the relationship between
cholesterol and AD according to sex). The third way to control for confounding in the design
phase of a study is called matching. Matching can be done at the population level or at the
individual level. Individual level matching means that participants are chosen according to
specific characteristics. For example, if a study matched subjects according to age then every 35
to 45 year old with high cholesterol that was enrolled in a study would be paired with a 35 to 45
year old with normal cholesterol. When matching is done at the population level, the goal is to
make sure that the distribution of important characteristics, such as age and gender, are similar
between cases and controls or exposed and unexposed individuals. This approach is effective
when wanting to control for a complex characteristic such as socioeconomic status, but matching
can be time consuming, greatly reduce sample size, and the effects of the characteristics that were
matched for can no longer be evaluated. Also, the fact that subjects were matched in the design
stage needs to be accounted for in the analysis stage of the study.
Confounding can be adjusted for in the analysis stage of a study by conducting either a
stratified analysis or multivariable analysis. A stratified analysis means that the sample is divided
according to a specific characteristic. For example, if sex is a potential confounding variable then
subjects can be stratified so that only men are included in one analysis and only women are
included in the other analysis. The results from these separate analyses can be compared to help
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clarify if gender is confounding the relationship between the independent and dependent
variables. Stratification is a straightforward method of controlling for confounding, but it is
difficult to control for multiple confounding variables because the number of substrata increases
rapidly. A multivariable analysis is appropriate when several variables need to be controlled for
in a study, and allows for the effect of an independent variable on the dependent variable to be
determined while controlling for the effects of potential confounders. A multivariable approach
was utilized in the dissertation research to take into account the effects of gender, education,
smoking, blood pressure and blood sugar, the use of cholesterol lowering medications, the use of
estrogen replacement, and APOE e4 allele status when examining the relationship between
cholesterol and AD.
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Table 2.1: Cholesterol Lowering Medications
Medication Examples
Statins
Atorvastatin
(Lipitor®)
Rosuvastatin
(Crestor®)
Simvastatin
(Zocor®)

Mechanism
Inhibits HMG-CoA
reductase to
decrease synthesis
of cholesterol by the
liver.

Effects of treatment
Lowers LDL
cholesterol and
triglycerides.

Niacin

Nicolar
Niaspan

Lowers LDL
cholesterol and
increases HDL
cholesterol.

Resins

Colestipol
(Colestid®)
Colesevelam
(WelChol®)

Fibrates

Gemfibrozil
(Lopid®)
Fenofibrate
(Tricor®)

Selective
cholesterol
absorption
inhibitors

Ezetimibe
(Zetia®)

Decreases the
amount of HDL
cholesterol that is
reabsorbed by the
liver.
Decreases the
reabsorption of bile,
which increases the
conversion of
cholesterol into bile
salts.
Decreases the
synthesis of
triglycerides and
increased synthesis
of HDL by the liver.
Decreases
cholesterol
absorption by the
small intestines.

Common side effects
Headache, dizziness,
and flushing of the
skin. Potentially
more serious side
effects include
muscle inflammation
(myositis) or muscle
weakness.
Flushing of the skin,
headache, nausea,
and diarrhea.

Decreases LDL
cholesterol and
increases HDL
cholesterol.

Constipation,
diarrhea, and nausea.

Decrease triglycerides
and increase HDL
cholesterol.

Indigestion,
abdominal pain, and
headache.

Decreases LDL
cholesterol.

Constipation,
dizziness, diarrhea.
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Table 2.2: Midlife Cholesterol and Alzheimer’s Disease

Total Cholesterol
Baseline Age/Year

Study

Population

Sample size

Kivipelto
et al.,
2000

Finland

48 AD, 1352
cntrl

Mielke et
al., 2010

Sweden
(women only)

80 AD, 1382
cntrl

Solomon et
al., 2009

United States

469 AD, 9248
cntrl

Midlife 40 – 45 yrs.

2005 –
2007

Taiwan

73 AD, 292 cntrl

Midlife >30 yrs./
1982 – 1986
Midlife age 40 – 59

2000 –
2001
1989

Chiang et
al., 2007
Notkola et
al., 1998

Finland (men
only)

1972, 1977, 1982
or 1987. Age
during baseline
defined as midlife
Midlife 38 – 60 yrs.

Follow up
Age/Year
Participants
between
65-70
yrs./1997
2000–2001

Result (95% CI)
<6.5 mmol/L vs. >6.5 mmol/L
OR 2.1 (1.2, 4.7) P<0.05

>6.5 mmol/L HR 1.48 (0.73,
2.96) P>0.05
Q1 vs. Q2 HR 2.05 (0.70,
6.04) P>0.05
Q1 vs. Q3 HR 2.51 (0.87,
7.26) P>0.05
Q1 vs. Q4 HR 2.82 (0.94,
8.43) P>0.05
<200 mg/dl vs. 200-239 mg/dl
HR 1.2 (.97, 1.6) P>0.05
<200 mg/dl vs. >240 mg/dl
HR 1.57 (1.23, 2.01) P<0.05
Q1 vs. Q2 HR 1.25 (0.96,
1.63) P>0.05
Q1 vs. Q3 HR 1.31 (1.01,
1.71) P>0.05
Q1 vs. Q4 HR 1.58 (1.22,
2.06) P>0.05
Chi-square (2df) 0.96, P>0.05

27 AD, 397 cntrl,
<6.5 mmol/L vs. >6.5 mmol/L
20 other
OR 3.1 (1.2, 8.5) P<0.05
dementia
Abbreviations: AD (Alzheimer’s disease), VD (vascular dementia), NA (data not provided), cntrl (control), OR (odds
ratio), RR (relative risk) HR (hazard ratio).

Study
Evans et al.,
2000

Population
African
American, >65
yrs
Hungary

Sample size
N=77
AD 46, cntrl 31
N=39
AD 24, cntrl 15

Sarajevo, Bosnia
and Herzegovina,
>65 yrs
United States

Li et al.,
2005

United States,
>65 yrs

Merched et
al., 2000

France

Kalman et
al., 1999
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Table 2.3: Late Life Cholesterol and Alzheimer’s Disease

Lepara et
al., 2009
Lesser et al.,
2001

Total Cholesterol
Baseline Age/Year
1990

Follow up Age/Year
NA

Result (95% CI)
OR 1.018 (NA)
P=0.027

AD 70.2, cntrl 64.8

NA

N=60
AD 30, cntrl 30

AD 79.9, cntrl 77.5

NA

N=106
AD 22, cntrl 84

1986 – 1994

Median 3.26 yrs
(median age 89)

N=2141
AD 152, cntrl
1989
N=157
AD 98, cntrl 59

74.9 years

Mean follow up 5.6
yrs.

AD 160 mg/dl vs.
cntrl 160 mg/dl
P>0.05
AD 5.4 mmol/L vs.
cntrl 5.9 mmol/L
P<0.05
AD 210.0 mg/dl vs.
cntrl 194.0 mg/dl
P<0.05
HR 1.001 (1.0, 1.1)
P>0.05

77.6 case; 75.4 cntrl

NA

AD 5.44 mmol/L vs.
cntrl 5.9 mmol/L
P<0.05
Reitz et al.,
United States,
N=2820
AD 82.6, cntrl 76.4
NA
Q1 vs. Q2 OR 0.96
2004
Medicare
AD 244, VD 119,
(0.61, 1.53) P>0.05
recipients >65 yrs stroke 231, cntrl
Q1 vs. Q3 OR 0.72
2226
(0.44, 1.16) P>0.05
Q1 vs. Q4 OR 0.94
(0.58, 1.52) P>0.05
Reitz et al.,
United States,
N=1168
1992 – 1994
AD 81.5, cntrl 77.8
Q1 vs. Q2 HR 0.58
2004
Medicare
AD 119, VD 48,
(0.34, 0.79)
recipients >65 yrs cntrl 856
Q1 vs. Q3 HR 0.82
(0.48, 1.41)
Q1 vs. Q4 HR 0.48
(0.26, 0.86)
Abbreviations: AD (Alzheimer’s disease), VD (vascular dementia), NA (data not provided), cntrl (control), OR (odds
ratio), RR (relative risk) HR (hazard ratio).
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Study
Wieringa et al.,
1997
Yoshitake et
al., 1995

Population
United
Kingdom
Japan, >65 yrs

Hayden et al.,
2006

United States,
>65 years

Dufouil et al.,
2005

France, >65 yrs

Kimm et al.,
2010

Korea, > 40 yrs

Kuusisto et al.,
1997
Ghebranious et
al., 2011

Sample size
N=70
AD 37, cntrl 33
N=828
AD 42, 725 cntrl, 61
other dementia
N=3264
AD 104, cntrl 3123,
37 VD

Total Cholesterol
Baseline Age/Year
77.4 case; 77.9 cntrl /
1994
1985 – 1992

Follow up Age/Year
NA
1985 – 1992

1995-1998

81.5 case; 73.7 cntrl /
1998 – 1999

N=8506
AD 112, cntrl 8394

AD 79.1, cntrl 74.1 /
1999 – 2001

NA

N=848505
AD 1851, cntrl
846654

1992 – 1995

1993 – 2006

Result (95% CI)
AD 6.01mmol/L vs. cntrl
6.1 mmol/L P>.05
RR 1.10 (0.80, 1.51)
P>0.05
History of high cholesterol
(No; ref)
HR 0.47 (0.19, 0.98)
P<0.05
<6.2 mmol/L vs. >6.2
mmol/L
OR 1.18 (.62, 2.23)
P>0.05
Normal vs. borderline
high: Men 1.2 (1.0, 1.4)
P=0.05
Normal vs. high: Men 1.2
(1.0, 1.5) P=0.05
Normal vs. borderline:
Women 1.0 (0.9, 1.2)
P>0.05
Normal vs. high: Women
1.1 (0.9, 1.3) P>0.05
OR 0.69 (0.52, 0.92)
P=0.011
AD 259.3 mg/dl vs. cntrl
259.0 mg/dl P>0.05

Finland, 65-74
N=961
1986-1988
1990 – 1991
yrs
AD 46, cntrl 915
United States,
N=455
AD 78.2, cntrl 87.2
NA
>60 yrs. for
AD 153, cntrl 302
cases, >80 yrs
for cntrls
Abbreviations: AD (Alzheimer’s disease), VD (vascular dementia), NA (data not provided), cntrl (control), OR (odds ratio),
RR (relative risk) HR (hazard ratio)
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Total Cholesterol
Sample size
Baseline Age/Year
N=382
70 yrs / 1971 - 1972
AD 19, 337 cntrl, 23
VD, 3 other dementia

Study
Mielke et al.,
2005

Population
Sweden, 70 yrs

Siest et al.,
2000

ApoEurope

N=918
AD 489, 429 cntrl

AD 74.5, 71.0 cntrl/
1996 – 1998

NA

Tan et al.,
2003

United States

N=1026
AD 77, cntrl 949

1988 - 1989

NA

Kalman et
al., 1999
Lepara et al.,
2009

Hungary

N=39
AD 24, cntrl 15
N=60
AD 30, cntrl 30

Lesser et al.,
2001
Wieringa et
al., 1997

United States

Yoshitake et
al., 1995

Japan, >65 yrs

Ghebranious
et al., 2011

United States, >60
yrs. for cases, >80
yrs for cntrls

Sarajevo, Bosnia and
Herzegovina, >65 yrs

United Kingdom

Follow up Age/Year
88 yrs / 1989 – 1990

LDL Cholesterol
AD 70.2, cntrl 64.8

NA

AD 79.9, cntrl 77.5

NA

N=106
AD 22, cntrl 84
N=70
AD 37, cntrl 33

1986 – 1994 (median
age 86)
77.4 case; 77.9 cntrl

Median 3.26 yrs
(median age 89)
NA

N=828
AD 42, 725 cntrl, 61
other dementia
N=455
AD 153, cntrl 302

1985 – 1992

1985 – 1992

AD 78.2, cntrl 87.2

NA

Result (95% CI)
Q1 vs. Q2 HR 1.05
(0.48, 2.29) P>0.05
Q1 vs. Q3 HR 0.97
(0.43, 2.17) P>0.05
Q1 vs. Q4 HR 0.31
(0.11, 0.85) P<0.05
AD 5.62 mmol/L vs.
cntrl 5.94 mmol/L
P<0.0001
HR 0.97 (0.90, 1.05)
P>0.05
AD 82.2 mg/dl, cntrl
86.5 mg/dl P>0.05
AD 3.51 mmol/L,
cntrl 4.08 mmol/L
P<0.05
AD 132.5 mg/dl, cntrl
119.5 mg/dl P<0.05
AD 3.78 mmol/L vs.
cntrl 3.89 mmol/L
P>0.05
RR 0.89 (0.63, 1.26)
P>0.05
AD 167.6 mg/dl vs.
cntrl 169.3 mg/dl
P>0.05

Abbreviations: AD (Alzheimer’s disease), VD (vascular dementia), NA (data not provided), cntrl (control), OR (odds ratio), RR
(relative risk) HR (hazard ratio)
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Study
Reitz et al.,
2004

Population
United States,
Medicare
recipients >65 yrs

LDL Cholesterol
Sample size
Baseline Age/Year
N=2820
AD 82.6, cntrl 76.4
AD 244, VD 119,
1992 – 1994
stroke 231, cntrl 2226

Reitz et al.,
2004

United States,
Medicare
recipients >65 yrs

N=1168
AD 119, VD 48, cntrl
856

Kalman et al.,
1999

Hungary

N=39
AD 24, cntrl 15

1992 – 1994

HDL Cholesterol
AD 70.2, cntrl 64.8

Follow up Age/Year
NA

AD 81.5, cntrl 77.8
1999 – 2002

NA

Result (95% CI)
Q1 vs. Q2 OR 0.87
(0.54, 1.40) P>0.05
Q1 vs. Q3 OR 0.84
(0.52, 1.36) P>0.05
Q1 vs. Q4 OR 1.02
(0.63, 1.65) P>0.05
Q1 vs. Q2 HR 0.99
(0.59, 1.65) P>0.05
Q1 vs. Q3 HR 0.78
(0.46, 1.34) P>0.05
Q1 vs. Q4 HR 0.80
(0.46, 1.40) P>0.05

AD 49.3 mg/dl vs.
cntrl 39.4 mg/dl
P<0.05
Lepara et al.,
Sarajevo, Bosnia
N=60
AD 79.9, cntrl 77.5
NA
AD 1.26 mmol/L vs.
2009
and Herzegovina,
AD 30, cntrl 30
cntrl 1.17 mmol/L
>65 yrs
P>0.05
Lesser et al.,
United States
N=102
1986 – 1994 (median Median 3.26 yrs
AD 41.5 mg/dl, cntrl
2001
AD 21, cntrl 81
age 86)
(median age 89)
38.5 mg/dl P>0.05
Li et al., 2005
United States, >65 N=2141
74.9 years /
Mean follow up 5.6
HR 1.00 (0.99, 1.01)
yrs
AD 152, cntrl 1989
1994 – 1996
yrs.
P>0.05
Merched et al.,
France
N=157
77.6 case; 75.4 cntrl
NA
AD 1.03 mmol/L vs.
2000
AD 98, cntrl 59
cntrl 1.45 mmol/L
P<0.0001
Tan et al., 2003
United States
N=1026
76.4 male; 76.1
NA
HR 1.1 (0.93, 1.31)
AD 77, cntrl 949
female
P>0.05
Abbreviations: AD (Alzheimer’s disease), VD (vascular dementia), NA (data not provided), cntrl (control), OR (odds ratio), RR (relative
risk) HR (hazard ratio)
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Table 2.3 (Continued)

Study

Population

Wieringa et al.,
1997
Yoshitake et
al., 1995

United Kingdom

Reitz et al.,
2004

United States,
Medicare
recipients >65
years

Japan

HDL Cholesterol
Sample size
Baseline
Age/Year
N=70
77.4 case; 77.9
AD 37, cntrl 33
cntrl
N=828
1985 – 1992
AD 42, cntrl 725, 61
other dementia
N=2820
AD 82.6, cntrl
AD 244, VD 119,
76.4
stroke 231, cntrl 2226 1992 – 1994

Follow up Age/Year

Result (95% CI)

NA

AD 1.42 mmol/L vs.
cntrl 1.39 mmol/L
RR 1.06 (0.77, 1.47)
P>0.05

1985 – 1992

NA

Q1 vs. Q2 OR 0.47
(0.28, 0.78) P<0.05
Q1 vs. Q3 OR 0.58
(0.35, 0.97) P<0.05
Q1 vs. Q4 OR 0.66
(0.41, 1.08) P>0.05
Reitz et al.,
United States,
N=1168
1992 – 1994
AD 81.5, cntrl 77.8
Q1 vs. Q2 HR 0.79
2004
Medicare
AD 119, vascular
1999 – 2002
(0.44, 1.42) P>0.05
recipients >65
dementia 48, cntrl
Q1 vs. Q3 HR 0.97
856
(0.54, 1.75) P>0.05
years
Q1 vs. Q4 HR 0.70
(0.37, 1.32) P>0.05
Ghebranious et United States, >60 N=455
AD 78.2, cntrl
NA
AD 59.5 mg/dl vs.
al., 2011
yrs. for cases, >80 AD 153, cntrl 302
87.2
cntrl 62.9 mg/dl
yrs for cntrls
P>0.05
Kuusisto et al., Finland, 65-74 yrs N=961
1986-1988
1990 – 1991
OR (0.25, 1.45)
1997
AD 46, cntrl 915
P>0.05
Abbreviations: AD (Alzheimer’s disease), VD (vascular dementia), NA (data not provided), cntrl (control), OR (odds ratio), RR
(relative risk) HR (hazard ratio)
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Table 2.4: Change in Cholesterol and Alzheimer’s Disease

Study

Population

Sample size

Mielke et
al., 2010

Sweden
(women 38 –
60 yrs
baseline)
JapaneseAmericans
(males only)
United States

AD 80, cntrl
1382

Stewart et
al., 2007
Tan et al.,
2003
Notkola et
al., 1998

Finland (men
only)

Total Cholesterol
Baseline
Follow up Age/Year
Age/Year
1968 - 1969
1974–1975, 1980–1981,
1992–1993, and 2000– 2001

AD 56, cntrl
971

1965-1968

1970-1972, 1971-1974,
1980- 1982, and 1991-1993

AD 77, cntrl
949

1948 – 1953

Biannual exams from 1948 –
1990

Result (95% CI)
Stable vs. decline HR 1.66 (0.71,
3.89) P>0.05
Stable vs. increase HR 1.03
(0.35, 3.04) P>0.05
AD x time Coefficient 2.2
AD x time2 Coefficient -0.33
AD x time3 Coefficient 0.0097
Change in cholesterol over 10 yr.
period
H.R. 1.01 (0.92, 1.11)
Greater decline in total
cholesterol for AD cases
compared to controls (P<0.008)

27 AD, 397
Midlife age
1989
cntrl, 20
40 – 59
other
dementia
Abbreviations: AD (Alzheimer’s disease), VD (vascular dementia), NA (data not provided), cntrl (control), OR (odds ratio),
RR (relative risk) HR (hazard ratio)

Table 2.5: Covariates
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Study

Age

Evans et
al., 2000
Kalman et
al., 1999
Lepara et
al., 2009
Lesser et
al., 2001
Li et al.,
2005
Merched
et al.,
2000
Reitz et
al., 2004
Siest et al.,
2000
Tan et al.,
2003
Wieringa
et al.,
1997
Yoshitake
et al.,
1995
Hayden et
al., 2006

X

Sex

Edu

Smoking

Statin

APOE

BMI

Diabetes

Hyper

Heart
disease

X

X

X

X

Fasting
cholest.

X
X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X
X

X

X

X

X

X

X

X

X

X

X
X

X

X
X

X

X

X

X

X

X

X

Abbreviations : BMI (body mass index), Edu (education), hyper (hypertension)

X

X
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Study

Age

Sex

Edu

Kuusisto et
al., 1997
Ghebranious
et al., 2011
Mielke et
al., 2005
Kivipelto et
al., 2000
Mielke et
al., 2010
Solomon et
al., 2009
Chiang et
al., 2007
Notkola et
al., 1998
Stewart et
al., 2007
Dufouil et
al., 2005
Kimm et al.,
2010

X

X

X

X

X

X

X

X

Smoking

Statin

APOE

BMI

X
X

X

X

X

X

X

X

X

X

X

X

X

X

Hyper

X

X

Heart
disease

Fasting
cholest
X

X

X

X

Diabetes

X

X

X

X
X

X

X

X

X

X

X

X

X

X

X
X

X

X

X

X

X

X

X

X

X

X

X

Abbreviations : BMI (body mass index), Edu (education), hyper (hypertension)

X
X

Chapter Three: A Life Span Approach to the Epidemiology of Alzheimer’s Disease
Previous epidemiological research provides evidence for a significant relationship
between cholesterol and AD, but the direction of this relationship appears to be dependent upon if
cholesterol is measured during midlife or late life. The age dependent relationship between
cholesterol and AD makes it important for investigators to provide strong justification for how
and why specific age boundaries to define midlife or late life were used. Unfortunately, the age
boundaries used to define midlife and late life in previous studies appear to be defined arbitrarily
and justification for why specific age boundaries were chosen has been limited to citing previous
studies that used similar boundaries. Based on the literature review presented in Chapter Two,
the sample populations of previous studies that have examined the relationship between
cholesterol and AD come from a variety of ethnic and cultural backgrounds and the historical
time periods in which these populations were examined also vary between studies. These factors
should be considered when conducting research on the relationship between distinct stages of the
life span because the normative behaviors and characteristics associated with distinct life stages
are shaped by social, cultural and historical influences that are dynamic. As a result, the
normative behaviors and characteristics associated with distinct life stages may change, which
leads to the socially imposed age boundaries used to define life stages to also change. Therefore,
sufficient justification as to how and why specific age boundaries were chosen to define life
stages when conducting research needs to be provided. The dissertation research used concepts
of the life span research framework to construct age boundaries for midlife and late life that were
based on changes in the relationship between cholesterol and chronological age. This approach
was influenced by the large body of research in developmental psychology that has focused on
defining life stages according to changes in mental, cognitive and personality characteristics with
age. More importantly, this approach provides sufficient justification for how and why specific
age boundaries for midlife and late life were chosen.
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The purpose of this chapter is to describe how the concepts of a life span framework were
engaged in this dissertation research. This chapter begins by providing necessary background
information for the reader to appreciate why age boundaries for midlife and late life were
constructed according to distinct changes in the relationship between cholesterol and
chronological age. This includes an introduction to the life span research framework, a summary
of the major concepts of life span research, and brief review of pertinent research from
developmental psychology that influenced the dissertation research. Section one concludes by
briefly describing how normative behaviors associated with distinct life stages are influenced by
social, cultural and historical contexts that change over time. This is relevant to the dissertation
research because behavioral changes initiated by social, cultural and historical events may
contribute to changes in the socially constructed age boundaries associated with distinct life
stages. Section two is a detailed description of the approach used to define age boundaries for
midlife and late life according to trends in the relationship between total cholesterol and
chronological age. This chapter concludes by summarizing the findings presented in section two
and describing the contributions of a life span approach to research on the etiology, progression
and prevention of AD. This section also introduces the life course perspective and briefly
summarizes the differences between the life course and life span. The life course perspective is
introduced in this chapter because the terms life course and life span are often used
interchangeably, but there are important differences between these terms that are relevant to the
dissertation research.
Review of the Life Span Research Framework
At the most basic level, the life span is the duration of time from birth to death. The life
span of an individual organism is influence by biological and environmental characteristics and
the life span of any given organism can range from only a few minutes or hours to many decades
or even centuries. When studying the human life span, biologists and scientists in related fields
focus their efforts on understanding the endogenous changes that occur over time and identifying
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factors that influence the duration of the life span, whereas social scientists are concerned with
understanding the behavioral, emotional and psychological changes that occur over time and the
influence of exogenous factors on the life span. All areas of science have made significant
contributions to our understanding of the human life span and there is growing appreciation for
the importance of studying how the life span is influenced by interactions between endogenous
and exogenous factors. As a research framework, the life span seeks to understand the
physiological, behavioral, cognitive and psychosocial changes that occur over time and to identify
factors that contribute to and influence the within person changes that occur as people age.
Studies that utilize the life span framework may examine a prolonged period of the life span and
often times study the relationship between two or more distinct life stages (childhood, young
adulthood, middle age or old age).
The concept of life span has a long history that is believed to have originated over two
hundred years ago when German psychologist J. N. Tetens wrote the first manuscript on human
development utilizing a life span perspective (Muller-Brettel & Dixon, 1990), which
subsequently ushered in the field of developmental psychology 12 (Baltes, Reese, & Lipsitt, 1980).
The theories of several prominent developmental psychologists that describe the stages of
psychosocial (Erikson, 1980), cognitive (Piaget, 1977) and personality (Jung, 2001) development
have contributed to the evolution of life span framework. A review of specific developmental
theories is beyond the scope of this chapter, but it is necessary to understand how these theories
have contributed to understanding the life span. Sigmund Freud is arguably the most influential
developmental theorist and many theories were proposed in response to his theory of
psychosexual development. Freud’s theory emphasized that an adult’s personality is heavily
influenced by childhood experiences and that personality traits are for the most part established
within the first five to six years of life. Many developmental theorists who studied under Freud

12

G. Stanley Hall has also been credited with founding developmental psychology in the United
States (White, 1992).
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also focused their attention on childhood and adolescence. However, Carl Jung, who was a
former student of Freud’s, recognized that humans continue to develop after childhood. Jung’s
theory of personality included four periods (childhood, youth, middle life and old age), but he
emphasized the importance of development during adulthood. One of the first theorists to
acknowledge that human development is a life long process and that no one stage is more
important than the others was Erik Erikson. Erikson’s stage theory of psychosocial development
was a direct response to the psychosexual development work conducted by Sigmund Freud.
Erikson agreed with Freud that early life experiences are important to human development, but
disagreed with the notions that childhood experiences are more important to development than
later life experiences, and that the majority of human development occurs within the first few
years of life. Erikson’s original theory of psychosocial development includes eight stages from
childhood through old age. His wife Joann Erikson added a ninth stage after he passed away to
account for the growing proportion of older adults who were living into their 80’s and 90’s and
displayed unique characteristics that differentiated them from younger age groups.
Concepts of Developmental Psychology and the Life Span Framework
Seven major concepts of developmental psychology are commonly incorporated into the
life span framework (Baltes, 1987). The first concept emphasizes that human development is a
life long process and that there is no distinct age period that takes precedence in regulating human
development. The second concept states that development does not always move in a positive
direction (i.e. growth) and that periods of growth may be followed by prolonged periods in which
a developmental domain remains constant or declines. Similarly, the third concept recognizes
that development is multidirectional. This means that during the same age period some domains
may exhibit trajectories of growth whereas other domains may exhibit trajectories of decline or
remain constant. The fourth concept states that early life events influence later life outcomes and
that an individual’s developmental trajectory is shaped by environmental conditions and
individual experiences. The fifth concept acknowledges that human development is influenced
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by the social and cultural factors that may be unique to a specific generation. The sixth concept
builds upon this notion by stating that historical context along with normative age related
developmental changes and unique non-normative events all interact to influence an individual’s
development over time. Therefore, to gain a complete understanding of human development
requires taking into account the environment in which a person has lived and the unique events
and experiences that shape a person’s development from birth until death. The final concept of
the life span framework acknowledges that gaining a complete understanding of human
development requires a multidisciplinary approach. The life span framework emerged from the
field of developmental psychology and research on the psychological, cognitive and intellectual
changes that occur with age, but a complete understanding of human development also requires
knowledge of the biological, physical and behavioral changes that occur with age.
Socially Constructed Stages of the Life Span
Chronological age by itself has little meaning and age should not be accepted as a valid
explanation for a behavior or health event. The perceived significance of chronological age is
due to the correlation between chronological age and important biological, physical, cognitive,
behavioral and social characteristics or events. This correlation allows for people to generate a
preconceived notion of a person’s physical or cognitive abilities, social standing or likelihood to
experience a particular health event based on their chronological age. However, changes to the
social structure and environment in which people age may alter the timing (i.e. age) in which a
person passes through socially constructed developmental landmarks (e.g. graduating college,
marriage, starting a family). This may lead to a change in the behavior associated with a
particular age period and change the social perceptions for specific life stages such as childhood,
young adulthood, middle age and old age. As an example, most Americans in the 1990’s
believed that men should be finished having children in their mid-forties and women in their late
thirties (Settersten & Hagestad, 1996). These social expectations are beginning to change,
especially among women, as more people are choosing to start a family later in life. This is
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indicated by a steady decline in the birth rates for women between 20 and 29 years of age from
1990 to 2010, but the birth rates among women between 30 and 44 have steadily increased over
the same period (Martin et al., 2012). The observed increase in fertility may be due to women
choosing to have children at an older age in order to pursue advanced educational opportunities
because of the emphasis that has been placed on education in Western societies due to an
increasingly competitive job market. Over time this may lead to a change in the socially imposed
age boundaries associated with young adulthood and middle age.
Defining Age Boundaries for Midlife and Late Life According to
Trends in Total Cholesterol
Previous studies that have examined the relationship between cholesterol and AD define
midlife and late life using predetermined age boundaries, and the justification for why specific
boundaries were chosen is limited to citing previous studies that used similar boundaries. While
this limited justification is generally accepted, such an approach to defining life stages does not
take into account that the age periods associated with distinct life stages are influenced by the
social and cultural characteristics of the environment in which people age. Therefore, instead of
using predetermined age boundaries for midlife and late life, the dissertation research employed a
more rigorous approach that define midlife and late life that was motived by the research of
Erikson, Jung, and other theorists who constructed developmental stages based on observed
changes to cognitive, psychosocial and emotional characteristics that occur with age. This
approach allowed for age boundaries to define midlife and late life to emerge out of the observed
trends between chronological age and total cholesterol.
The results from cross-sectional and longitudinal studies indicate that cholesterol tends to
increase during young adulthood and middle age and decline during old age (Carroll et al., 2005;
Ferrara et al., 1997; P. W. Wilson et al., 1994). While dietary changes (Johansson et al., 2012),
weight loss and weight gain (Ferrara et al., 1997) and the use of cholesterol lowering medications
(Carroll et al., 2005) all contribute to the apparent relationship between cholesterol and
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chronological age, there is evidence that the rate of cholesterol synthesis by the liver also
increases through middle age and then declines later in life (Miettinen, Gylling, Raitakari,
Hallikainen, & Viikari, 2008; Tilvis et al., 2011). Visually examining the cross-sectional and
longitudinal changes in total cholesterol with age will provide insight into the developmental
trajectory of total cholesterol across the life span and suggests a novel approach to obtain age
cutoffs to define midlife and late life. The following section provides a detailed description of
how the life span framework was utilized to determine age cutoffs for midlife and late life based
on the trajectories of total cholesterol among participants of the Framingham Heart Study (FHS)
Original and Offspring Cohorts.
Methods
Age boundaries for midlife and late life were obtained by visually examining crosssectional trends in the relationship between total cholesterol and chronological age during the first
clinical examinations for the Original and Offspring Cohort. The Original and Offspring Cohorts
were examined separately to account for potential cohort effects that may influence cholesterol.
A total of 3,092 participants of the Original Cohort (60.9% of initial cohort) had a recorded
measure for total cholesterol for the first clinical examination (exam dates 1948 – 1953) and
4,928 participants of the Offspring Cohort (98.2% of initial cohort) had a recorded measure of
total cholesterol for the first clinical examination (exam dates 1971 – 1975). The age range
during the first clinical examination for participants of the Original Cohort with a recorded
measure of total cholesterol was 29 – 74 (mean 44.1 years). The mean age of the 1,987
participants of the Original Cohort who did not have a recorded measure of total cholesterol was
44.2 years (range 28 – 62), which was not significantly different compared to the participants
who did have measure of total cholesterol. The age range during the first clinical examination for
participants of the Offspring Cohort with a recorded measure of total cholesterol was 6 – 70
(mean 36.2 years).
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Scatterplots describing the relationship between total cholesterol and age during the first
clinical examination for the Original and Offspring Cohorts were created to determine if there
were any outlying values in the data (Figures 3.1 and 3.2) 13. The average measure of total
cholesterol for the Original Cohort was 221.5 mg/dl (range 96 mg/dl – 503 mg/dl) and the
majority of measures were between 191 mg/dl and 249 mg/dl. The Offspring Cohort had lower
average total cholesterol (196.0 mg/dl, range 96 mg/dl – 450 mg/dl) and the majority of measures
were between 169 mg/dl and 220 mg/dl. Subjects with recorded measures of total cholesterol that
were 1.96 standard deviations above or below what would be expected based on their age and sex
or had a history of using cholesterol lowering medications were removed from the sample
populations. This was done so that the relationship between cholesterol and chronological age
would not be influenced by unexpectedly high or low measures of cholesterol potentially due to
genetic factors or diseases that disrupt cholesterol homeostasis. Once these subjects were
removed, the trends in the cross-sectional relationship between total cholesterol and chronological
age were visually examined to identify age boundaries for midlife and late life.
Results
Age Ranges for Midlife in the Original and Offspring Cohorts: Apparent differences in
the trends for total cholesterol between the Original (Figure 3.3) and Offspring Cohorts were
observed (Figure 3.4) and there were differences in the trends of total cholesterol according to
sex in both cohorts (Figures 3.5 and 3.6). Based on Figure 3.3, total cholesterol increased
steadily among subjects of the Original Cohort who were in their early thirties to mid fifties.
However, total cholesterol increased steadily among women who were 30 to 55 years of age and
then plateaued among women in their late fifties and early sixties (Figure 3.5). In general, there
was little change in total cholesterol among men with increasing age. Total cholesterol increased
slightly for men in their thirties and fifties before plateauing between fifty and sixty years of age
13

Figure 3.1 indicates that there was one subject in the Original Cohort who was considerably
older than the other subjects during the first clinical exam and was therefore removed from the
analysis. There were no outlying values for age in the Offspring Cohort (Figure 3.2).
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(Figure 3.5). Based on Figure 3.5, midlife was defined in the Original Cohort as between 30 and
55 years of age.
The relationship between age and total cholesterol appeared to be almost perfectly linear
in the Offspring Cohort (Figure 3.4). When the Offspring Cohort was stratified according to sex,
total cholesterol appeared to plateau in men by 50 years of age, whereas the trend for total
cholesterol remained linear for women (Figure 3.6). The linear trend in total cholesterol for the
Offspring Cohort may be due to the age distribution of subjects during the first clinical exam.
While the age range during the first clinical exam for the Offspring Cohort was similar to the
Original Cohort, only 2.5 percent of subjects in the Offspring Cohort were older than 55 years of
age compared to 12.6 percent in the Original Cohort during their respective first clinical exams.
Therefore, the above analysis was repeated for the Offspring Cohort utilizing data from the
second clinical exam because 15.4 percent of the subjects were older than 55 years. A total of 43
subjects reported using cholesterol-lowering medications during the second clinical exam. There
were 143 subjects in the 95th percentile and 45 subjects in the 5th percentile for total cholesterol
(see Figure 3.7). Based on Figure 3.8, total cholesterol increased steadily until approximately 55
years of age when the trend plateaued and then began to decline. However, there were clear
differences in the trends for total cholesterol when subjects were stratified according to sex
(Figure 3.9). Women exhibited four distinct trends in total cholesterol. There was a decreasing
trend for total cholesterol among women in their late teens to late twenties, which was followed
by a steady increase among women in their early thirties to mid-forties. The trend in total
cholesterol increased slightly among women in their late forties to early fifties, which may
indicate the approaching onset of menopause. A total of 404 women reported that they had not
menstruated during the previous year due to natural causes. The average age of these women was
54.5 years and their average total cholesterol was 226.5 mg/dl. The trend in total cholesterol
plateaued among women in their late fifties and early sixties. There was an increase in total
cholesterol among women in their mid to late sixties, but it is unlikely that this increase is of any
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real meaning because there were relatively few subjects between the ages of sixty and seventy
during the second clinical exam. There were no observable fluctuations in the trend for total
cholesterol for men as was observed in women. In general there was a slight increasing trend in
total cholesterol until the mid forties at which point the trend plateaued. Based on Figure 3.9,
midlife was defined for the Offspring Cohort as between 30 and 45 years of age.
Age Cutoffs for Late Life in the Original and Offspring Cohorts: While distinct trends in
total cholesterol that may be used to define midlife in both FHS cohorts were identified, the
above analysis did not detect specific ages where the trend in total cholesterol began to decline
that may indicate the transition to late life. A potential explanation is that the age in which
cholesterol begins to decline may not actually occur within the age range of the subjects included
in the cross sectional analyses and that subjects with older chronological age would need to be
included in the sample before a decreasing trend in total cholesterol may be observed. A second
explanation for the observed trends in cholesterol is a sampling bias due to the cross sectional
design of the analysis. A decline in body mass, muscle mass and other health characteristics are
representative of an overall decline in functioning that occurs as a person approaches death (Bales
& Ritchie, 2002). Subjects with low cholesterol, especially among older age groups, may not
have been recruited to participate in the FHS due to illness or death and may explain why a
decreasing trend in total cholesterol consistent with the transition into late life was not detected in
the cross-sectional analysis. Another limitation of utilizing a cross-sectional design is that
apparent age related differences in the outcome of interest are often times confounded by the
unique characteristics of a particular age group, also known as a cohort effect. The relationship
between cholesterol and chronological age for the Original and Offspring Cohorts were plotted
separately, but the wide age distribution among participants recruited into both Cohorts means
that there is still the potential for cohort effects to be present.
The limitations of examining cross-sectional trends in cholesterol can be addressed by
utilizing the repeated measures of cholesterol that have been collected from participants of the
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FHS Original and Offspring Cohorts over the course of the study. The trajectories of total
cholesterol for subjects in the Original and Offspring Cohorts who were within their respective
age ranges for midlife during the first clinical exam were examined longitudinally to determine
late life according to the age of onset for a prolonged decline in total cholesterol for men and
women. Subjects who had a history of ever using cholesterol-lowering medications [Original
Cohort n= 493 (9.7%); Offspring Cohort n= 926 (18.5%)] were excluded from the analysis and
all measures of total cholesterol were within the 5th and 95th percentiles according to age and
gender adjusted norms.
The trajectories of total cholesterol for the Original and Offspring Cohorts both had a
parabolic shape in which there was a prolonged increasing trend in total cholesterol, followed by
a plateau and then a decreasing trend. Despite the similarities in the overall trajectories of total
cholesterol, there were apparent differences between the Original and Offspring cohorts and when
the trajectories were stratified according to sex. The longitudinal trajectory of total cholesterol
for men and women in the Original Cohort indicates that total cholesterol began to decline at
approximately 65 years of age (Figure 3.10). The accelerated decline in total cholesterol for men
was preceded by a slight decline in total cholesterol beginning at roughly 50 years of age,
whereas the trajectory of total cholesterol for women continued to increase until 55 and remained
constant until 65 years of age (Figure 3.11). Therefore, based on the ages in which changes in
the trajectory of total cholesterol were observed in Figures 3.10 and 3.11 late life will be defined
as 65 years of age or older in the Original Cohort.
The overall trajectory of total cholesterol for the Offspring Cohort followed a smooth
trend and there were no abrupt changes in the trajectories of total cholesterol (Figure 3.12), but
differences in the longitudinal trends of total cholesterol between men and women were visually
apparent once the trajectories of total cholesterol were stratified according to sex (Figure 3.13).
Total cholesterol began to decline at approximately 60 years of age for women, but similar to
what was observed in the Original Cohort, the initial decline in total cholesterol for men occurred
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earlier at approximately 50 years of age. Based on Figure 3.13, late life will be defined in the
Offspring Cohort as 60 years of age and older.
Summary
Based on the cross-sectional and longitudinal trends between cholesterol and
chronological age, midlife was defined as between 30 and 55 years of age for the Original Cohort
and between 30 and 45 years of age for the Offspring Cohort. Late life was defined as 65 years
of age in the Original Cohort and 60 years of age in the Offspring Cohort 14. These definitions for
midlife and late life are similar to those used in previous studies, but the approach employed in
the dissertation research provides stronger justification for the proposed age cutoffs than citing
previous research. A narrower age range was chosen for the Offspring Cohort because of the
observed increase in total cholesterol among women that occurred at approximately 50 years of
age. The slight increase in total cholesterol may be partly due to the onset of menopause. This
trend was not observed among women in the Original Cohort and data regarding the onset of
menopause was not collected during the first clinical exam for the Original Cohort, which
prevented the potential influence of menopause on cholesterol from being examined. Subtle
differences in the average age at which cholesterol began to decline between the Original and
Offspring Cohort were also observed. Based on the longitudinal changes in cholesterol with
advancing age, late life was defined as 65 years of age and older for the Original Cohort and 60
years of age and older for the Offspring Cohort. The younger age cutoff for late life used for the
Offspring Cohort does not suggest these participants are approaching late life at a younger age
compared to participants of the Original Cohort. Rather, the younger average age in which total
cholesterol begins to decline may be due to an increased understanding of the importance of
controlling high cholesterol. The most apparent differences between the Original and Offspring
14

These definitions for late life are not meant to imply that adults who are 60 or 65 years of age
and older are a homogeneous group. It is generally accepted that there are specific stages within
late life (old, old-old and oldest old) that have distinct physical, cognitive and psychosocial
characteristics.
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Cohorts in the longitudinal trajectories of total cholesterol is that participants of the Original
Cohort had much higher total cholesterol by the time they were 60 years of age due to a rapid
increase in total cholesterol from approximately 30 to 55 years of age, whereas participants of the
Offspring Cohort exhibited a much more subtle increase in total cholesterol during the same
period and therefore had much lower cholesterol by the time they were 60 years of age. These
differences in total cholesterol may be due to differences in diet, exercise, smoking history and
other factors that directly modify total cholesterol. By the time the Offspring Cohort was initiated
in 1971, the discoveries from several studies that utilized data from the Original Cohort had made
significant progress towards identifying risk factors for heart disease (Dawber, 1960; Kannel,
1967; Kannel, Dawber, Kagan, Revotskie, & Stokes, 1961). These discoveries contributed to the
growing social awareness of the importance of controlling high cholesterol, high blood pressure,
engaging in regular exercise and the dangers of smoking. The influence of the greater social
awareness is reflected by the lower total cholesterol, on average, of the Offspring Cohort
compared to the Original Cohort. The Offspring Cohort had lower average total cholesterol
(196.0 mg/dl, range 96 mg/dl – 450 mg/dl) and the majority of measures were between 169 mg/dl
and 220 mg/dl. The difference in average total cholesterol between the Offspring and Original
Cohorts during their respective examinations may also be due to differences in the use of
cholesterol lowering medications between the two cohorts. Data regarding the use of cholesterol
lowering medications was not collected until the sixth clinical examination for the Original
Cohort (years 1958 – 1963) because the benefits of niacin, also known as vitamin B3, for
controlling high cholesterol were not reported until 1955 by Altschul et al. (1955). By the time
the Offspring Cohort was initiated in 1971, several anti-cholesterol agents were available and the
use of cholesterol lowering medications has been assessed during each clinical examination for
the Offspring Cohort.
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Contributions of the Life Span Framework to Alzheimer’s Disease Research
Alzheimer’s disease is characterized by the accumulation of neuritic plaques that are
comprised of the amyloid beta (Aβ) protein and neurofibrillary tangles that form from the
hyperphosphorylation of the protein tau in the brain (McKhann et al., 2011). The progressive
decline in cognitive functioning associated with AD does not begin to occur until the
accumulation of these neuritic plaques and neurofibrillary tangles surpasses a critical threshold.
This threshold model of AD was proposed by Blessed, Tomlinson, and Roth (1968) based on
their findings that older adults with dementia had significantly higher plaque count compared to
subjects without dementia, but the correlation between plaque count and dementia symptoms was
not significant among subjects with advanced dementia. This led to the hypothesis that sufficient
damage to the brain has occurred once the number of plaques in the brain surpasses a critical
threshold, and continued accumulation does not necessarily result in more severe dementia
symptoms (Blessed et al., 1968). The poor correlation between brain pathology and degree of
cognitive impairment (Bennett et al., 2006; Giannakopoulos et al., 2003; Haroutunian et al., 2008;
Knopman et al., 2003) suggests that the relationship is influenced by a person’s ability to engage
other cognitive processes to compensate for increasing neuropathology (Stern, 2002). This
supports the hypothesis that a critical threshold of brain pathology varies from person to person,
which adds an additional challenge to determining where in the disease process a critical
threshold is located. An active model of reserve provides an explanation for why people with
anatomically similar brains and similar pathology may express differing degrees of cognitive
impairment. An active model of reserve is supported by evidence that older adults with higher
educational attainment engage additional regions of the brain when performing cognitive tasks
(Scarmeas et al., 2003; Springer, McIntosh, Winocur, & Grady, 2005), have higher cognitive
function despite similar AD pathology (Bennett et al., 2003), and have greater brain pathology at
time of AD diagnosis (Stern, Alexander, Prohovnik, & Mayeux, 1992) compared to older adults
with less educational attainment. These findings have important implications when interpreted
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using a life span framework because plausible pathways for the observed associations between
psychosocial characteristics during childhood and the risk for dementia during old age become
apparent. As an example, a child born into a family of high socioeconomic status will likely be
provided with educational opportunities and a mentally stimulating environment from a young
age. These early life advantages may contribute to additional advantages later in life, such as
earning a college degree and working in a stimulating environment. Advantages accumulate over
the life span and contribute to greater brain and cognitive reserves during old age. This decreases
a person’s risk for AD by increasing the critical threshold that pathological changes to the brain
must surpass before cognitive declines are observed.
The threshold model for AD has had significant implications for treatment and prevention
because it has increased the urgency to determine when in the disease process a person who
develops AD crosses the critical threshold. Available treatments for AD temporarily improve
clinical symptoms and slow the progression of the disease (S. L. Rogers, Farlow, Doody, Mohs,
& Friedhoff, 1998; Rosler et al., 1999), but there are currently no treatments that reverse or stop
the declines in cognitive and physical functioning associated with AD. This is possibly due to
treatments being administered too late in the disease process when irreversible damage to the
brain has already occurred (Roh & Holtzman, 2012). This has led to a significant shift in the
therapeutic approach to AD from administering disease-modifying treatments to patients who are
in the mild to moderate stages of the disease to the preclinical stages of the disease before
cognitive symptoms are observed. The challenge is determining how early in the disease process
the critical threshold is crossed and sufficient and irreversible damage to the brain has occurred.
Advances in brain imaging techniques and the discovery of biomarkers that reflect pathological
changes to the brain have allowed for the presence of AD neuropathology to be detected many
years before clinical symptoms associated with AD are observed (Jack et al., 2013; Jack et al.,
2010). The period between the onset of AD neuropathology and clinically observable symptoms
represents the preclinical stages of AD (Jack, Albert, et al., 2011). Adults with biomarker
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evidence for accumulation of beta-amyloid (Aβ) protein in the brain, neurodegeneration, or both,
but no detectable cognitive impairment are believed to be in the early stages of preclinical AD;
adults with biomarker evidence for Aβ accumulation or neurodegeneration who exhibit subtle
impairment on cognitive assessments are believed to be on the verge of progressing from
preclinical AD into mild cognitive impairment (Sperling et al., 2011). Clinical trials to determine
efficacy of disease-modifying treatments administered during preclinical AD will need to be large
and will require prolonged follow up periods (Blennow, Hampel, & Zetterberg, 2014).
Fortunately, these challenges have not discouraged investigation into this area of research and
several programs are in place for clinical trials on disease-modifying agents and preclinical AD
(Bateman et al., 2012; Garber, 2012; Reiman, Langbaum, & Tariot, 2010).
A life span approach also has implications for research focused on determining if there is
a period within the life span that interventions may have the greatest lasting effects. In
epidemiology, a critical period is a limited time frame in which an exposure has a greater
protective or adverse effect for a disease compared to if the exposure is present outside of the
critical period (Kuh, Ben-Shlomo, Lynch, Hallqvist, & Power, 2003). Midlife is a potential
critical period for dementia due to the identification of factors related to vascular health
associated with an increased risk for dementia, including hypertension (Kivipelto et al., 2000)
high cholesterol (Kivipelto et al., 2002) and obesity (Whitmer, Gunderson, Quesenberry, Zhou, &
Yaffe, 2007). The relationship between middle age and cognitive functioning later in life is
supported by evidence that pathological changes to the brain associated with AD begin many
years or even decades prior to the onset of cognitive decline (Jack et al., 2013). There is evidence
that hypertension and related conditions negatively impact the brain by decreasing blood flow to
the brain (Beason-Held, Moghekar, Zonderman, Kraut, & Resnick, 2007). The decrease in blood
flow deprives the brain of oxygen and may lead to brain infarcts or “mini” strokes. Over time the
damage from these brain infarcts accumulates, making the brain more sensitive to AD
neuropathology (Kalaria, 2010) and increasing the likelihood of developing AD (Vermeer et al.,
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2003). Furthermore, the inflammatory affects of poor vascular health on the brain may contribute
to Aβ deposition (Lee et al., 2008). These plausible biological mechanisms suggest that
interventions targeting vascular risk factors during midlife may substantially reduce the future
prevalence of dementia (Barnes & Yaffe, 2011). The challenge, however, is several decades must
pass before the effectiveness of interventions administered during middle age for cognitive
functioning during old age can be determined. Furthermore, there may be a threshold effect in
which a person must engage in regular exercise, consume a healthy diet or other positive health
behaviors for a prolonged period of time for benefits to have a lasting effect into old age. This
increases the importance of encouraging people to adopt positive health behaviors during
adolescence and young adulthood so these behaviors become a part of their everyday routines and
carry through middle age and into old age.
The vast majority of epidemiological studies have focused on midlife as a potential
critical period for AD, but it is necessary to consider the importance of childhood and
adolescence when examining AD. These life stages are potential critical periods because it is
during childhood and adolescence that foundational experiences occur that often times shape
health behaviors. These behaviors, when reinforced and carried through life as habits, may
influence cognitive development through the life span. Childhood and adolescence have
potentially significant implications to AD research when interpreted in the contexts of cumulative
advantage and threshold models of AD, which points to the need for careful selection of controls
during the design stage of a study that takes into account early life biopsychosocial
characteristics.
Differences between the Life Span and Life Course
The life span framework acknowledges that the social and cultural environment in which
people age changes over time and that these changes influence human development. An
argument can be made that the fifth and sixth concepts of the life span framework add an
additional layer of complexity that requires a life course perspective. The life course is the
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temporal sequence of events, transitions, and trajectories that occur within socially constructed
life domains (e.g. education, work, family) from birth until death, such as graduating from high
school, entering the workforce, marriage or retirement (Elder, 2000; Elder, Johnson, & Crosnoe,
2003). Glen Elder and his colleagues have proposed five principals of the life course framework
(Elder et al., 2003): (1) principal of life span development, (2) principle of agency, (3) principle
of time and place, (4) principle of timing, and (5) the principle of linked lives. The principle of
life span development is similar to the first concept of the life span framework and emphasizes
that human development and aging is an ongoing process from birth until death. The remaining
principles distinguish the life course framework from the life span framework. The second
principle recognizes that an individual’s behavior and choices are influenced by the social
constraints that are presented to them. The third principal of time and place acknowledges that an
individual’s life course is influenced by historical events and geographic processes that shape the
society and culture in which they live. The fourth principle of timing acknowledges that the
influential effects of specific events depend on the timing (i.e. age and historic period) in which
the event occurs. The fifth principle emphasizes that successive generations are connected
through shared relationships that emerge, both predictably and vicariously, from membership in a
vast array of social groups throughout life.
There are similarities between the life span and life course perspectives that need to be
acknowledged. First, the life course and the life span recognize that human development and
aging is a life long process that is ongoing from birth until death. Second, both constructs
acknowledge the relationship between early life events and later life outcomes. Finally, both life
course and life span emphasize the influence of characteristic social and cultural environments on
human development and aging. These similarities often lead to confusion as when to use the term
life span or life course, but there are important differences between these two terms. First, the life
course perspective emphasizes that people live their lives interdependently (Alwin, 2012; Elder,
1994), meaning people are influenced by the choices, behaviors and actions of people around
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them (Elder et al., 2003). The life span perspective does not acknowledge this interdependence in
which people live their lives. Second, there is an important difference between the life span and
life course in regards to the treatment of past time. Life span constrains the past to early life
experiences, situations, and influences that occur once a person is born, whereas the life course
recognizes that the pre-birth past influence of both current and anticipated future perceptions and
behaviors. This needs to be acknowledged because lessons learned from the experiences of
previous generations (e.g. parents, grandparents, societal/cultural events) can be passed down
from generation to generation, which is not considered in the life span framework. Finally, the
life course recognizes that the choices and decisions made in the present may be shaped by
anticipation of what may happen in the future (Hosier, Downer, Watkins, & Zanjani, 2012b),
which is also not considered in the life span framework. An example of how the anticipation of
future events may influence present-day behavior is the use of cancer screening among women
with a family history of breast cancer (Andersen, Smith, Meischke, Bowen, & Urban, 2003;
Isaacs et al., 2002). Additional examples of this notion are readily available in scientific
literature, but critical theoretical development of the future aspect of the life course is lacking.
The life course perspective emphasizes the trajectories of socially constructed domains,
but health is an additional domain that plays a significant role in the life course. Incorporating
health into the life course perspective makes this a useful approach for conducting AD research
because genetic, physiological, behavioral and social factors all contribute to the etiology and
progression of AD. A thorough discussion of the life course and the implications of a life course
perspective for AD research are discussed in chapter six of this dissertation.
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Figure 3.1: Scatter Plot of Total Cholesterol According to Chronological Age,
Original Cohort

Figure 3.2: Scatter plot of total cholesterol according to chronological age,
Offspring Cohort

Figure 3.3: Cross-Sectional Trend in Total Cholesterol, Original Cohort
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Figure 3.4: Cross-Sectional Trend in Total Cholesterol, Offspring Cohort

Figure 3.5: Cross-Sectional Trends in Total Cholesterol Stratified by Sex, Original Cohort

Figure 3.6: Cross-Sectional Trends in Total Cholesterol Stratified by Sex, Offspring Cohort
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Figure 3.7: Scatter Plot of Total Cholesterol According to Chronological Age, Offspring
Cohort (Exam 2)

Figure 3.8: Cross-Sectional Trends in Total Cholesterol, Offspring Cohort (Exam 2)

Figure 3.9: Cross-Sectional Trends in Total Cholesterol Stratified by Sex, Offspring Cohort
(Exam 2)
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Figure 3.10: Longitudinal trends in total cholesterol, Original Cohort

Figure 3.11: Longitudinal Trends in Total Cholesterol Stratified by Sex, Original Cohort

Figure 3.12: Longitudinal Trend in Total Cholesterol, Offspring Cohort
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Figure 3.13: Longitudinal Trends in Total Cholesterol Stratified by Sex, Offspring Cohort
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Chapter Four: Research Design and Methodology
This dissertation presents a secondary analysis of cognitive, phenotypic and genetic data
collected from subjects of the FHS Original Cohort and Offspring Cohort. A brief overview of
the study design and methodology for each of the specific aims of the dissertation research is first
provided followed by an overview of the FHS and detailed descriptions of the sample populations
and statistical methods for each specific aim, which are provided in subsequent sections of this
chapter.
Overview of Specific Aims
The research addressed three specific aims. Aim One utilized a cross-sectional study
design and involved examining cognitive data collected from participants of the FHS Offspring
Cohort between 1999 and 2005 using a neuropsychological battery to calculate a series of three
composite scores of cognitive functioning: (1) a composite score that provided equal weight to
each subtest included in the neuropsychological battery; (2) a composite score that provided equal
weight to each cognitive domain assessed by the neuropsychological battery; and (3) an
abbreviated summary score comprised of the subtests that assessed learning and memory.
Receiver operating characteristic (ROC) analysis was conducted to determine which of the three
summary scores was best able to differentiate between participants who were classified as having
normal cognition, test-based impaired learning and memory (ILMTB), test-based multi-domain
impaired (MDITB), or dementia based on the area under the curve (AUC), sensitivity, specificity,
positive predictive value, negative predictive value and overall accuracy for each of the summary
scores. The summary score that was best able to differentiate between the cognitive groups was
used as the measure of cognitive functioning in Aim Three. Aim Two utilized a longitudinal
study design. Repeated measures of total cholesterol and HDL cholesterol collected from
subjects of the FHS Original Cohort between 1948 and 2005 were used to model the longitudinal
trajectories of total cholesterol, HDL cholesterol and total/HDL ratio from midlife to late life.
Generalized additive mixed modeling allowed for the longitudinal trajectories of total cholesterol,
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HDL cholesterol and total/HDL ratio according to AD status to be visually examined. Aim Three
also utilized a longitudinal study design. For this aim, repeated measures of total cholesterol
collected from participants of the FHS Offspring Cohort between 1971 and 2008 were used to
predict subject-specific trajectories of total cholesterol using a growth-curve approach via mixed
effects regression models. The subject-specific trajectories of cholesterol were plotted according
to degree of cognitive functioning. This allowed for visual interpretations of the relationship
between cognitive functioning and subject-specific trajectories of cholesterol to be made.
The Framingham Heart Study
The FHS is an ongoing prospective cohort study of residents from Framingham,
Massachusetts created with the goal of generating knowledge on the onset and progression of
cardiovascular disease and lung disease, as well as genetic and environmental risk factors for
these diseases. The FHS includes a total of five cohorts: (1) Original, (2) Offspring, (3) Third
Generation, (4) Omni 1, and (5) Omni 2.
The FHS Original Cohort was initiated in 1948 and included adults residing in
Framingham, Massachusetts who did not have cardiovascular disease. A total of 5079
participants between the ages of 28 and 74 (mean age 44.2 years) completed a baseline clinical
exam between 1948 and 1953. Thirty clinical examinations have been completed since 1948, and
141 participants (mean age 92, range 88-102) attended the thirtieth clinical exam, which
concluded in 2010.
The Offspring Cohort was initiated in 1971 and includes children, and their spouses, who
had one or both parents who were subjects of the Original Cohort (Feinleib, Kannel, Garrison,
McNamara, & Castelli, 1975). A total of 5124 subjects between the ages of 5 and 70 (mean age
36) attended the first clinical exam between 1971 and 1975. Eight clinical exams have been
completed since 1971 and 3021 (mean age 67, range 40 – 93) subjects attended the most recent
examination, which concluded in 2008. Data collection for the ninth clinical examination began
in 2011.
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Beginning in 2002, 4095 individuals who had one or more parents who were subjects in
the FHS Offspring Cohort attended the first clinical examination for the Third Generation Cohort
(Splansky et al., 2007). Only two clinical exams have been completed since 2003.
The FHS also includes two Omni Cohorts, which were initiated to reflect the increasing
ethnic diversity of Framingham Massachusetts. The Omni 1 cohort was initiated in 1994 and is
comprised of 506 residents of Framingham, Massachusetts and surrounding areas who responded
to being a member of a minority group (Quan et al., 1997). The third clinical exam was
completed in 2008 and was attended by 298 subjects. Data collection for the fourth examination
is ongoing. A second Omni cohort began in 2003 and included 410 subjects from Framingham
Massachusetts. The Omni 2 cohort includes subjects who are unrelated to subjects of the Omni 1
cohort, but many of the subjects in this cohort are related to subjects in the Omni 1 cohort. The
Omni Cohorts include subjects of African-American, Hispanic, Asian, Indian, and Native
American descent.
During each wave of data collection for the five cohorts, subjects received an extensive
physical examination, which included non-invasive tests (e.g. body composition, x-ray, and
pulmonary function), lab tests (e.g. lipid and hormone levels), and a health history questionnaire
to assess health behavior and the onset of any health conditions since the previous wave of data
collection. DNA collection from living members of the Original and Offspring Cohorts began in
the 1980’s and genotyping has been performed using Affymetrix 100K and 550K SNP chips
(Cupples et al., 2007). Current information regarding the status, recruitment and data collection
for the five FHS cohorts can be found at http://www.framinghamheartstudy.org.
Aim One: Summary Score for the FHS Neuropsychological Battery
Sample Population
A total of 2557 members of the FHS Offspring Cohort received a neuropsychological
battery between 1999 and 2005. There were 1713 (67.0%) subjects from the Offspring Cohort
who attended a follow-up evaluation prior to 2007 in which they received the same
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neuropsychological battery. There were 325 members of the FHS Original Cohort who also
received a neuropsychological battery between 1999 and 2005. Members of the Original Cohort
were excluded from all analyses in Aim One because of significant differences in cognitive
functioning between the Original and Offspring Cohorts that remain after adjusting for education,
age, and sex (Au et al., 2004). Subjects of the Offspring Cohort with missing data for one or more
subtests of the neuropsychological battery during the baseline examination (n=54, 2.1%) were
excluded from the final sample. This was done so the summary scores for each subject would
reflect the same combination of overall measures of cognitive functioning. The final sample
included 2503 subjects from the FHS Offspring Cohort.
The FHS Neuropsychological Battery
The cognitive assessments included in neuropsychological battery were the Boston
Naming Test (Goodglass & Kaplan, 1983), Trail Making Tests A and B (TMT A, B) (Armitage,
1946), Finger Tapping Test (Shimoyama, Ninchoji, & Uemura, 1990), Hooper Visual
Organization Test (Hooper, 1966), Wide Range Achievement Test-3 Reading (WRAT)
(Wilkinson, 1993), and subtests from the Wechsler Memory Scale (Wechsler, 1945; logical
memory immediate and delayed recall, paired-associate memory, visual reproduction immediate
and delayed recall), and Wechsler Adult Intelligence Scale (Wechsler, 1955; similarities). A brief
description of the cognitive abilities examined by each assessment is provided in the Table 4.1.
A higher score on each subtest of the neuropsychological battery, with the exception of the TMT
A and B, indicates better cognitive function. The TMT A and B are timed assessments that
require a subject to connect a random alphabetic sequence (TMT A) and alphanumeric sequence
(TMT B). The times to complete the TMT A and TMT B subtests were used to create an
additional measure that represented cognitive flexibility by calculating TMT B minus TMT A
(Arbuthnott & Frank, 2000; Corrigan & Hinkeldey, 1987).
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Case Definitions for Dementia and Cognitive Impairment
Incident cases of dementia in the Offspring Cohort have been recorded as part of the
Epidemiology of Dementia study since 1986 (Bachman et al., 1992; Bachman et al., 1993) 15.
Thirty-six subjects diagnosed with dementia received the FHS neuropsychological battery
between 1999 and 2005, but seven cases (n=5 AD; n=2 other dementia) had missing data for one
or more assessments.
Subjects included in the final sample were randomized to either a training set or
validation set. The training set was used to estimate the effects of age, sex (coded as 0=male,
1=female), and education (<high school, some college, college degree) on cognitive performance
among subjects with normal cognition (absent of dementia or a decline >1.5 standard deviations
on one or more subtests). The effects of these characteristics on cognitive performance were
determined using a univariate model (UV; Table 4.2) in which each variable was examined
separately and a multivariable (MV) model that included age, sex, and education in the same
model. The regression coefficients from the MV model were used to calculate predicted scores
for each of the cognitive assessments based on a subject’s age, sex and educational attainment
(Table 4.3). The cognitive assessments included in the FHS neuropsychological battery were
used to classify subjects into the following cognitive groups: (1) normal cognition (NC); (2) testbased impaired learning and memory (ILMTB); and (3) test-based multidomain impaired (MDITB).
A classification of ILMTB was given to subjects with no dementia and who had impaired
performance on one or more assessments of learning and memory, but non-impaired performance
on all other assessments (Abner et al., 2012). A classification of MDITB was given to participants
with no dementia and who had impaired performance on one or more assessments in the
neuropsychological battery, which could include learning and memory subtests. A classification
of NC was given to participants who did not have an impaired performance on any assessments.
15

A more detailed description of the protocol used to diagnose dementia in the FHS is provided
in the methods for Aim Two.
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Impaired performance for each assessment was defined as >1.5 SD below age, sex, and education
expected norms based on the estimates for age, sex, and education obtained from the test sample.
This definition of impairment is consistent with the criteria provided by the National Institute on
Aging- Alzheimer’s Association workgroup (Albert et al., 2011).
Generating Summary Scores for the FHS Neuropsychological Battery
Composite Subtests Summary Score: All of the assessments included in the FHS
neuropsychological battery, with the exception of the Finger Tapping Test and WRAT, and the
calculated measure of cognitive flexibility (TMT B minus TMT A) were included in this
summary score. The Finger Tapping Test was excluded because this assessment is frequently
used to measure motor functioning (Volkow et al., 1998). The WRAT was excluded because this
assessment is a word identification test that measures literacy (Davis, Michielutte, Askov,
Williams, & Weiss, 1998) and is often used as a proxy for educational quality (Manly, Jacobs,
Touradji, Small, & Stern, 2002). The composite subtests summary score was calculated by first
transforming the score of each assessment into a z score by subtracting an individual subject’s
assessment score minus the sample mean and dividing by the standard deviation. The z scores for
TMT A and B and cognitive flexibility were multiplied by -1 to account for these being timed
assessments. Once a z score was calculated for each assessment, the average of the z scores was
calculated to obtain the summary score.
Learning and Memory Summary Score: The learning/memory summary score was
obtained by calculating the average of the six z-scores for the subtests that assessed learning and
memory. The average of the z-scores was used for the summary score as opposed to the sum of
the scores so that each assessment provided equal weight to the summary score.
Composite Domains Summary Score: The specific cognitive domains assessed by the FHS
neuropsychological battery were determined by conducting a factor analysis, followed by an
orthogonal (varimax) rotation. A total of three factors were extracted (eigenvalue >1) and a
fourth factor with an eigenvalue of 0.9 was also included (remaining eigenvalues <0.71). The
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following subtests loaded onto the four factors based on a rotated factor pattern score above 0.5:
visual/spatial memory [Visual Memory Immediate Recall (0.90), Visual Memory Delayed Recall
(0.9), Hooper Visual Organization Test (0.5)]; verbal memory [Logical Memory Immediate
Recall (0.93), Logical Memory Delayed Recall (0.90)]; new learning [Paired Associates
Immediate Recall (0.88), Paired Associates Delayed Recall (0.9)]; and attention/concentration
[TMT A (0.87), TMT B (0.77)]. Cognitive flexibility was added to the attention/concentration
domain. Once these cognitive domains were identified, the next step was to sum the scores for
the subtests to create a total score for each specific cognitive domain. These total scores were
then transformed into z scores and the average of these z scores was calculated to obtain the
composite domain summary score.
Statistical Analysis
Receiver operator characteristic (ROC) analysis was conducted to obtain ROC curves for
each of the summary scores. The area under the curve (AUC) is interpreted as the probability that
a randomly selected subject who is a case (dementia, ILMTB, or MDITB) has a lower summary
score than a randomly selected subject who was classified as having normal cognition. To
control for the effects of age, sex and educational attainment, the residuals of the summary scores
were obtained by calculating the difference between the observed summary score and predicted
summary score given a subject’s age, sex and educational attainment. The ROC analysis was
also used to determine the sensitivity (proportion of cases who were correctly identified),
specificity (the proportion of controls who are correctly identified), positive predictive value
(ppv; the probability that subjects who test positive for the disease are true cases), negative
predictive value (npv; the probability that subjects who test negative are true controls), and
diagnostic accuracy (proportion of cases and controls who are correctly identified) for the cutpoint of the residuals for each summary score. The ROC curve analysis was conducted using
data from the validation sample.
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Aim Two: Differences in the Longitudinal Trajectories of Cholesterol from Midlife to Late
Life According to Alzheimer’s Disease Status
Sample Population
A total of 5079 subjects of the FHS Original Cohort between the ages of 28 and 74 (mean
age 44.2 years) completed a baseline clinical exam between 1948 and 1953. Thirty clinical
examinations have been completed since 1948 and 141 participants (mean age 92, range 88-102)
attended the thirtieth clinical exam, which concluded in 2010. A sub-cohort of subjects from the
FHS Original Cohort who were said to be absent of dementia was established from 1976 to 1978
with the purpose of recording incident cases of dementia (Bachman et al., 1993). A total of 3210
subjects were said to be absent of dementia and these subjects have been evaluated during each
biennial examination to assess dementia status (yes / no), date last known to be cognitively intact,
and date of incident dementia, death or censoring. Because the purpose of this aim was to
examine trajectories of cholesterol from midlife to late life, subjects who were younger than 30
years (n=21, <1%) or older than 55 years (n=174, 5.4%) during the first clinical exam were
excluded from the final sample. An additional 124 subjects (3.9%) who were younger than 65
years of age when they were last known to be cognitively intact were also excluded. The age
cutoffs for midlife (age 30 – 55) and late life (age > 65) were based on distinct trends in the
relationship between total cholesterol and chronological age among subjects of the Original
Cohort (see Chapter Three for a detailed description of how the definitions for midlife and late
life were obtained).
Diagnosis of Dementia in the FHS Original Cohort
The methods used in the FHS to diagnose dementia have been previously described
(Bachman et al., 1992; Bachman et al., 1993). From 1976 to 1978 surviving members of the FHS
Original Cohort were screened for dementia using the Mini Mental State Exam (MMSE; Folstein,
Folstein, & McHugh, 1975) to establish a dementia-free cohort of 3210 subjects. These 3210
subjects received the MMSE during each subsequent clinical examination. Subjects who scored
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below the education-adjusted cut-off score on the MMSE (score < 22 for < 7 yrs. Education;
score < 24 for 8 to 11 yrs. Education; score < 25 for high school graduate; and score < 26 for any
education beyond high school), declined three or more points since the previous examination, or
were referred by themselves, a family member, family physician, or FHS physician were given a
comprehensive neuropsychological battery. The neuropsychological battery included subtests
that assessed the following cognitive domains: (1) verbal and visual learning, (2) attention, (3)
language, (4) visuospatial construction, and (5) abstract thinking (Farmer et al., 1987). A subject
was said to be cognitively impaired if they performed at a level one or more standard deviations
below age-adjusted norms on three or more of the five cognitive domains assessed by the
neuropsychological battery. An expert panel reviewed all available records for subjects who met
the criteria for cognitive impairment to determine if the cognitive impairment was likely due to
dementia. Subjects were considered as having dementia if they met the criteria for cognitive
impairment for at least one year and exhibited progressive cognitive decline over a prolonged
period. For cases of dementia, the panel also reviewed dementia severity (mild or moderate) and
dementia subtype (Alzheimer’s disease [AD], AD with stroke, vascular dementia [VaD], AD with
VaD [mixed dementia], or other). For the purposes of this study, only subjects diagnosed with
AD were included in the final sample.
Measures of Cholesterol
Measures for total cholesterol and HDL cholesterol were collected from participants of
the FHS Original Cohort using standard laboratory procedures (Abel, Levy, Brodie, & Kendall,
1952). Fasting measures for total cholesterol were collected during twenty clinical examinations
(clinical exams 1-11, 13-15, 20, 22, 24-27) and measures of HDL cholesterol were collected
during ten clinical examinations (clinical exams 9-11, 15, 20, 22, and 24-27). Total/HDL ratio
was calculated by dividing the measure of total cholesterol by the measure of HDL cholesterol.
The distributions for total/HDL ratios were highly right skewed so log transformations were used.
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Statistical Analysis
The demographic characteristics of the final sample were described according to AD
status (non-demented or AD). T-tests were used to compare group means for continuous
variables and chi-square tests were used to compare group differences for categorical variables.
The trajectories of total cholesterol, HDL cholesterol, and log-total/HDL ratio according to AD
status were modeled using generalized additive mixed models (GAMM; Lin & Zhang, 1999)
implemented using the gamm4 package (S. Wood & Scheipl, 2013) in R (http://www.rproject.org). GAMM are semi-parametric models that utilize a data driven approach to model a
non-linear relationship between the dependent and independent variables as opposed to including
quadratic, cubic or higher level polynomial terms. The general form of the GAMM used for this
study is:
𝑔�𝑢𝑖𝑗 � = 𝑿𝑻𝒊 𝜷 + 𝑠𝐴𝐷 �𝑥𝑖𝑗 �𝐴𝐷𝑖 + 𝑠1−𝐴𝐷 �𝑥𝑖𝑗 �(1 − 𝐴𝐷𝑖 ) + 𝑏𝑖 + 𝜖𝑖𝑗

(4.1)

where 𝑢𝑖𝑗 = E(Yij) is the expected value of cholesterol for the ith subject during the jth

observation given the covariates included in the model (see Covariates), and bi is a subject-

specific random effect that allows for the baseline value of cholesterol to vary for each subject;
g(

is the link function that specifies the relationship between the expected value of cholesterol
)

and the covariates included in the model. The link function for the model was the identity
function because total, HDL, and log-total/HDL cholesterol ratio were continuous variables. Xi is
a k-length vector comprising the k time-invariant covariates of subject i and 𝜷 is a k-length vector
of the fixed effects for the corresponding k covariates; xij is the age of the ith subject during the

jth observation; sAD and s1-AD are the smoothing terms that were generated for subjects with AD
and subjects without dementia, respectively. ADi is an indicator variable denoting AD status in
the ith subject. Since every subject is either AD or non-demented, the term 1-ADi specifies
subjects who do not have AD and prevents over parameterization of the model. The inclusion of
two different smooth terms allowed for the trajectories of cholesterol to vary according to AD
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status. The smoothing function models the potentially non-linear trajectory of cholesterol with
advancing age. A thin plate regression spline function was applied to age for both AD and nondemented subjects. An advantage of the thin plate regression spline function over other
smoothing functions is that the number and placement of knots that control the flexibility of the
model do not need to be specified (S. Wood, 2003). The more knots included in the model, the
more precisely the model will fit the data, but this is at the risk of over fitting the data and
producing a curve that is not sufficiently smooth. Concerns of over fitting are addressed by
adding a second derivative function on the penalty to the least squares fitting approach (S. Wood,
2003) providing a tradeoff between model fit and model smoothness (S. Wood, 2006). The term
𝜖𝑖𝑗 is the within-subject error term, which is the difference between the observed measure of

cholesterol and the expected measure of cholesterol based on the model. Both bi and 𝜖𝑖𝑗 are

assumed to be randomly distributed with mean zero and variances of 𝜎𝑏2 and 𝜎𝜖2 , respectively. An

additional assumption is that bi and 𝜖𝑖𝑗 are independent of one another.

The estimated trajectories of total cholesterol, HDL cholesterol, and log-total/HDL ratio

based on the models were plotted along with point-wise 95% confidence intervals that were
constructed by calculating the upper and lower bounds for each predicted measure of cholesterol.
This allowed for the trajectories of total cholesterol, HDL cholesterol and log-total/HDL ratio
according to AD status to be visually examined. The degree to which the trajectories of
cholesterol departed from linearity is reflected by the effective degrees of freedom (EDF) of the
smooth term (James, Witten, Hastie, & Tibshirani, 2013). A smooth term with x EDF can be
interpreted as an x degree polynomial term. An EDF of 1 indicates that the trajectory is linear
and increasing values of EDF indicate greater degrees of non-linearity
Covariates
Data for several potential confounding variables were collected during each clinical
examination using standard laboratory procedures and a medical history interview. Educational
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attainment was initially recorded according to the following categories: (1) none, (2) fourth grade
or less, (3) fifth, sixth or seventh grade, (4) completed grade school, (5) some high school, (6)
graduated high school, (7) some college, (8) college graduate or (9) post graduate. For the
purposes of this study, educational attainment was dichotomized according to receiving a high
school degree (< high school degree or > high school degree). Smoking status was assessed
during each clinical examination and subjects were dichotomized as having ever reported
smoking (yes/no). The use of cholesterol lowering medications (statins, fibrates, resins, or
niacin) was assessed during clinical examinations 7-27. Subjects were dichotomized as having
reported ever using a cholesterol lowering medication during a clinical examination (yes/no).
Data for systolic and diastolic blood pressure was collected during each clinical examination and
blood glucose was measured during clinical exams 1-11, 13-15, 20, 22, 24-27. Blood pressure
and blood glucose were included in the models as the average of these measures across all of the
clinical examinations attended by the subject. APOE e4 allele status was dichotomized according
to the presence of one or more APOE e4 alleles (e4+ or e4-).
A subsequent analysis was conducted that included the use of supplemental estrogen as a
covariate. Estrogen replacement therapy is an effective approach for maintaining a healthy lipid
profile for women who are approaching or experiencing menopause (Vehkavaara et al., 2001).
There is evidence that women who take supplemental estrogen are at a decreased risk for AD
(Kawas et al., 1997; Paganini-Hill & Henderson, 1994), but some studies have reported no
benefits of estrogen use (Brenner et al., 1994) or even an increased risk for cognitive impairment
among estrogen users (Shumaker et al., 2004; Shumaker et al., 2003). Based on the results from
previous studies, additional models were used to visually inspect for differences in the trajectories
of total cholesterol, HDL cholesterol and log-total/HDL cholesterol ratio according to AD status
after controlling for the effects of a history of using supplemental estrogen. The use of
supplemental estrogen (oral, patch, or cream) was assessed during clinical exams 17-27 and was
included in the models as having reported using supplemental estrogen (yes/no).
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Aim Three: Subject-Specific Trajectories of Total Cholesterol According to
Cognitive Functioning
Sample population
The FHS Offspring Cohort began in 1971 and includes the children of the Original
Cohort and their spouses. Details regarding the design and methods of data collection of the FHS
Offspring Cohort have been described previously (Feinleib et al., 1975). Eight clinical
examinations were completed between 1971 and 2008. A total of 5124 subjects between the ages
of 5 and 70 (mean age 36) attended the first clinical exam and 3021 (mean age 67, range 40 – 93)
subjects attended the eighth clinical examination.
Beginning in 1999, subjects who were actively participating in the FHS Offspring Cohort
were recruited to participate in a secondary study in which they received a comprehensive
neuropsychological battery (Massaro et al., 2004). A total of 2557 subjects of the Offspring
Cohort received a neuropsychological battery between 1999 and 2005. Because the purpose of
this study was to examine trajectories of cholesterol from midlife to late life, subjects who were
not between 30 and 45 years of age during the first clinical examination and were not 60 years of
age or older upon receiving the neuropsychological battery were not included in the final sample.
The age cutoffs for midlife (age 30 – 45) and late life (age > 60) were based on distinct trends in
the relationship between total cholesterol and chronological age among subjects of the Offspring
Cohort (see Chapter Three for a detailed description of how the definitions for midlife and late
life were obtained). These definitions are different than those used in Aim Two because the ages
in which visually apparent changes in total cholesterol varied between the Offspring and Original
Cohorts. A total of 967 subjects (37.8%) were between 30 and 45 years of age during the first
clinical exam and 60 years of age or older upon receiving a baseline neuropsychological battery.
Subjects who had received a diagnosis of dementia (n=13) and did not complete all of the
assessments included in the neuropsychological battery (n=16) were removed from the sample.
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Finally, subjects who did not have data for apolipoprotein E (APOE) genotype (n=206) were
removed from the sample. The final sample included 761 subjects.
Measure of Cognitive Functioning
A description of the FHS neuropsychological battery was provided in the methods for
specific aim one. A summary score of the FHS neuropsychological battery was obtained by
standardizing a subject’s raw score for each cognitive assessment according to the sample mean
and standard deviation, followed by calculating the average of these standardized scores. The
findings from aim one of the dissertation research provided evidence that this method produces a
summary score that is able to accurately differentiate between subjects classified as having
normal cognition, cognitive impairment, and dementia (see Chapter Five Aim One for complete
results). Subjects were grouped into quartiles based on their summary score for the FHS
neuropsychological battery. This was necessary to visually examine potential differences in
subject-specific trajectories of total cholesterol according to cognitive functioning. Subjects in
the first quartile represent those who had a summary score in the bottom 25 percent of the sample
population and subjects in the fourth quartile were those who had a summary score in the top 25
percent of the sample population. Subjects in the second and third quartiles were treated as the
reference category for the purposes of identifying potential differences in the trajectories of total
cholesterol among subjects with low or high cognitive functioning.
Measures of Cholesterol
Fasting measures for total cholesterol have been collected from subjects during all eight
clinical examinations. It should be noted that fasting cholesterol measures, especially when used
for epidemiological studies, are subject to biases emerging from different effects that control
individual adherence to prescriptive fasting prior to blood draws.
Statistical Analysis
The demographic characteristics of the final sample were described according to the
quartiles of cognitive functioning. Analysis of variance was used to compare group means for
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continuous variables and chi-square tests were used to compare group differences for categorical
variables.
Mixed effects modeling (Laird & Ware, 1982) was used to visually examine the subjectspecific trajectories of total cholesterol split according to the cognitive quartiles. This approach
was used because it provides valid estimates when data are highly unbalanced due to differences
in the number and timing at which subjects are observed (Cnaan, Laird, & Slasor, 1997). The
general form of the mixed effects model is given by:
2
+ 𝜖𝑖𝑗
𝑌𝑖𝑗 = 𝑿𝑻𝒊 𝜷 + 𝑏1𝑖 + 𝑏2𝑖 𝑎𝑔𝑒𝑖𝑗 + 𝑏3𝑖 𝑎𝑔𝑒𝑖𝑗

(4.2)

where Yij is the measure of cholesterol for subject i during the jth observation. Xi is a k-length
vector of values for the time-invariant covariates for subject i and β is the k-length vector of fixed
effects for the corresponding covariates; ageij is the age of subject i during the jth observation; b1i
is the random intercept for subject i and b2i is the random slope term for subject i. A quadratic
term for age was also included as a fixed effect and random effect to account for a non-linear
relationship between cholesterol and age. The generalized additive mixed models that were used
in Aim Two could not be utilized in this specific aim because a smoothing function cannot be
included as a random effect, which is necessary for a smooth function to be applied to each
subject’s trajectory of total cholesterol. The random effects b1i, b2i and b3i are all assumed to be
2
2
2
randomly distributed with mean zero and variances of 𝜎𝑏1
, 𝜎𝑏2
and 𝜎𝑏3
, respectively. The

random intercept represents how much an individual’s baseline measure of cholesterol deviates
from the population average, whereas the random trajectory represents how an individual’s
change in cholesterol with age deviates from the population average. Finally, 𝜖𝑖𝑗 is the within-

subject measurement error, which allows for a measure of cholesterol during any observation

period to vary randomly above or below a subject’s mean trajectory of cholesterol. The error
terms are assumed to be independent and normally distributed with a mean 0 and variance 𝜎𝜖2 .
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An additional assumption is that the random effects (b1i, b2i and b3i) and 𝜖𝑖𝑗 are independent of

one another.

Two-way interaction terms for age by cognition quartile and age-squared by cognition
quartile were included in all models to determine if subjects in the first and fourth cognitive
quartiles had different trajectories of cholesterol compared to subjects in the middle two quartiles.
Two-way interactions between age and sex, and age-squared and sex were included to account for
differences in the trajectories of cholesterol between men and women. Random effects for age
and age-squared were included in the model to allow for the trajectory of cholesterol to vary for
each subject. A random intercept term was also included to account for each subject having a
different baseline measure of cholesterol. Estimates for subject-specific trajectories of cholesterol
were obtained by combining the values for the random and fixed effects. As an example, if 𝛽̂1 is

the fixed effect for the intercept and 𝛽̂2 and 𝛽̂3 are the fixed effects for the trajectory of

cholesterol (i.e. the population average cholesterol trajectory), and 𝑏�1𝑖 is the random intercept and

𝑏�2𝑖 and 𝑏�3𝑖 are the random trajectories then the subject-specific intercept is 𝛽̂1 + 𝑏�1𝑖 and the
subject-specific trajectory is 𝛽̂2 + 𝛽̂3 + 𝑏�2𝑖 + 𝑏�3𝑖 .

The random effects for each subject are predicted by the best linear unbiased predictor

(BLUP) via maximum likelihood to estimate the covariance between the repeated measures of
cholesterol (Fitzmaurice, Laird, & Ware, 2011). The BLUP shrinks each subject’s predicted
trajectory towards the population average trajectory based on the degree of within-subject
variability (i.e. the random fluctuations of the repeated measures of cholesterol from a single
subject) compared to the between-subject variability (i.e. the variation in the measures of
cholesterol from different subjects). The trajectory of cholesterol for a subject whose repeated
measures of cholesterol have high within-subject variability relative to the between-subject
variability will be shrunk closer to the population average trajectory compared to a subject whose
repeated measures of cholesterol have relatively low within-subject variability. The degree to
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which a subject’s trajectory is pulled towards the population average trajectory is also influenced
by the number of times a subject has been observed. The fewer observations for a subject the
closer their trajectory is shrunk to the population average.
Covariates
Data for several potential confounding variables were collected during each clinical
examination using standard laboratory procedures and a medical history interview. Measures of
total cholesterol were collected during all eight clinical examinations. Educational attainment
was assessed during the neuropsychological battery and was recorded as: (1) less than high
school, (2) high school degree, (3) some college and (4) college degree or higher. Smoking status
was assessed during each clinical examination and subjects were dichotomized as having ever
reported smoking (yes/no). The use of cholesterol lowering medications (statins, fibrates, resins,
or niacin) was assessed during all eight clinical examinations. Subjects were dichotomized as
having ever used a cholesterol lowering medication (yes/no). Data for systolic and diastolic
blood pressure was collected during each clinical examination and measures for blood glucose
were recorded for the first through seventh clinical examinations. Blood pressure and blood
glucose were included in the analysis as the average of these measures across all of the clinical
examinations attended by the subject. Data for apolipoprotein E (APOE) genotype was recorded
for 761 subjects. There were 587 subjects who did not carry an APOE e4 allele, 158 who were
heterozygous for the e4 allele and 16 who were homozygous for the e4 allele. APOE e4 allele
status was dichotomized according to the presence of one or more APOE e4 alleles (e4+ or e4)
due to the low number of APOE e4 homozygotes in the final sample.
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Table 4.1: Cognitive Assessments in the FHS Neuropsychological Battery
Assessment
Boston Naming Test
Trail Making Test A
Trail Making Test B
HVOT

Score
0-36
0-300 (sec)
0-300 (sec)
0-30

Cognitive ability
Naming and language
Simple attention
Complex attention
Visuoperceptual skills,
executive function
Premorbid intelligence
Verbal memory

*Mean (SD)
27.4 (2.5)
0.55 (0.26)
1.4 (0.77)
25.0 (3.2)

WRAT
0-57
48.7 (5.1)
Logical memory
0-24
11.5 (3.5)
immediate recall
Logical memory delayed
0-24
Verbal memory
10.5 (3.7)
recall
Paired-associates,
0-21
New learning
13.9 (3.4)
immediate recall
Paired-associate delayed
0-21
New learning
8.2 (1.5)
recall
Visual reproductions
0-14
Visual memory
9.0 (3.2)
immediate recall
Visual reproduction
0-14
Visual memory
8.2 (3.4)
delayed recall
Similarities
0-26
Abstract reasoning
16.8 (3.6)
The Trail Making Test (TMT) A and B are timed assessments with a maximum of five minutes
(300 seconds) being allowed to complete the assessment. A longer time to complete each of the
assessments indicates lower cognitive performance.
HVOT - Hooper visual organization test
WRAT - Wide range achievement test
The mean score for TMT B – TMT A was 0.85 (SD=0.66)
*Mean and SD for final sample (N=2503)
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Table 4.2: Effects of Age, Sex and Education on Assessments in the FHS
Neuropsychological Battery (Univariate Model).

Subtest
LMI
LMD
PASI
PASD
VRI
VRD
TMT A
TMT B
TMT (B-A)
HVOT
Similarities
BNT

Age
-0.056
(-0.080, -0.31)
-0.066
(-0.091, -0.40)
-0.084
(-0.11, -0.059)
-0.035
(-0.046, -0.024)
-0.11
(-0.13, -0.088)
-0.11
(-0.13, -0.085)
0.0059
(0.0044, 0.0074)
0.024
(0.020, 0.028)
0.018
(0.014, 0.021)
-0.12
(-0.14, -0.099)
-0.089
(-0.11, -0.064)
-0.064
(-0.081, -0.047)

Univariate Model
Sex
Some College
0.77
1.03
(0.31, 1.23)
(0.44, 1.62)
0.95
1.25
(0.47, 1.43)
(0.64, 1.87)
0.68
1.29
(0.83, 1.75)
(0.077, 1.29)
0.17
0.50
(0.31, 0.70)
(-0.89, 0.43)
-0.33
1.19
(-0.76, 0.11)
(0.63, 1.74)
-0.27
1.28
(-0.74, 0.19)
(0.69, 1.87)
-0.029
-0.050
(-0.057, -8.0e-4) (-0.087, -0.013)
0.022
-0.16
(-0.62, 0.11)
(-0.27, -0.051)
0.051
-0.011
(-0.020, 0.12)
(-0.20, -0.018)
0.20
0.59
(-0.22, 0.63)
(0.033, 1.14)
-0.43
1.60
(-0.90, 0.034)
(1.04, 2.17)
-0.49
1.13
(-0.82, -0.17)
(0.74, 1.53)

College
2.10
(1.58, 2.62)
2.16
(1.62, 2.71)
1.23
(0.70, 1.77)
0.41
(0.18, 0.64)
1.89
(1.40, 2.38)
2.09
(1.57, 2.61)
-0.057
(-0.090, -0.024)
0.31
(-0.41, -0.22)
-0.26
(-0.34, -0.18)
1.02
(0.53, 1.51)
3.09
(2.59, 3.59)
1.96
(1.61, 2.31)

*Based on subjects included in the test set that were absent of dementia or decline >1.5 SD on
one or more subtests.
Bold P<0.01 Underlined P<0.05 but not P<0.01
Referent category for sex is male. Referent category for education is high school degree or less.
LMI = Logical Memory, Immediate Recall; LMD = Logical Memory, Delayed Recall; PASI =
Paired Associates, Immediate Recall; PASD = Paired Associates, Delayed Recall; VRI = Visual
Reproductions, Immediate Recall; VRD = Visual Reproduction, Delayed Recall; TMT A (B) =
Trail Making Test A (B); HVOT = Hooper Visual Organization Test; BNT = Boston Naming
Test
TMT A, B and B-A are timed assessments; higher score indicates lower performance
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Table 4.3 Effects of Age, Sex and Education on Assessments in the FHS Neuropsychological
Battery (Multivariable Model).

Subtest
LMI
LMD
PASI
PASD
VRI
VRD
TMT A
TMT B
TMT (B-A)
HVOT
Similarities
BNT

Age
-0.041
(-0.065, -0.017)
-0.050
(-0.75, -0.25)
-0.076
(-0.10, -0.052)
-0.033
(-0.043, -0.023)
-0.099
(-0.12, -0.077)
-0.10
(-0.12, -0.072)
0.0056
(4.0e-3, 7.0e-3)
0.022
(0.018, 0.026)
0.017
(0.013, 0.020)
-0.12
(-0.14, -0.095)
-0.068
(-0.091, -0.045)
-0.050
(-0.066, -0.034)

Multivariable Model
Sex
Some College
0.90
1.18
(0.73, 1.62)
(0.31, 1.48)
1.36
1.09
(0.89, 1.82)
(0.49, 1.70)
0.44
1.55
(1.10, 2.00)
(-0.15, 1.02)
0.062
0.60
(0.40, 0.79)
(-0.19, 0.31)
-0.052
0.85
(-0.46, 0.36)
(0.31, 1.38)
0.04
0.95
(-0.40, 0.48)
(0.38, 1.53)
-0.031
-0.038
(-0.065, -9.8e-3) (-0.067, 4.8e-3)
-0.028
-0.24
(-0.11, 0.051)
(-0.19, 0.019)
0.0096
-0.053
(-0.058, 0.077)
(-0.14, 0.035)
0.36
0.19
(-0.04, 0.76)
(-0.33, 0.71)
0.074
1.37
(-0.36, 0.50)
(0.81, 1.92)
-0.20
0.96
(-0.50, 0.10)
(0.57, 1.34)

College
2.21
(1.69, 2.74)
2.29
(1.74, 2.83)
1.30
(0.78, 1.83)
0.42
(0.20, 0.65)
1.53
(1.05, 2.01)
1.75
(1.23, 2.27)
-0.045
(-0.078, -0.013)
-0.24
(-0.33, -0.15)
-0.20
(-0.27, -0.12)
0.68
(0.21, 1.15)
2.86
(2.36, 3.37)
1.73
(1.38, 2.09)

*Based on subjects included in the test set that were absent of dementia or decline >1.5 SD on
one or more subtests.
Bold P<0.01 Underlined P<0.05 but not P<0.01
Referent category for sex is male. Referent category for education is high school degree or less.
LMI = Logical Memory, Immediate Recall; LMD = Logical Memory, Delayed Recall; PASI =
Paired Associates, Immediate Recall; PASD = Paired Associates, Delayed Recall; VRI = Visual
Reproductions, Immediate Recall; VRD = Visual Reproduction, Delayed Recall; TMT A (B) =
Trail Making Test A (B); HVOT = Hooper Visual Organization Test; BNT = Boston Naming
Test
TMT A, B and B-A are timed assessments; higher score indicates lower performance
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Chapter Five: Results
Specific Aim One
Sample Characteristics
The demographic characteristics of the subjects included in the validation sample
according to cognitive status are provided in Table 5.1. Among subjects who completed a
neuropsychological battery, 619 (49.5%) were classified as having normal cognition (NC), 214
(17.1%) were classified as test-based impaired learning and memory (ILMTB), 399 (31.9%) were
classified as multidomain impaired (MDITB). There were 19 (1.5%) subjects who had received a
diagnoses of dementia. There were significant differences for age (P<0.01) and educational
attainment (P=0.02) between all four of the cognitive groups. There were no differences in the
proportion of males and females in any of the cognitive groups.
Effects of Age, Sex, and Education on Cognitive Function
Significant differences in the assessment scores of the FHS neuropsychological battery
according to age, sex, and educational attainment were detected in the univariate (UV) and
multivariable (MV) models. Cognitive performance on all of the assessments significantly
decreased with age in the UV model (P<0.01). The effect of age remained after controlling for
the effects of education and sex. Subjects with a college degree had significantly higher
performance (P<0.01) on all assessments compared to subjects with <high school degree even
after accounting for the effects of age and sex. Women performed better than men on Logical
Memory (Immediate and Delayed Recall) and Paired Associates (Immediate and Delayed
recall), whereas men performed better than women on TMT A and Boston Naming Test.
However, the effect of sex on the Boston Naming Test was no longer significant once education
was included in the model. No significant differences according to sex in the UV or MV models
were observed for Visual Recognition (Immediate and Delayed recall); TMT B; Hooper Visual
Organization Test; Similarities, or cognitive flexibility (TMT B – TMT A).
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Ability of Summary Scores to Differentiate between Cognitive Groups
NC and Dementia: Older adults diagnosed with dementia were considered to be cases in
this analysis. All three summary scores were very accurate when differentiating between
subjects classified as NC and subjects diagnosed with dementia. The areas under the curve
(AUC 16; the probability that a randomly selected dementia case has a lower score than a
randomly selected NC control) among the three summary scores were all greater than 96 percent
(Table 5.2; Figure 5.1). The composite subtest summary score had significantly higher
specificity and overall test accuracy compared to the composite domains summary score, but not
compared to the learning/memory summary score. These results provide evidence for the use of
the composite subtests summary score for differentiating between NC and dementia subjects.
NC and ILMTB: Subjects with ILMTB were considered to be cases in this analysis. There
were no significant differences in AUCs among the three summary scores (Table 5.3; Figure
5.2). The learning/memory summary score had the greatest sensitivity (84.6 [79.0-89.1]),
specificity (78.8 [75.4-82.0]), npv (93.7 [91.2-95.6]), ppv (58.0 [52.3-63.6]), and overall test
accuracy (80.3 [77.4-83.0]). However, these differences were not statistically significant
compared to the other summary scores. Based on these results, there are no apparent differences
between the three summary scores in their ability to differentiate between ILMTB and NC.
NC and MDITB: Subjects with MDITB were considered to be cases in this analysis. The
composite subtests summary score had significantly greater AUC (90.5 [88.6-92.4]) and higher
overall test accuracy (83.3 [80.9-85.5], compared to the composite domains and
learning/memory summary scores (Table 5.4; Figure 5.3). In addition, the composite domains
summary score had a significantly greater AUC (85.8 [83.4-88.1]) compared to the

16

A receiver operator characteristic (ROC) curve is a plot of the sensitivity and specificity for
different cut-points of each summary score and shows the tradeoff between sensitivity and
specificity (i.e. as sensitivity increases, specificity decreases). Sensitivity and specificity is for
the optimal cut-off score for each summary score.
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learning/memory summary score (80.0 [77.2-82.7]). The composite subtest summary score had
significantly higher specificity, ppv, and overall test accuracy compared to the composite
domains and learning/memory summary scores, in addition to a higher npv compared to the
learning/memory summary score. Based on this evidence, a summary score that assesses only
learning and memory should be avoided when differentiating between normal and MDITB
subjects in the FHS.
Dementia and ILMTB : Older adults diagnosed with dementia were considered to be cases
in this analysis. The composite subtests summary score had the greatest AUC (89.3 [77.7-100]),
but the wide confidence interval due to the small number of subjects diagnosed with dementia
prevented any differences in AUC according to cognitive status from being observed. The
composite subtests summary score also had the highest specificity (93.0 [88.7-96.0]), ppv (51.6
[33.1-69.8]) and overall test accuracy (92.2 [88.1-95.4]) among the three summary scores (Table
5.5; Figure 5.4). However, there were no significant differences between the three summary
score for any of these measures. Based on these results, there is insufficient evidence for a
summary score that performs substantially better when differentiating between ILMTB and
dementia.
Dementia and MDITB: Older adults diagnosed with dementia were considered to be cases
in this analysis. There were no significant differences between the AUCs for any of the three
summary scores (Table 5.6; Figure 5.5). The learning/memory summary score had higher
specificity (92.2 [89.2-94.7]), ppv (29.5 [16.8-45.2]) and overall test accuracy (91.1 [88.0-93.7]),
but these values were not significantly higher compared to the other summary scores. As was
observed when comparing ILMTB and dementia, there is insufficient evidence for a best summary
score when differentiating between MDITB and dementia.
ILMTB and MDITB: Subjects with MDITB were considered to be cases in this analysis.
The composite subtest summary score had significantly greater AUC (65.7 [61.4-69.9]) compared
to composite domains summary score, but not the learning/memory summary score (Table 5.7;
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Figure 5.6). The composite subtests summary score had the highest sensitivity (58.6 [53.6-63.5])
among the three summary scores, which was significantly higher compared to the composite
domains summary score (43.9 [38.9-48.9]). The composite domains summary score had a
significantly higher specificity, but significantly lower sensitivity compared to the
learning/memory summary score. There was no difference in specificity between the composite
subtest and composite domains summary scores. Based on this evidence, the composite subtest
score is best able to differentiate between ILMTB and MDITB due to the significantly higher AUC
and sensitivity compared to the composite domains summary score. However, the composite
domains score should be utilized if there is a greater priority on correctly identifying ILMTB.
Specific Aim Two
Sample Population
The descriptive characteristics of subjects of the FHS Original Cohort included in the
final sample according to AD status are provided in Table 5.8. The final sample included a total
of 2449 subjects, of which 2102 who did not have dementia and 347 who had received a
diagnosis of AD. The final sample was comprised predominately of females (n=1428, 58.3%)
and the majority of subjects had a high school degree or less (n=1632, 68.5%). There was no
association between AD and educational attainment, but females were more likely than males to
be diagnosed with AD (P<0.01). There were 386 (15.8%) subjects who reported taking a
cholesterol-lowering medication during one or more clinical examinations. There was no
difference in the proportion of subjects who reported using cholesterol-lowering medications
according to AD status. Subjects diagnosed with AD had slightly, albeit significantly, lower
average blood glucose (P<0.01), systolic blood pressure (P=0.01) and diastolic blood pressure
(P<0.01) compared to subjects without dementia. Subjects without dementia were more likely to
have a history of smoking compared to subjects diagnosed with AD (P<0.01). The apparent
protective effect of smoking against AD may be due to smokers dying before they would have
been diagnosed with AD (Kryscio et al., 2013).
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Data for APOE genotype was available for 568 subjects (23.2%) included in the final
sample. There were 125 subjects who carried one or more APOE e4 alleles (e4+) and 443
subjects who did not carry any APOE e4 alleles (e4-). As expected, subjects who were APOE
e4+ were more likely to be diagnosed with AD compared to subjects who were APOE e4(P<0.01).
Trajectories of Cholesterol According to Alzheimer’s Disease Status
The unadjusted and adjusted trajectories of total cholesterol, HDL cholesterol, and logtotal/HDL ratio according to AD status are presented in Figures 5.7-5.9. Solid lines represent the
mean measures of cholesterol according to AD status and the shaded regions represent the pointwise 95% confidence interval for each measure of cholesterol. The degree of non-linearity for the
trajectories as reflected by the estimated EDF of the smoothing term, and the model fit by
adjusted R2, which is interpreted as the proportion of total variance explained by the model with
an adjustment for model complexity, are presented in Table 5.9. According to visual inspection,
there were no differences in the unadjusted mean trajectories of total cholesterol, HDL
cholesterol, and log-total/HDL ratio as indicated by the considerable overlap of the 95%
confidence intervals (Figure 5.7 [unadjusted] – Figure 5.9 [unadjusted]). Inclusion of
covariates to the models noticeably reduced the variability in estimated cholesterol trajectories as
indicated by the 95% confidence intervals for each trajectory; however, trajectories of cholesterol
in Figures 5.7-5.9 did not substantially change as covariates were added to the models as
indicated by the consistent EDF values of the smooth terms and little change in the adjusted R2
for each model (Table 5.9). This may be due to covariates being included solely as fixed effects
and not being incorporated into the smoothing term of the model.
Trajectories of total cholesterol for non-demented subjects and subjects diagnosed with
AD both followed non-linear trends (Table 5.9). There were little to no differences in the
trajectories of total cholesterol between AD and non-demented subjects once the effects of sex,
educational attainment, smoking history, blood pressure, blood glucose, and history of using
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cholesterol-lowering medications were controlled for in the models (Figure 5.7, model 1 –
model 4). When APOE e4 allele status was included as a covariate (Figure 5.7, model 5), nondemented and AD subjects exhibited a similar increasing trend in total cholesterol from 30 to 55
years of age, but AD subjects had consistently higher total cholesterol after 55 years of age
compared to non-demented subjects. Subjects diagnosed with AD maintained a consistent level
of HDL that remained linear even as covariates were added to the models as indicated by the
EDFs of 1 in Table 5.9. HDL cholesterol also remained fairly constant from 50 to 75 years of
age for non-demented subjects, but the overall trend was non-linear due to an increase in HDL
cholesterol after 75 years of age. A declining trajectory for log-total/HDL ratio was observed for
all subjects. There were little to no differences in the log-total/HDL ratios according to AD status
from 50 to 70 years of age, but subjects without dementia did exhibit a greater decline in
total/HDL ratio after 70 years of age.
Trajectories of Cholesterol According to APOE e4 Allele Status
The trajectories of total cholesterol, HDL cholesterol, and log-total/HDL ratio according
to APOE e4 allele status were examined because of the established relationship between APOE
and AD, the apoE protein’s role in cholesterol metabolism, and the known differences in the
concentrations of cholesterol according to APOE genotype. Only the estimated trajectories of
total cholesterol, HDL cholesterol, and log-total/HDL ratio for the unadjusted and fully adjusted
models are provided in Figure 5.10 because there were no substantial changes in the EDF for the
smoothing terms as covariates were added to the models (Table 5.10). Subjects who did not
posses an APOE e4 allele (e4-) had consistently lower total cholesterol from midlife to late life
compared to subjects with one or more e4 alleles (Figure 5.10). In general, subjects who were
APOE e4- had slightly higher HDL cholesterol and lower log-total/HDL ratio from midlife to late
life compared to subjects who possessed one or more APOE e4 alleles (e4+). All subjects
exhibited a non-linear decline in log-total/HDL ratio due to an increase in HDL cholesterol with
advancing age.
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Trajectories of Cholesterol According to Alzheimer’s Disease and APOE e4 Allele Status
Models stratified according to AD and APOE e4 allele status were used to determine if
the trajectories of total cholesterol, HDL cholesterol, and log-total/HDL ratio according to AD
status differed between subjects who were APOE e4+ and those who were APOE e4- (Figure
5.11; Table 5.11). The trajectories of cholesterol stratified according to AD status and APOE e4
allele status did not change substantially as covariates were added to the models, and only the
unadjusted and fully adjusted models that controlled for sex, education, smoking, average blood
pressure, average blood glucose, and use of cholesterol lowering medications were used to
examine the potential interactive effect of AD and APOE e4 allele status on trajectories of
cholesterol.
Subjects diagnosed with AD and who were APOE e4+ maintained higher total cholesterol
from midlife to late life compared to AD e4-, non-demented e4+, and non-demented e4- subjects
(Figure 5.11, total cholesterol). This finding suggests that consistently higher total cholesterol
among subjects diagnosed with AD is due to these subjects being more likely to be APOE e4+. A
non-linear increase in HDL cholesterol with age was observed for non-demented e4- subjects,
whereas subjects who were non-demented and APOE e4+ maintained consistent measures of
HDL cholesterol with age (Figure 5.11, HDL cholesterol). The increase in HDL cholesterol was
most pronounced among subjects diagnosed with AD and who were APOE e4+, but subjects
diagnosed with AD and were APOE e4- exhibited a slight decrease in HDL cholesterol with age.
Finally, AD e4+ subjects exhibited a linear decline in log-total/HDL ratio, whereas non-linear
declines in log-total/HDL ratio were observed for all other groups.
Trajectories of Cholesterol According to Alzheimer’s Disease Status and Sex
Models stratified according to AD status and sex were used to determine if the
trajectories of total cholesterol, HDL cholesterol, and log-total/HDL ratio for men and women
differed according to AD status (Figure 5.12; Table 5.12). Based on the unadjusted and adjusted
models for total cholesterol (Figure 5.12), women had lower total cholesterol compared to men
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until approximately 50 years of age. Total cholesterol increased for both men and women during
midlife, but there was visual evidence for a greater increase in cholesterol among women during
this period. Total cholesterol appeared to decline at a similar trajectory for men and women
following 60 years of age, although women maintained higher total cholesterol compared to men.
Despite the clear differences in total cholesterol between men and women in the unadjusted and
adjusted models, there were no dramatic differences in the trajectories of total cholesterol
between men and women according to AD status. However, there was visual evidence for
differences in the trajectories of total cholesterol according to AD status and sex once APOE was
included as a covariate (Figure 5.12, total cholesterol fully adjusted) and these differences were
most apparent among men. Total cholesterol increased for men regardless of AD status, but men
without dementia exhibited a decline in total cholesterol at a younger age compared to men with
AD. Compared to men without dementia, men diagnosed with AD had lower cholesterol during
midlife, but maintained higher cholesterol following 60 years of age. A similar trend was
observed among women, but the apparent differences in total cholesterol according to AD status
were much less pronounced than in men. Women diagnosed with AD maintained slightly higher
total cholesterol after 60 years of age compared to women who did not have dementia, but the
overall trajectories of total cholesterol were similar for the two groups. The visually apparent
differences in the trajectories of total cholesterol between the adjusted and fully adjusted models
need to be interpreted with some caution because only 23 percent of the final sample (n=568
subjects) had data for APOE genotype.
There were obvious differences in the trajectories of HDL cholesterol according to sex,
with women maintaining higher HDL cholesterol compared to men in the unadjusted, adjusted
and fully adjusted models. The trajectories of HDL cholesterol for men and women without
dementia in the unadjusted and adjusted models exhibited a cubic trend, whereas the trajectories
for subjects with AD were more linear. When APOE e4 allele status was included as a covariate,
there was an increasing trend in HDL cholesterol among women diagnosed with AD, whereas
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men diagnosed with AD exhibited an accelerated decline at approximately 70 years of age. The
visually observed differences between the adjusted and fully adjusted models may be partially
due to the reduced sample size for the fully adjusted model.
Despite maintaining considerably higher total cholesterol compared to men, women had a
lower log-total/HDL cholesterol ratio compared to men due to the higher measures of HDL
cholesterol. Based on the adjusted model, there was a decreasing trend for the ratio of total to
HDL cholesterol among men and women but there were no substantial differences according to
AD status. The addition of APOE to the model did not have an apparent effect on trajectories of
total cholesterol for women. Men without dementia exhibited an accelerated decline in logtotal/HDL cholesterol ratio at approximately 75 years of age due to an increase in HDL
cholesterol, whereas the decline in log-total/HDL cholesterol ratio for men with AD followed a
linear trend.
Adjusting for the Effects of Supplemental Estrogen Use: A total of 133 subjects (3.6%)
reported having used supplemental estrogen. Eight men reported using supplemental estrogen,
but these subjects were excluded from the analysis to avoid confounding results. There were no
discernable differences in the trajectories of total cholesterol, HDL cholesterol or log-total/HDL
ratio according to AD status when supplemental estrogen use was included in the models (Figure
5.13) compared to the trajectories of total, HDL cholesterol and log-total/HDL ratio for women in
Figure 5.12.
Specific Aim Three
Sample Characteristics
A summary of the descriptive characteristics for the final sample according to cognitive
quartile is provided in Table 5.13. Subjects in the lowest quartile of cognitive functioning were
significantly older during the first clinical exam (representing midlife) and upon receiving a
neuropsychological battery (representing late life) compared to subjects in the highest quartile of
cognitive functioning. Also, subjects in the lowest cognitive quartile had significantly lower
107

educational attainment compared to the other groups. Finally, the lowest cognitive quartile had
slightly higher average blood glucose levels compared to the other quartiles. There were no
differences in history of smoking, blood pressure, use of cholesterol lowering medications or
APOE e4 allele status.
Relationship between Subject-Specific Trajectories of Total Cholesterol and Cognition
The subject-specific trajectories for total cholesterol were plotted according to cognitive
quartile and visually examined (Figure 5.14). There was considerable variability in the subjectspecific trajectories of total cholesterol within each of the cognitive quartiles. Upon close visual
examination, subjects in the lowest cognitive quartile appeared to exhibit a slightly greater
decline in total cholesterol compared to the other quartiles.
A subsequent analysis was performed to determine if significant differences in the
population-average trajectories of total cholesterol according to cognitive quartile could be
detected. Subjects in the fourth cognitive quartile had significantly lower total cholesterol
compared to the second and third quartiles (𝛽̂ =-6.4 mg/dl, SE=2.3 mg/dl, P=0.02). This

difference remained significant after controlling for the effects of sex, educational attainment,
smoking, cholesterol medication use, blood glucose, blood pressure, and APOE e4 allele status
(Figure 5.15; Table 14). There were no significant differences in the quadratic trend in total
cholesterol according to cognitive quartile.
Conclusion
In general, the findings from the specific aims were surprising given what has been
reported in previous studies. Subjects in the FHS Offspring Cohort diagnosed with dementia had
higher than expected cognitive performance on the neuropsychological battery, and the utility of
the three summary scores to differentiate between normal and dementia subjects was lower than
expected. This may be due to a sampling bias in which subjects with severe physical or cognitive
impairments due to dementia would not be healthy enough to receive a neuropsychological
battery. The findings from Aim Two and Three were surprising because there was not sufficient
108

evidence to suggest that there are differences in midlife cholesterol according to AD status, but
older adults with high cognitive functioning had significantly lower cholesterol during midlife
compared to subjects with low cognition. The inconsistent findings of Aims Two and Three may
be due to the peculiar characteristics of FHS participants and cohort differences between the
Original and Offspring Cohorts. A thorough summary of the findings from the dissertation
research, and an interpretation of these findings within the context of prior research, is provided
in Chapter Six.
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*Table 5.1: Demographic Characteristics
Characteristic
Age (SD)
Education, n (%)
< High school
Some college
College degree
Male, n (%)

Normal
(n=619)
60.7 (9.2)

ILM
MDI
(n=214)
(n=399)
59.7 (8.7) 63.5 (9.8)

Dementia
(n=19)
73.6 (5.6)

193 (31.1)
159 (25.7)
267 (43.1)
282 (45.6)

68 (31.8)
84 (39.2)
62 (29.0)
97 (45.3)

8 (42.1)
6 (31.6)
5 (26.3)
7 (36.8)

164 (41.1)
103 (25.8)
132 (33.1)
197 (49.4)

P-value
<0.01
0.02

0.50

*Results based on subjects included in the validation set.
SD = standard deviation, n = number of subjects
Table 5.2: Differentiating between Normal and Dementia
Normal and
Composite,
Composite,
Learning/memory
dementia
subtest
domains
subtests
AUC (95% CI)
97.2 (93.6-100.0)
97.1 (93.7-100.0)
96.9 (94.0-99.7)
Cut-off
-0.18
-0.13
-0.19
Sensitivity
89.5 (66.9-98.7)
89.5 (66.9-98.9)
84.2 (60.4-96.6)
Specificity
96.8 (95.1-98.0)
92.7 (90.4-94.6)
93.5 (91.3-95.3)
PPV
45.9 (29.5-63.1)
27.4 (16.9-40.2)
28.6 (17.3-42.2)
NPV
99.7 (98.8-100.0)
99.7 (98.8-100.0)
99.5 (98.5-99.9)
Test accuracy
96.6 (94.8-97.8)
92.6 (90.3-94.5)
93.3 (91.0-95.1)
The optimal cut-off score for each summary score is the point on the receiver operating
characteristic curve that is closest to (0, 1).
Table 5.3: Differentiating between Normal and ILMTB
Normal and ILMTB
AUC (95% CI)
Cut-off
Sensitivity
Specificity
PPV
NPV
Test accuracy

Composite,
subtest
86.6 (83.9-89.4)
0.13
83.2 (77.5-87.9)
75.1 (71.5-78.5)
53.6 (48.1-59.1)
92.8 (90.2-94.9)
77.2 (74.2-80.0)

Composite,
domains
87.4 (84.8-90.1)
0.14
79.9 (73.9-85.1)
78.7 (75.2-81.4)
56.4 (50.6-62.1)
91.9 (89.2-94.1)
79.0 (76.1-81.7)
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Learning/memory
subtests
89.5 (87.2-91.9)
0.11
84.6 (79.0-89.1)
78.8 (75.4-82.0)
58.0 (52.3-63.6)
93.7 (91.2-95.6)
80.3 (77.4-83.0)

Table 5.4: Differentiating between Normal and MDITB
Normal and MDITB

Composite,
subtest
90.5 (88.6-92.4)
0.02
79.2 (74.9-83.1)
85.9 (83.0-88.6)
78.4 (74.1-82.3)
86.5 (83.5-89.1)
83.3 (80.9-85.5)

AUC (95% CI)
Cut-off
Sensitivity
Specificity
PPV
NPV
Test accuracy

Composite,
domains
85.8 (83.4-88.1)
0.14
75.7 (71.2-79.8)
78.7 (75.2-81.8)
69.6 (65.0-73.9)
83.4 (80.1-86.3)
77.5 (74.8-80.0)

Learning/memory
subtests
80.0 (77.2-82.7)
0.19
70.9 (66.2-75.3)
72.9 (69.2-76.3)
62.7 (58.1-67.2)
79.5 (76.0-82.8)
72.1 (69.2-74.8)

Table 5.5: Differentiating between Dementia and ILMTB
Dementia and ILMTB

Composite,
subtest
89.3 (77.7-100.0)
-0.49
84.2 (60.4-96.6)
93.0 (88.7-96.0)
51.6 (33.1-69.8)
98.5 (95.7-99.7)
92.2 (88.1-95.4)

AUC (95% CI)
Cut-off
Sensitivity
Specificity
PPV
NPV
Test accuracy

Composite,
domains
88.1 (76.0-100.0)
-0.62
84.2 (60.4-96.6)
90.7 (85.9-94.2)
44.4 (27.9-61.9)
98.5 (95.6-99.7)
90.1 (85.6-94.2)

Learning/memory
subtests
80.7 (67.1-94.3)
-0.90
68.4 (43.4-87.4)
92.5 (88.1-95.7)
44.8 (26.4-64.3)
97.1 (93.7-98.9)
90.6 (86.1-94.0)

Table 5.6: Differentiating between Dementia and MDITB
Dementia and MDITB
AUC (95% CI)
AUC (95% CI)
Cut-off
Sensitivity
Specificity
PPV
NPV

Composite,
subtest
84.2 (71.3-97.1)
-0.81
78.9 (54.4-93.9)
87.5 (83.8-90.6)
23.1 (13.5-35.2)
98.9 (97.1-99.7)
87.1 (83.5-90.1)

Composite,
domains
85.9 (74.2-97.5)
-1.1
78.9 (54.4-93.9)
89.2 (85.8-92.1)
25.9 (15.3-39.0)
98.9 (97.2-99.7)
88.8 (85.3-91.6)

Learning/memory
subtests
84.4 (74.0-94.7)
-0.89
68.4 (43.4-87.4)
92.2 (89.2-94.7)
29.5 (16.8-45.2)
98.4 (96.5-99.4)
91.1 (88.0-93.7)

Table 5.7: Differentiating between ILMTB and MDITB
ILMTB and MDITB
AUC (95% CI)
Cut-off
Sensitivity
Specificity
PPV
NPV
Test accuracy

Composite,
subtest
65.7 (61.4-69.9)
-0.19
58.6 (53.6-63.5)
65.0 (58.2-71.3)
75.7 (70.6-80.4)
45.7 (40.0-51.5)
60.8 (56.9-64.7)

Composite,
domains
56.1 (51.6-60.6)
-0.40
43.9 (38.9-48.9)
74.3 (67.9-80.0)
76.1 (70.0-81.4)
41.5 (36.5-46.6)
54.5 (50.4-58.5)
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Learning/memory
subtests
59.7 (55.3-64.2)
-0.21
57.6 (52.6-62.5)
57.9 (51.0-64.6)
71.9 (66.6-76.7)
42.3 (36.6-48.2)
57.7 (53.7-61.7)

Table 5.8: Demographic Characteristics according to Alzheimer’s Disease Status
Characteristic
No Dementia (n=2102) AD (n=347) P-value
*Age, midlife (SD)
40.2 (6.7)
42.2 (6.9
<0.01
**Age, late life (SD)
81.9 (7.6)
78.6 (6.5)
<0.01
Sex, n (%)
<0.01
Female
1196 (56.9)
232 (66.9)
Male
906 (43.1)
115 (33.1)
§
Educational attainment, n (%)
0.24
< High school
1410 (68.9)
222 (65.7)
> High school
636 (31.1)
116 (34.3)
Smoking history, n (%)
<0.01
No
663 (31.5)
160 (46.1)
Yes
1439 (68.5)
187 (53.9)
Use of cholesterol lowering medications, n (%)
0.97
No
1770 (84.2)
293 (84.4)
Yes
332 (15.8)
54 (15.6)
Avg. blood glucose, mg/dl (SD)
108.2 (19.0)
105.2 (15.2)
0.01
Avg. systolic blood pressure, mmHg (SD)
136.5 (15.0)
134.4 (13.4)
0.01
Avg. diastolic blood pressure, mmHg (SD)
80.1 (8.0)
78.0 (6.5)
<0.01
§§
APOE e4 allele status, n (%)
<0.01
APOE e4378 (80.9)
65 (64.4)
APOE e4+
89 (19.1)
36 (35.6)
*Age during the first clinical examination represents midlife
**Age in which a person was last observed to be cognitively intact represents late life
§
A total of 2384 had data for educational attainment
§§
A total of 568 had data for APOE e4 allele status
SD = standard deviation and n = number of subjects
T-tests were used to compare group means for continuous variables (age, blood glucose, and
blood sugar) and chi-square tests were used to compare group differences for categorical
variables (sex, education, cholesterol medication use, and APOE e4 allele status).
Percentages for categorical variables are based on column total. Value may exceed 100 due to
rounding.
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Table 5.9: EDF and Adjusted R2 for Trajectories of Total, HDL and Total/HDL Ratio
according to Alzheimer’s Disease Status
Total cholesterol HDL cholesterol Log-total/HDL
EDF
Adj. R2
EDF
Adj. R2 EDF Adj. R2
Model
1. Unadjusted (n=2449)
0.09
0.002
0.06
Non-demented
7.6
5.4
5.7
AD
6.4
1.7
4.2
2. Model 1 + gender and
0.11
0.11
0.09
education (n=2384)
Non-demented
7.6
5.4
5.7
AD
6.5
1.9
4.1
3. Model 2 + smoking (n=2384)
0.11
0.11
0.10
Non-demented
7.6
5.4
5.7
AD
6.5
1.9
4.1
4. Model 3 + blood pressure and
0.13
0.12
0.12
blood glucose (n=2384)
Non-demented
7.6
5.4
5.7
AD
6.5
2.0
4.0
5. Model 4 + cholesterol
0.17
0.12
0.14
medications (n=2384)
Non-demented
7.6
5.4
5.7
AD
6.5
2.0
4.0
6. Model 6 + APOE e4 allele
0.19
0.14
0.12
status (n=557)
Non-demented
7.0
3.7
4.3
AD
5.5
2.1
2.4
There were 65 subjects who had missing data for educational attainment. Data for APOE was
recorded for 568 subjects, but 11 of these subjects had missing data for educational attainment.
There were no missing data for smoking, blood pressure, blood glucose or use of cholesterol
lowering medications.
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Table 5.10: EDF and Adjusted R2 for Trajectories of Total, HDL and Total/HDL Ratio
according to APOE e4 Allele Status
Total cholesterol HDL cholesterol
Log-total/HDL
Model
EDF
Adj. R2
EDF
Adj. R2
EDF Adj. R2
1. Unadjusted (n=568)
0.11
0.003
0.04
e47.2
3.6
4.4
e4+
5.4
2.2
3.1
2. Model 1 + gender and
0.12
0.13
0.09
education (n=557)
e47.2
3.3
4.2
e4+
5.5
1.9
3.1
3. Model 2 + smoking history
0.12
0.13
0.09
(n=557)
e47.2
3.3
4.3
e4+
5.5
1.9
3.1
4. Model 3 + blood pressure and
0.14
0.14
0.11
blood glucose (n=557)
e47.2
3.3
4.2
e4+
5.5
1.9
3.1
5. Model 4 + use of cholesterol
0.18
0.14
0.12
lowering medications
(n=557)
e47.2
3.3
4.2
e4+
5.5
1.9
3.1
There were 11 subjects who had missing data for educational attainment. There were no missing
observations for smoking history, blood pressure, blood glucose or use of cholesterol lowering
medications.
Table 5.11: EDF and Adjusted R2 for Trajectories of Total, HDL and Total/HDL Ratio
Stratified by AD and APOE e4 Allele Status

Model
Unadjusted (n=568)
Non-demented e4Non-demented e4+
AD e4AD e4+
Adjusted (n=557)
Non-demented e4Non-demented e4+
AD e4AD e4+

Total cholesterol
EDF
Adj. R2
0.12
7.2
5.4
4.9
4.3
0.19
7.1
5.4
4.9
4.3

HDL cholesterol
EDF
Adj. R2
0.01
3.9
2.2
1.0
3.0
0.14
3.6
2.2
1.0
2.9

Log-total/HDL
EDF
Adj. R2
0.04
4.4
3.1
2.3
1.2
0.12
4.2
3.0
2.3
1.1

Adjusted model included sex, educational attainment (< high school, > high school), smoking
history, diastolic and systolic blood pressure, blood glucose and history of cholesterol lowering
medications. Of the 568 subjects with APOE data, 11 had missing data for educational
attainment.
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Table 5.12: EDF and Adjusted R2 for Trajectories of Total, HDL and Total/HDL Ratio
Stratified by AD and Sex
Total cholesterol
HDL cholesterol
Log-total/HDL
Model
EDF
Adj. R2
EDF
Adj. R2
EDF
Adj. R2
Unadjusted (n=2449)
0.14
0.11
0.09
Non-demented female
7.7
5.7
5.0
Non-demented male
7.9
4.7
6.3
AD female
6.5
1.8
3.1
AD male
5.6
1.0
3.7
Adjusted (n=2384)
0.19
0.12
0.14
Non-demented female
7.7
5.7
5.0
Non-demented male
7.9
4.5
6.3
AD female
6.6
2.1
3.0
AD male
5.6
1.0
3.6
Fully adjusted (n=557)
0.22
0.14
0.12
Non-demented female
7.1
3.8
3.9
Non-demented male
6.1
2.9
4.3
AD female
5.5
1.9
4.3
AD male
3.9
1.9
1.0
Adjusted model included educational attainment (< high school, > high school), smoking history,
diastolic and systolic blood pressure, blood glucose and history of cholesterol lowering
medications.
Fully adjusted model includes the covariates from the adjusted model plus APOE e4 allele status.
There were 65 subjects who had missing data for educational attainment. Data for APOE was
recorded for 568 subjects, but 11 of these subjects had missing data for educational attainment.
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Table 5.13: Demographic Characteristics of Final Sample According to Cognitive Quartile
Cognitive Quartile
Characteristic
Quartile 1
Quartile 2-3
Quartile 4
P-value
*Age, midlife (SD)
40.1 (3.3)
39.1 (3.7)
38.1 (3.5)
<0.01
**Age, late life (SD)
67.1 (3.3)
66.3 (3.7)
65.2 (3.4)
<0.01
Sex, n (%)
0.12
Female
88 (44.4)
192 (50.9)
102 (54.8)
Male
110 (55.6)
185 (49.1)
84 (45.2)
Educational attainment, n (%)
<0.01
< High school
26 (13.1)
11 (2.9)
1 (0.5)
High school degree
88 (44.4)
137 (36.3)
36 (19.4)
Some college
52 (26.3)
111 (29.4)
46 (24.7)
College degree
32 (16.2)
118 (31.3)
103 (55.4)
Ever smoked, n (%)
0.43
No
56 (28.3)
125 (33.2)
55 (29.6)
Yes
142 (71.7)
252 (66.8)
131 (70.4)
Use of cholesterol lowering
0.82
medications, n (%)
No
95 (48.0)
172 (45.6)
89 (47.8)
Yes
103 (52.0)
205 (54.4)
97 (52.2)
Avg. blood glucose, mg/dl (SD) 102.2 (20.3) 100.7 (17.9)
97.8 (15.5)
0.05
Avg. systolic blood pressure,
127.6 (11.9) 127.5 (12.0) 125.1 (12.1)
0.06
mmHg (SD)
Avg. diastolic blood pressure,
77.5 (6.6)
77.2 (6.3)
76.6 (6.3)
0.33
mmHg (SD)
APOE e4 allele status, n (%)
0.11
APOE e4163 (82.3)
281 (74.5)
143 (76.9)
APOE e4+
35 (17.7)
96 (25.5)
43 (23.1)
*Age during first clinical examination represents midlife
**Age upon receiving neuropsychological battery represents late life
SD = standard deviation, n = number of subjects
Analysis of variance was used to compare group means for continuous variables (age, blood
glucose, and blood pressure) and chi-square tests were used to compare group differences for
categorical variables (sex, education, cholesterol medication use, and APOE e4 allele status).
Percentages for categorical variables are based on column total. Value may exceed 100 due to
rounding.
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Table 5.14: Association between Cholesterol Trajectory and Cognitive Quartile

Age
Age^2
Cognition
Quartile 2-3 (ref)
Quartile 1
Quartile 4
Age*quartile 1
Age^2*quartile 1
Age*quartile 4
Age^2*quartile 4
Sex
Female (ref)
Male
Education
High school (ref)
< High school
Some college
College degree
Smoking history
No (ref)
Yes
Cholesterol medications
No (ref)
Yes
Blood glucose
Systolic blood pressure
Diastolic blood pressure
APOE e4 allele
e4- (ref)
e4+

Estimate (SE)
0.14 (0.09)
-0.09 (0.006)

t-value
1.5
-15.2

P-value
0.14
< 0.01

-1.5 (2.6)
-5.7 (2.7)
-0.14 (0.13)
-0.001 (0.009)
-0.06 (0.14)
0.01 (0.009)

-0.56
-2.1
-1.1
-0.16
-0.47
1.2

0.58
0.03
0.29
0.87
0.64
0.23

-12.1 (2.3)

-5.3

< 0.01

5.0 (4.3)
0.08 (2.2)
-2.9 (2.2)

1.2
0.04
-1.3

0.24
0.97
0.19

1.1 (1.9)

0.57

0.57

8.7 (1.8)
-0.09 (0.05)
0.11 (0.11)
0.18 (0.20)

4.9
-1.7
1.0
0.92

< 0.01
0.09
0.30
0.36

0.05 (2.1)

0.03

0.98

Results based on mixed effects regression model controlling for the effects of sex, education,
smoking, cholesterol medication use, blood glucose, blood pressure and APOE e4 allele status

117

Figure 5.1: ROC Curves, Normal Cognition and Dementia.

Figure 5.2: ROC Curves, Normal Cognition and ILMTB

Figure 5.3: ROC Curves, Normal Cognition and MDITB
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Figure 5.4: ROC Curves, Dementia and ILMTB

Figure 5.5: ROC Curves, Dementia and MDITB

Figure 5.6: ROC Curves, ILMTB and MDITB
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Figure 5.7: Trajectories of Total Cholesterol Stratified by Alzheimer’s Disease Status

Model 1: adjusted for sex and educational attainment (< high school, > high school) n=2384
Model 2: model 1 plus smoking (ever smoker yes, no) n=2384
Model 3: model 2 plus average blood pressure and average blood glucose n=2384
Model 4: model 3 plus use of cholesterol lowering medications (ever user yes, no) n=2384
Model 5: model 4 plus APOE e4 allele status (e4+, e4-) n=557

Figure 5.8: Trajectories of HDL Cholesterol Stratified by Alzheimer’s Disease Status

Model 1: adjusted for sex and educational attainment (< high school, > high school) n=2384
Model 2: model 1 plus smoking (ever smoker yes, no) n=2384
Model 3: model 2 plus average blood pressure and average blood glucose n=2384
Model 4: model 3 plus use of cholesterol lowering medications (ever user yes, no) n=2384
Model 5: model 4 plus APOE e4 allele status (e4+, e4-) n=557
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Figure 5.9: Trajectories of Total/HDL Ratio Stratified by Alzheimer’s Disease Status

Model 1: adjusted for sex and educational attainment (< high school, > high school) n=2384
Model 2: model 1 plus smoking (ever smoker yes, no) n=2384
Model 3: model 2 plus average blood pressure and average blood glucose n=2384
Model 4: model 3 plus use of cholesterol lowering medications (ever user yes, no) n=2384
Model 5: model 4 plus APOE e4 allele status (e4+, e4-) n=557
Figure 5.10: Trajectories of Total, HDL and Total/HDL Ratio Stratified by APOE e4 Allele
Status

Adjusted trajectories control for the effects of sex, educational attainment, smoking, average
blood pressure, average blood glucose, and use of cholesterol lowering medications. Unadjusted
model includes 568 subjects. Eleven subjects who had missing data for educational attainment
were excluded from the adjusted models (n=557).
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Figure 5.11: Trajectories of Total, HDL, and Total/HDL Ratio Stratified by Alzheimer’s
Disease and APOE e4 Allele Status

Adjusted trajectories control for the effects of sex, educational attainment, smoking, average
blood pressure, average blood glucose and use of cholesterol lowering medications. Adjusted
models include 557 subjects.
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Figure 5.12: Trajectories of Total, HDL, and Total/HDL Ratio Stratified by Alzheimer’s
Disease and Sex

The adjusted models controlled for the effects of educational attainment, smoking, average blood
pressure, average blood glucose and use of cholesterol lowering medications. The fully adjusted
models included APOE e4 allele status plus all of the covariates in the adjusted model. The
sample sizes for the unadjusted, adjusted and fully adjusted models were 2449, 2384 and 557
subjects, respectively. There were 65 subjects who had missing data for educational attainment.
Data for APOE was recorded for 568 subjects, but 11 of these subjects had missing data for
educational attainment.
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Figure 5.13: Trajectories of Total, HDL and Total/HDL Ratio Among Women Adjusted for
Supplemental Estrogen use Stratified by Alzheimer’s Disease Status

The adjusted models controlled for the effects of sex, educational attainment, smoking, average
blood pressure, average blood glucose, use of cholesterol lowering medications and use of
supplemental estrogen. The fully adjusted models included APOE e4 allele status plus all of the
covariates in the adjusted model. There were 1390 subjects included in the adjusted models.
There were 337 subjects included in the fully adjusted models.
Figure 5.14: Subject-Specific Trajectories of Total Cholesterol Stratified by
Cognitive Quartile

Subject-specific trajectories of total cholesterol were obtained by combining the fixed and
random effects for the model that included sex, educational attainment, smoking, cholesterol
medications, blood glucose, blood pressure, and APOE e4 allele status as covariates.
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Figure 5.15: Total Cholesterol Trajectories Stratified by Cognitive Quartile

Trajectories of total cholesterol adjusted for the effects of sex, educational attainment, smoking,
cholesterol medications, blood glucose, blood pressure, and APOE e4 allele status.

Copyright © Brian Gregory Downer, 2014
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Chapter Six: Discussion and Conclusion
A number of factors have been implicated in pathological changes in cognition later in
life, and in pathological changes that eventually lead to AD. Diet represents one dominant set of
factors, and cholesterol is one particular factor within this domain that has attracted recent
attention in scholarship. This dissertation has sought to add to this scholarship.
The research reported in this dissertation, based on longitudinal data taken from the FHS,
employed a life span approach to promote understanding of the relationship between cholesterol
levels and cognitive function. A first task (and Specific Aim One) of the research was to
determine the best way to empirically express cognitive functioning, given that FHS includes
multiple measures of cognitive function. The resulting metric was later applied (in Specific Aim
Three) to an analysis of the relationship between life span cholesterol trajectories and cognitive
function among older adults who had not received a diagnosis of dementia. An intermediate task
(Specific Aim Two) sought to identify relationships between life span cholesterol trajectories
(specifically total, HDL, and total/HDL ratio) and AD, recognizing that this pathological
condition was not addressed in the last Specific Aim.
This final chapter of the dissertation offers a critical summary of the findings from
Specific Aims one through three, which will be presented in turn. A central theme that emerges
from critical evaluation, not only of the findings but also of the foundational literature, is the
potential of life course concepts for informing ongoing epidemiological research involving
cognitive function. The life course concepts will be covered, and will be followed by specific
directions for research that may effectively situate this dissertation’s research within a life course
framework and, consequently, identify areas of ongoing research.
Discussion of Research Findings
Defining Midlife and Late Life Based on Total Cholesterol
This segment of the research employed a rigorous approach to define age boundaries for
midlife and late life by visually examining age-related changes in total cholesterol and identifying
126

age periods in which there was a prolonged increase in total cholesterol (representing midlife) and
the ages in which there was a prolonged decline in total cholesterol (representing late life). Based
on examination of both the cross-sectional and longitudinal trends, midlife was defined as
between 30 and 55 years of age for the Original Cohort, and between 30 and 45 years of age for
the Offspring Cohort. Late life was defined as 65 and older for the Original Cohort, and 60 years
and older for the Offspring Cohort. Findings illuminated potentially significant cohort
differences in changes to total cholesterol across the life span. Subsequent research should focus
on identifying factors that may have contributed to these cohort differences and if these factors
also contribute to potential cultural differences in life span trajectories of cholesterol and other
measures of vascular health.
This portion of the research also presents a clear challenge to widely accepted notions of
what constitutes old age, middle age, and other life stages. Aging research has seemingly taken
for granted the importance of sufficiently justifying why certain age boundaries for various life
stages are chosen and the implications that arbitrarily selecting age boundaries may have on
findings. A critical evaluation of how age boundaries for midlife, late life, and other life stages
should be obtained is warranted. It is commonly recognized, for example, that age 65 represents
a dominant stage boundary largely as a consequence of policy measures in the U.S. dating back to
1935 (REF). These policies, though based on cursory observation of physiological change and
health status at the time, were essentially derived from consideration of the balance between
chronological age and economic productivity and need, even though productivity and need are
not simply a matter of physiological capacity. Once established, a break-point of 65 years
(‘retirement age’) gathered a certain temporal momentum and has endured as an emerging
requirement of replication of results within the ‘Scientific Method’ that gained increasing
credibility through the 20th Century (REF?). Yet a life course view would suggest that complex
societal changes, ranging from medical advances to political economic priorities and
communication/media technologies might well be expected to alter health status at advanced ages
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along with the potential productivity levels associated with age. In short, the link between
chronological age and both physiological capacity and economic productivity is likely much
different today than it was in 1935.
Specific Aim One
Aim One sought to calculate a series of three summary scores for the FHS
neuropsychological battery and utilize receiver operating characteristic analysis to determine
which summary score was best able to differentiate between subjects classified as having normal
cognitive function, test-based impaired learning and memory (ILMTB), test-based multidomain
impairment (MDITB), and dementia. The relatively high values for the area under the curve
(AUC), sensitivity, and specificity indicate that all three summary scores were able to accurately
differentiate between the four cognitive groups, but significant differences between the three
summary scores were detected when classifying normal versus dementia, normal versus MDITB,
and ILMTB versus MDITB. When compared to the composite subtests summary score, the
composite domains summary score was not as accurate when differentiating between normal
versus dementia, and ILMTB versus MDITB, whereas the learning/memory score was less accurate
when differentiating between normal versus MDITB. Based on these findings, the composite
subtests summary score was determined to have the highest utility when differentiating between
the four cognitive groups and was used as the measure of cognitive functioning for Aim Three.
Many population-based cohort studies assess cognitive functioning using a
neuropsychological battery comprised of a collection of cognitive assessments that are included
for reasons linked to the specific goals of the study. But there are considerable differences
between studies in the number and type of cognitive assessments included in the
neuropsychological battery, which makes it challenging to compare the results of the subtests
summary score obtained in Specific Aim One from the FHS neuropsychological battery to
summary scores obtained from other studies. A total score for the Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) neuropsychological battery has been reported to
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accurately differentiate between older adults with normal cognition, mild cognitive impairment
(MCI) and AD (Chandler et al., 2005). Compared to the results reported by Chandler et al.
(2005), the composite subtests summary score from Specific Aim One had a similar AUC,
sensitivity, and specificity when differentiating between normal, cognitively impaired and
dementia subjects. This suggests that a summary score that is the sum of the subtests included in
the neuropsychological battery has similar utility compared to the composite subtest method used
in Specific Aim One.
A total score was not calculated in Specific Aim One because this method does not take
into account the differential weighting of each assessment within the summary score due to the
variation in the minimum and maximum possible scores for each assessment. As a result, a
subject’s total score may not accurately represent their overall level of cognitive functioning
because the total score may be highly influenced by performance on only one or two subtests.
Furthermore, a total score approach does not account for the different scales in which some
cognitive assessments are scored. The FHS neuropsychological battery includes the Trail Making
Test (TMT) A and B, which are timed assessments measured in either minutes or seconds
(subjects are typically allowed a maximum of five minutes, 300 seconds, to complete each
assessment). The relative weight of the TMT A and TMT B scores in a total summary score
would vary substantially depending on if the time to complete the assessments was measured in
seconds or minutes. A potential resolution would be to not include the TMT A and B
assessments in a total summary score, but these assessments are sensitive to the presence of
dementia (Rasmusson, Zonderman, Kawas, & Resnick, 1998) and mild cognitive impairment
(Ashendorf et al., 2008) and not including these assessments would potentially decrease the
utility of the summary score.
Limitations: There are important limitations of Specific Aim One that should be
acknowledged. First is the low number of participants who had received the neuropsychological
battery and were diagnosed with dementia. A total of 1251 subjects in the validation sample
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completed a neuropsychological battery, but only 19 of these subjects had received a diagnosis of
dementia. The low prevalence of dementia is due to the relatively young age of the Offspring
Cohort. This limited the ability to detect statistically significant differences between the three
summary scores when classifying between dementia and the other cognitive groups. The low
power was reflected by the wide confidence intervals for area under the curve (AUC), sensitivity,
specificity, negative predictive value (npv), positive predictive value (ppv) and total accuracy in
the analyses that included participants with dementia. The low prevalence of dementia must also
be taken into consideration when interpreting the ppv and npv for the summary scores because
these metrics are influenced by disease prevalence (Altman & Bland, 1994). The ppv of a
diagnostic measure increases as the prevalence of the disease increases, whereas the npv
decreases as the prevalence of the disease increases. This means that in a population were the
prevalence of a disease is low, a relatively high number of people will be incorrectly classified as
having the disease compared to the number of people who test positive and truly have the disease.
A second limitation is that calculating specificity, sensitivity, ppv, npv and overall
accuracy of the three summary scores required comparing the classification results from the
summary scores to those obtained from a predetermined gold standard. The gold standard for
classifying participants as MDITB and ILMTB was consistent with the diagnostic criteria for MCI
established by the National Institute on Aging and Alzheimer’s Association (NIA-AA)
workgroup (Albert et al., 2011). The NIA-AA workgroup defines MCI as cognitive performance
that is >1.5 standard deviations below what a person would be expected to perform based on their
age and level of education. The NIA-AA workgroup emphasizes that persons diagnosed with
MCI are able to maintain their ability to independently perform activities of daily living (ADLs),
such as paying bills, cooking a meal, or shopping. While the FHS includes measures for ADLs,
this criterion was not included in the classification of MDITB and ILMTB because these measures
were not collected concurrently with the neuropsychological battery. Not including the ability to
independently perform activities of daily living in the diagnostic criteria utilized in Aim One
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raises the possibility that some participants classified as ILMTB or MDITB may have dementia if
their level of cognitive impairment limited their ability to independently perform ADLs.
Finally, the results from the ROC analysis may over-estimate the ability of the summary
scores to differentiate between the cognitive subgroups because the cognitive assessments used to
classify participants as normal, MDITB and ILMTB were also used to create the three summary
scores. However, biases that may have arisen as a result of utilizing this approach were
minimized because the summary scores were not used to classify subjects as normal, MDITB, and
ILMTB.
Future Research: The findings from this Specific Aim have identified important research
questions and limitations that need to be addressed by future research. First, this analysis should
be replicated using data from a study that has specifically recruited subjects with dementia. The
increased number of dementia cases would bias the ppv and npv of the summary scores, but
would increase the likelihood of detecting significant differences in the classification accuracy of
the three summary scores. This would also potentially allow analyses for specific subtypes of
dementia, such as AD and vascular dementia, to be conducted. Next, the gold standard criteria
used to classify participants as normal, ILMTB, and MDITB in this research can be refined by
including measures of ADLs, repeated measures of cognitive functioning to assess cognitive
decline, and measures for brain pathology. Including these measures may improve the ability to
accurately classify participants as normal, ILMTB and MDITB according to the gold standard.
Finally, the mini-mental status exam (MMSE; Folstein, Folstein & McHugh, 1975) was not
included as part of the neuropsychological battery. The MMSE is commonly used in clinical
settings to assess cognitive functioning and it would be beneficial to determine if the summary
scores are better able to differentiate between specific cognitive groups compared to the MMSE.
Conclusion: All three summary scores were able to accurately differentiate between the
normal, ILMTB, MDITB and dementia subgroups, but the findings indicate that the composite
subtests summary score has the highest utility among the three summary scores. Based on the
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results of this Specific Aim, the composite subtests summary score was deemed appropriate as
the measure of cognitive functioning in aim three. Furthermore, the study design and methods
utilized in aim one can be replicated and used by other investigators to create summary scores for
the neuropsychological batteries employed in other studies.
Specific Aim Two
Specific Aim Two utilized a longitudinal study design to examine the relationship
between trajectories of total cholesterol, high-density lipoprotein (HDL) cholesterol and
total/HDL cholesterol ratio from midlife to late life and AD using generalized additive mixed
models (GAMMs). The purpose of this Specific Aim was to determine if there were differences
in the longitudinal trajectories of cholesterol between older adults diagnosed with AD and those
who do not have dementia.
In general, Specific Aim Two findings do not provide strong evidence that there are
substantial differences in the trajectories of total cholesterol, HDL cholesterol or total/HDL ratio
from midlife to late life between older adults diagnosed with AD and older adults without
dementia. Total cholesterol increased until approximately 60 years of age, which was followed
by a steady decline with advancing age for older adults with AD, as well as for older adults
without dementia. HDL cholesterol increased with age for older adults diagnosed with AD and
those without dementia. The increase in HDL followed a linear trend for subjects with AD,
whereas the increase in HDL cholesterol followed a cubic trend for subjects without dementia.
Finally, both subjects with AD and subjects without dementia exhibited a steady decline in
total/HDL cholesterol ratio, which accelerated at approximately 70 years of age.
There were slight differences in the trajectories of total, HDL and total/HDL cholesterol
ratio according to AD status when the effects of sex, educational attainment, smoking history,
blood pressure, blood glucose and history of using cholesterol-lowering medications were
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controlled for in the adjusted models 17. These differences became more apparent when
apolipoprotein E (APOE) e4 allele status was added to the adjusted models 18. The overall
trajectories of cholesterol did not dramatically change once APOE e4 allele status was added as a
covariate, but older adults diagnosed with AD had higher measures of total cholesterol and HDL
cholesterol compared to older adults without dementia. Older adults without dementia had
slightly higher total/HDL cholesterol ratio, but these subjects exhibited an accelerated decline in
total/HDL cholesterol ratio following 70 years of age, whereas older adults with AD maintained a
constant decline.
There were substantial differences in the trajectories of total cholesterol, HDL
cholesterol, and total/HDL cholesterol ratio when stratified according to sex and AD status.
Women had lower total cholesterol during midlife compared to men, but women exhibited a
dramatic increase in total cholesterol up until approximately 60 years of age. Men and women
exhibited a similar rate of decline in total cholesterol following 60 years of age. The measures of
HDL cholesterol remained relatively constant with age for men and women; however, women
had much higher measures of HDL cholesterol compared to men. Finally, the ratio of total
cholesterol to HDL cholesterol declined with age for both men and women, with an accelerated
rate of decline occurring at approximately 70 years of age. While there were visually apparent
differences in total cholesterol, HDL cholesterol and total/HDL cholesterol ratio between men
and women, there were little to no differences according to AD status for men or women
according to the adjusted models. When APOE e4 allele status was included as a covariate (fully
adjusted model), men who developed AD had lower cholesterol from 30 to 50 years of age and
maintained higher total cholesterol following 55 years of age compared to men who did not
develop dementia. Women who developed AD maintained slightly higher total cholesterol

17

The adjusted model included sex, educational attainment, smoking history, blood pressure,
blood glucose and history of using cholesterol-lowering medications
18
The fully adjusted models included APOE e4 allele status plus all of the covariates in the
adjusted model.
133

following 55 years of age compared to women who did not develop AD. In the fully adjusted
model, men who developed AD had higher HDL cholesterol compared to men who did not
develop AD, but AD subjects exhibited a decline in HDL cholesterol at 70 years of age whereas
non-demented subjects exhibited a slight increase in HDL cholesterol. These differences in HDL
cholesterol among men contributed to an accelerated decline in the total/HDL cholesterol ratio
among men without dementia whereas men with AD exhibited a steady decline in total/HDL
cholesterol ratio. There were no substantial differences in the trajectories of HDL cholesterol or
total/HDL cholesterol ratio according to AD status among women.
When the trajectories of total cholesterol were stratified according to AD status and
APOE e4 allele status, subjects who were diagnosed with AD and carried one or more APOE e4
alleles had consistently higher cholesterol from midlife to late life compared to non-demented
subjects who did not carry an APOE e4 allele. When the trajectories of HDL cholesterol were
stratified according to AD and APOE e4 allele status, subjects diagnosed with AD and who were
e4+ exhibited an increase in HDL cholesterol, whereas HDL cholesterol declined for AD e4subjects. The trajectories of total/HDL cholesterol ratio, according to AD and APOE e4 status,
followed a similar decreasing trend. The greatest differences in total/HDL cholesterol ratio were
observed during midlife, but these differences became less apparent with advancing age.
There is limited research on the relationship between longitudinal trajectories of
cholesterol and AD. A study conducted by Stewart et al. (2007) examined the longitudinal
trajectories of total cholesterol according to dementia status utilizing data from the Honolulu-Asia
Aging study. In this study, men who developed AD exhibited an accelerated decline in total
cholesterol compared to men who did not develop dementia, whereas the opposite relationship
was observed among men in the FHS Original Cohort. Men who did not develop AD in the FHS
Original Cohort exhibited a greater rate of decline in total cholesterol beginning at 45 to 50 years
of age compared to men who eventually developed AD. Furthermore, men who did not develop
AD had higher cholesterol during midlife and lower cholesterol during late life compared to men
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who did develop AD. These findings conflict with findings from previous studies that have
reported high total cholesterol during midlife (Notkola et al., 1998; Solomon, Kivipelto, et al.,
2009) and low total cholesterol during late life (Reitz et al., 2004; Siest et al., 2000) to be
associated with AD. The findings from Specific Aim Two are consistent with a study conducted
by Lesser et al. (2001) in which older adults with AD had, on average, higher total cholesterol
and HDL cholesterol compared to older adults without dementia. Furthermore, a study conducted
by Solomon et al. (2007) observed that subjects who developed dementia had a significantly
greater decline in total cholesterol from midlife to late life, but had higher concentrations of total
cholesterol during midlife and late life compared to older adults without dementia.
One hypothesis for an age-dependent relationship between peripheral cholesterol and AD
is that high peripheral cholesterol contributes to an increase in AD neuropathology, which may
lead to a decline in cholesterol due to a disruption in neurological mechanisms that regulate
peripheral cholesterol homeostasis (Mielke et al., 2005). The findings from this Specific Aim do
not support such a hypothesis 19. Rather, the longitudinal trajectories of total cholesterol
according to AD status suggest that men in particular with high cholesterol during midlife, who
are able to reduce their cholesterol later in life, may be less likely to develop AD compared to
men who do not reduce their cholesterol with advancing age. The use of cholesterol lowering
medications was controlled for in the analysis and there were no differences in the use of
cholesterol lowering medications among men according to AD status. Other factors that may
lower total cholesterol, such as consuming a low fat diet and regular physical activity, may
contribute to the apparent decline in cholesterol during midlife among men who do not develop
AD.
Limitations: Certain limitations in this Specific Aim Two need to be acknowledged.
First, potentially important covariates such as smoking, measures for blood pressure and blood
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A significant limitation of the hypothesis proposed by Mielke (2005) is the blood brain barrier
effectively limits the exchange of cholesterol between the periphery and the brain.
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glucose, and use of cholesterol lowering medications, were not able to be included in the models
as time-dependent covariates. A time-dependent covariate means that the value or status of the
variable changes over time, whereas the vale or status of a time-independent covariate remains
fixed for the duration of the study, e.g. sex. Dichotomizing subjects as ever smokers and ever
medication users, or calculating the averages for blood pressure and blood glucose may, for
example, oversimplify the potential relationship between these variables and the trajectories of
cholesterol. This is a possible explanation for why adjusted R2 values in the models did not
substantially change as these covariates were added to the models. An alternative approach that
was used in the dissertation research was to calculate the total number of clinical examinations
that a person reported being a smoker or taking cholesterol lowering medications. This was done
to account for the duration in which a person was a smoker or took cholesterol-lowering
medications. A limitation of this approach, however, was it did not account for differences
between subjects in the number of times a subject was observed over the course of the study. To
clarify, a subject who attended twelve clinical examinations and reported smoking during six
examinations is likely to be much different compared to a subject who attended seven
examinations and reported smoking during six examinations. The difference in the number of
clinical examinations attended by the two subjects is potentially meaningful because of the higher
proportion of clinical exams in which the second subject reported smoking. Additional research
can address this limitation by including the ratio of clinical exams in which a subject reported
smoking or using cholesterol-lowering medications as covariates. A second limitation of treating
smoking and medication use as time-independent covariates is the age in which a person started
or stopped these behaviors and the duration of these behaviors are not accounted for in the
analysis. This can be addressed by including the age in which a person first reported smoking or
using cholesterol-lowering medications as covariates in the models.
Another limitation is that data regarding the use of symptomatic treatments for AD, such
as Donepezil and Memantine, do not appear to have been collected from subjects of the FHS
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Original Cohort. The use of symptomatic treatments for AD may be an important confounding
variable because there is evidence that acetylcholinesterase inhibitors (AChEI) influence
cholesterol levels. In a cross-sectional study of 105 AD patients conducted by Adunsky, Chesnin,
Ravona, Harats, and Davidson (2004), patients who had been prescribed donepezil (n=35) had
significantly higher total cholesterol, VLDL, LDL, and triglycerides, but not HDL cholesterol,
compared to AD patients who had not been prescribed donepezil. Furthermore, efficacy of
atorvastatin, a frequently prescribed cholesterol medication commonly known as Lipitor, for the
treatment of mild to moderate AD has been shown to be higher among patients with total
cholesterol levels above 220 mg/dl compared to patients with total cholesterol < 200 mg/dl
(Sparks et al., 2006). These findings provide evidence that the higher cholesterol among older
adults who developed AD relative to subjects without dementia may be due to a healthy volunteer
bias among AD subjects. Older adults diagnosed with AD who remained in the FHS may have
been able to do so because of their use of AChEI and other symptomatic treatments for AD,
which may have altered their lipid profile.
Conclusion: The findings from Specific Aim Two do not provide sufficient evidence that
the longitudinal trajectories of total cholesterol, HDL cholesterol and total/HDL cholesterol ratio
differ between older adults with AD and those without dementia. Immediate attention should be
placed on conducting research that uses more refined techniques for controlling for the effects of
smoking and medication use. These techniques should focus on accounting for the timing and
duration of smoking and medication use. Additional research should also focus on quantifying
the differences in cholesterol according to AD status that were identified in this dissertation
research using other longitudinal methods such as group based modeling. Finally, future research
should focus on generating evidence that provides insight into potential biological mechanisms
that support cholesterol being an important risk factor for AD and the potential confounding
effects of symptomatic treatments for AD. An area of research worth investigating is examining
if cholesterol outside of the brain is correlated with measures of biomarkers that reflect
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pathological changes in the brain consistent with AD. A significant relationship between
cholesterol and AD biomarkers would provide evidence that there are potential biological
mechanisms that explain how abnormal concentrations of cholesterol during the life span modify
the risk for AD. Plausible biological mechanisms for a relationship between cholesterol and AD
would justify additional research in this area.
Specific Aim Three
There is considerable heterogeneity in cognitive functioning among older adults who do
not have dementia and subtle cognitive impairment may be an early warning sign of dementia.
This, along with evidence for a significant relationship between total cholesterol and cognitive
functioning among older adults without dementia (Elias, Elias, D'Agostino, Sullivan, & Wolf,
2005; Henderson, Guthrie, & Dennerstein, 2003; Solomon, Kareholt, et al., 2009), were the
motivating factors for investigating if there is a visually apparent relationship between a person’s
unique trajectory of total cholesterol and cognitive functioning during old age.
Specific Aim Three utilized a longitudinal study design to examine the relationship
between subject-specific trajectories of total cholesterol from midlife to late life and cognitive
functioning among older adults without dementia. There was not strong visual evidence for a
relationship between the subject-specific trajectories of total cholesterol from midlife to late life
and a subject’s level of cognitive functioning during old age. When the averages of the subjectspecific trajectories for each of the cognitive quartiles were examined, subjects in the fourth
quartile had significantly lower total cholesterol compared to the second and third quartiles at 55
years of age. However, the estimated difference in total cholesterol between the two groups was
only 5.7 mg/dl and this difference, while statistically significant, is unlikely to have significant
clinical meaning. Subjects in the first cognitive quartile also had lower total cholesterol at 55
years of age compared to the second and third quartiles, but this difference was not statistically
significant. Interaction terms between the linear term and cognition, and the quadratic term and
cognition were included in the mixed effects models to determine if the trajectories of total
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cholesterol from midlife to late life differed according to cognitive quartile. Neither of the
interaction terms were statistically significant indicating that there was not a significant difference
in the mean trajectories of total cholesterol from midlife to late life according to cognitive
quartile.
The results from this Specific Aim align with a study reporting that high total cholesterol
during midlife (age 47 - 51) was associated with lower episodic memory and psychomotor speed
twenty-one years later (Solomon, Kareholt, et al., 2009). However, another study that utilized
data from the FHS Original Cohort reported that non-demented older adults, between the ages of
55 and 88 during the 14th or 15th clinical examination, whose average total cholesterol from the 4th
through 12th clinical examinations was < 200 mg/dl had lower cognitive functioning compared to
subjects whose average measures of total cholesterol were between 200 to 239 mg/dl or > 240
mg/dl (Elias et al., 2005). Also, Henderson et al. (2003) reported a positive correlation among
healthy women 52 to 63 years of age between memory function and an increase in total
cholesterol eight years before memory function was assessed. Finally, a study of adults 65 years
of age and older did not report a significant relationship between total cholesterol and memory or
language (Reitz, Luchsinger, Tang, Manly, & Mayeux, 2005).
There are several explanations for the apparent differences in the findings of aim three of
the dissertation research compared to the findings reported by Elias et al. (2005). First, there are
important differences in overall approaches of the two studies. Based on how the repeated
measures of total cholesterol were utilized in the analysis, Elias et al. (2005) were able to
determine if the average measure of total cholesterol during a prolonged period is associated with
cognitive functioning later in life. This approach did not allow for potentially important changes
in the trajectory of total cholesterol to be detected, which was the purpose of the Third Specific
Aim. Second, the wide age range of subjects included in the final sample by Elias et al. (2005)
may have influenced the relationship between total cholesterol and cognition. The age range of
subjects during the 4th through 12th clinical examinations was between 30 and 35 years, with the
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youngest subject during the 4th clinical examination being 34 years of age and the oldest being 69
years of age. The findings presented in Chapter Three of this dissertation indicate a strong
relationship between total cholesterol and chronological age in the FHS Original Cohort, with
total cholesterol increasing during midlife and declining later in life. Subjects who were in their
thirties during the fourth clinical examination likely exhibited an increase in total cholesterol
during the subsequent nine clinical examinations, whereas total cholesterol likely decreased over
the same period for subjects in the 50’s and 60’s during the fourth clinical examination. While
age was included as a covariate by Elias et al. (2005), this may not have fully accounted for the
potential confounding effects of age on the relationship between cholesterol and cognition. A
third explanation is the unique characteristics of the Offspring and Original Cohorts that may
contribute to the differences in total cholesterol across the life span. These characteristics have
been highlighted in Chapter Three of this dissertation.
Limitations: There are limitations of the research for Specific Aim Three that need to be
acknowledged. First, potentially important covariates, such as smoking, use of cholesterol
lowering medications, blood pressure and blood glucose were included in the models as timeindependent covariates. Not taking into account the time-dependent nature of these covariates
may not adequately adjust for the effects that these variables have on the relationship between
cholesterol and AD. This is especially relevant for smoking and medication use because the age
and duration of these behaviors influence vascular health (Celermajer et al., 1993; Dempsey &
Moore, 1992; Herrington et al., 2002; Young-Xu et al., 2003). A second limitation is that
characterizing non-linear trajectories using mixed effects models requires specifying a functional
form by including quadratic, cubic or higher order polynomial terms in the model. Imposing a
predetermined structure on the data may be too restrictive and this was the motivating factor for
utilizing GAMM in Specific Aim Two. Despite this limitation, mixed effects models were still
utilized for Specific Aim Three because the methods that allow for smoothing terms to be applied
to subject-specific trajectories fall outside the feasible limits of the immediate dissertation
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research. Finally, dividing subjects into quartiles according to their cognitive summary score
does not take into account that some older adults maintain normal functioning in certain cognitive
domains but may have impairment in other cognitive domains. This prevented potential
relationships between the subject-specific trajectories of total cholesterol and specific cognitive
domains from being detected. Identifying subjects who are ILMTB, MDITB and normal cognition
and then examining the subject-specific trajectories of total cholesterol according to these
cognitive groups can address this limitation.
Conclusion: To summarize, the findings from this Specific Aim do not provide strong
evidence of a significant relationship between an individual’s unique trajectory for total
cholesterol from midlife to late life and their level of cognitive functioning during old age.
Subjects who were in the highest quartile for cognitive functioning had significantly lower total
cholesterol compared to subjects in the middle two cognitive quartiles. Additional research is
needed to clarify the relationship between the longitudinal trajectories of total cholesterol and
cognitive functioning later in life. This research should focus on incorporating the duration of
smoking and cholesterol medication use, as well as the age in which these behaviors started, into
the analysis as these characteristics may play an important role in the relationship between
cholesterol and cognitive function.
The Life Course as a Conceptual Lens
The life span perspective is well suited for conducting research that is focused on
understanding the developmental characteristics of humans as they age, identifying factors that
may modify physiological, intellectual or other developmental characteristics with advancing age,
or the relationship between different developmental stages. This dissertation employed a life
span perspective by examining trajectories of cholesterol from midlife to late life to determine if
these trajectories were related to AD and cognitive functioning later in life. A life span approach
also supports an age-continuous view to reveal subtle but potentially important time points of
change that are often obscured by a life stage emphasis. This approach offers avenues to advance
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current understanding of the relationship between cholesterol and cognition, but does not prove
an adequate conceptual framework for examining the true complexity of the interacting factors
that influence cholesterol levels through the life span and their association with cognitive
functioning during old age. A life course view may resolve this shortcoming of the life span
approach.
Simply put, the life course is a person’s life, or life span, in full context (J. F. Watkins,
1999). This context refers to the notion that aging is more than the passage of time measured
chronologically by the accumulation of years. Rather, aging is reflected by ongoing changes that
occur within personal (e.g. physical, cognitive and psychological) and social (e.g. family, work
and education) domains from birth until death (Settersten, 2006). Many of the significant events
and transitions that occur within these personal and social domains (e.g. acquiring verbal
language, puberty, graduating high school, leaving the family home, entering the workforce) are
highly correlated with chronological age. This has made chronological age a useful index for
predicting a person’s physical, cognitive or psychological characteristics, as well as their social
standing and the roles a person is expected to fill within society (Settersten & Mayer, 1997).
Furthermore, this use of chronological age has resulted in normative behaviors and characteristics
associated with distinct life stages that are socially constructed. This leads to the expectation that
people move through the life course in a sequential fashion that follows a predictable order and
questions or concerns are often raised when a person deviates from these social norms (e.g.
developmental delays during childhood, teenage pregnancy, older adult in a college classroom).
The variability in the timing and order in which events, experiences and transitions within
personal and social domains occur are due to the influence that family, education, health, and
social and cultural factors (e.g. cohort effects) and the complex interactions between these factors
have on a person’s life course. These factors provide the context of the life span and introduce
the socio-cultural influences that shape the life course. Additional layers of complexity are added
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to this context when the influences of time (past, present, future), space (the environment in
which events occur), and the actions of those around us are taken into account.
The scholarly pursuit of identifying factors that modify the timing and ordering of the life
course and the potential implications that mistimed events and transitions have on later life
outcomes has made the life course an extensively studied area of research. However, the
concepts of the life course are valuable tools for developing research questions, designing studies
and even influencing data collection (Elder et al., 2003; Settersten, 2006). Engaging the life
course as a conceptual research framework is the focus of the rest of this chapter. The remainder
of this chapter is organized as follows. First, the core concepts of the life course are presented
along examples from relevant areas of research. Next, the application of life course concepts in
epidemiology is introduced. These sections are meant to provide sufficient background
knowledge on life course concepts so that the influence these concepts have for conceptualizing
future research in AD can be better appreciated. This chapter concludes by describing how life
course concepts can be applied to future research that will, hopefully, advance the current
scientific understanding of AD.
Concepts of the Life Course
Every person has their own unique life course that is shaped by (1) endogenous (internal)
and exogenous (external) factors, (2) early life choices, events and experiences, as well as the
choices, events and experiences we anticipate happening in the future, (3) the timing in which
events, experiences, and transitions occur and (4) the interdependence in which people live their
lives with those around them.
Endogenous and Exogenous Factors that Shape the Life Course: Endogenous factors
that shape a person’s life course include the genes they inherit from their parents, their physical
and mental traits, as well as their intelligence, and emotional and personality characteristics.
Endogenous factors shape a person’s life course by influencing the choices and decisions a person
makes in response to their environment. Exogenous factors that shape a person’s life course may
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be grouped into distinct life domains 20. These domains include: (1) Family, which includes
personal relationships outside of our immediate and extended family; (2) Place and home, which
refers to the places/homes that we have lived, as well as personal notions of home; (3) Education,
which includes formal learning experiences (e.g. high school, college) and informal learning
experiences (e.g. learning a skill from a family member); (4) Employment, which includes formal
work experiences (e.g. paying jobs) and informal work experiences (e.g. helping a friend for no
pay); (5) Recreation and leisure, which are the hobbies and activities we engage in for enjoyment;
(6) Spirituality, which includes traditional religious activities as well as personal beliefs; (7)
Historical context, which is the current cultural and social environment that is shaped by
significant events (e.g. war, economic climate, or political events); and (8) Health, which includes
personal and family health characteristics, significant health events and health behaviors.
Components of Time and Space: The notion that the life course is influenced by events
and experiences that occurred earlier in life is one of the key constructs of the life course
perspective. In some cases the influence of an event or experience on the life course is
immediately apparent, such as getting married or having a child. Other times the significance of a
past event is not recognized until many years later once a person has been able to reflect back on
their experiences. The majority of life course scholars emphasize the influence an actual event or
experience has on a person’s life course, but the memories associated with that event or
experience often times have far greater implications than the event itself. This is especially
relevant for life course research that is interested in outcomes among older adults. Normative
declines in memory can make it challenging to recall the specific details of a past experience or
the details may become altered or exaggerated as a result of a person rehearsing the story in their
mind.
20

The formal conceptualization of life domains is largely unpublished. Focus has been given to
the domains of education, family, work, and historical context and the influence of these domains
on the life course (Elder, 1994, 1998; Elder, Shanahan, & Clipp, 1994), but less attention has
been given to leisure (Settersten, 2006), health (Moser & Watkins, 2008; Settersten, 2006) and
the interdependence of the life domains (Hosier, Downer, Watkins, & Zanjani, 2012a).
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The influence of previous events and experiences on the life course provides a link
between the past and the present, but the present is also linked with the future. Many of the
choices and decisions we make in the present are made with the mindset of what we anticipate
may happen in the future. This may include a person deciding to start saving for college once
their child is born in the anticipation that their child will want to attend college or a person
choosing to complete an advanced directive in case they are unable to express the type of medical
care they want to receive. The future time frame of the life course is often times neglected by
researchers, but recognizing the influence that anticipated events have on the present has
significant implications for research that is focused on identifying motivating factors for present
health behaviors. These implications are elaborated upon in subsequent sections of this chapter.
The concept of space is important for the context of the life course because it emphasizes
the socio-cultural factors that influence a person’s life. Space refers to the environment in which
events and experiences take place. There are several different levels, or zones, of space that
range from “personal” space all the way to the social and cultural environments in which people
live their lives. Social and cultural factors play an important role in shaping the life course
because these factors can change over time as significant events alter social and cultural norms.
These changes in social and cultural norms often times manifest as cohort effects.
Influence of Timing on the Life Course: Chronological age by itself has little meaning
and age alone is typically not accepted as a valid explanation for a behavior or health event. The
perceived significance of chronological age is due to the correlation between chronological age
and important biological, physical, cognitive, behavioral and social characteristics or events.
Significant educational, career, or family events often times mark the transition from one distinct
life stage to another. For example, leaving a parent’s home, graduating from college and entering
the workforce is a series of life events within the domains of family, education and work that
signify the transition from young adulthood into adulthood. The correlation between
chronological age and events within socially constructed domains has allowed for the life course
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to be recognized as a collection of distinct and sequential life stages (e.g. childhood, adolescence,
young adulthood middle age and old age). The structuring of the life course serves an important
purpose because it guides members of a society on what role they are expected to play in society,
as well as plan for significant life events, such as marriage or retirement, which tend to occur
within a specific age range.
The principle of timing proposes that the effect a significant life event has on a persons
life course depends on the timing in which the event occurs (Elder et al., 2003). Because many
social constructs, such as education and work, are structured according to chronological age, a
person’s life course can be altered if they experience a significant life event at an age that is not
within the normative age range imposed by their cultural or society. For example, early entry into
parenthood often times has dramatic consequences and teenage mothers and fathers complete
fewer years of education (Pirog-Good, 1993), are more likely to require government assistance
(Bissell, 2000), and have lower income during adulthood (Moore et al., 1993) compared to those
who delay parenthood.
The effect of timing on the life course is exemplified by the study The Children of the
Great Depression (Elder, 1974). In this study, Elder utilized data from the Oakland Growth Study
and Berkeley Guidance Study to examine the effects that economic deprivation early in life, as a
consequence of the Great Depression, had on educational attainment, career success and family
during adulthood and if these effects differed based on the age in which children experienced the
Great Depression. The children of the Oakland Growth Study were born during the early 1920’s
and were able to progress through childhood during the stable economic climate prior to the Great
Depression, whereas children of the Berkeley Guidance Study were born during the late 1920’s
and experienced early childhood during the worst period of the Great Depression (Elder, 1998).
In general, children of the Oakland Growth Study had better outcomes for educational attainment,
work, and family during adulthood compared to the children of the Berkeley Guidance Study.
Elder attributed these differences between the Oakland Growth Study and Berkeley Guidance
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Study to the different life experiences of the two cohorts during the Great Depression. The
hardships and disadvantages experienced by the participants the Berkeley Guidance Study during
childhood influenced their life course trajectories in education, career and family through
adolescence and young adulthood, and caused the trajectories of these domains to be much
different than those for children born several years earlier.
Interdependence of Lives: The notion that a person’s life course is shaped by the choices,
behaviors and actions of others is an important characteristic of the life course perspective (Elder
et al., 2003). The influence of the interdependent nature in which people live their lives on the
life course is exemplified by examining how children’s health behaviors are often modeled after
the behavior of their parents. In a study examining parental smoking history and adolescent
smoking behavior, adolescents who had one parent who was a current smoker were 2.3 times as
likely to have ever tried smoking and adolescents with two parents who were current smokers
were four times as likely to have ever tried smoking compared to adolescents whose parents were
never smokers (den Exter Blokland, Engels, Hale, Meeus, & Willemsen, 2004).
The social implications of the principle of linked lives are apparent by research on the
relationship between social networks and smoking behavior (Christakis & Fowler, 2008).
Utilizing data from the FHS, Christakis and Fowler (2008) observed that people whose spouse
quit smoking decreased that person’s chances of smoking by 67 percent, if a sibling quit smoking
then that person’s chances of smoking decreased by 25 percent and if a co-worker quit smoking
then that person’s chances of smoking decreased by 34 percent. Relationships between social
networks and social connectedness for self-reported levels of happiness (Fowler & Christakis,
2008) and obesity (Christakis & Fowler, 2007) have also been observed in the FHS.
In order to fully appreciate the complexity of the life course, it is necessary to examine the
interplay between all of the factors that shape the life course. An example is to identify the
factors that may influence a person’s career choice as an adult. The type of career a person
chooses to pursue is likely to have been influenced by their intellectual capacity, previous
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educational experiences and family expectations. A person who exceled in school from an early
age due to their natural ability to learn or because their parents had the means to provided them
with resources that fostered educational development will likely have different career aspirations
compared to a child who struggled early on in school due to delays in intellectual development or
because their family did not place significant importance on education. A person’s career choices
may be further modified based on the current social and economic environment in which they
live. For example, college students who graduate during an economic recession may choose to
attend graduate school to pursue an advanced degree or to receive training in a profession that
may show promising opportunities for gainful employment.
The Life Course as a Research Perspective
As a research perspective, Elder et al. (2003) describes the life course as a conceptual
framework for creating research questions, developing concepts and designing studies.
Following Elder’s landmark study The Children of the Great Depression (Elder, 1974), there has
been a steady increase in the amount of research that has utilized a life course perspective due to
the growing appreciation for the complex interplay between the domains of people’s lives and the
influence that social and cultural characteristics have on these relationships. The majority of
research has focused on the influence that interactions within socially constructed domains, such
as family, education and work have on the life course and only recently has the influence of
health on the life course begun to receive attention by the life course research community. In one
of the first studies to utilize a life course perspective to study health, Elder et al. (1994) examined
the effects that late military deployment to World War II (i.e. deployment after age 33) had on the
health outcomes of men later in life. In general, men who were older than 33 years of age upon
military deployment were at greater risk for poor physical health after returning from war
compared to men who were deployed at a younger age potentially as a consequence of more
severe disruptions to work, family and other domains of social support.
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Life Course Epidemiology: The majority of life course research has been conducted in the
fields of psychology, sociology, demography and related disciplines, but the life course
perspective has begun to be utilized by other disciplines. Epidemiology is one such discipline
that has adopted a life course perspective to study the potential long-term effects that biological,
behavioral and psychosocial exposures during gestation, childhood, adolescence, young
adulthood and across generations have on health outcomes during adulthood (Kuh & BenShlomo, 2004). The purpose of life course epidemiology is to examine the cumulative effects
that prolonged exposures to specific risk factors have on disease risk later in life (Ben-Shlomo &
Kuh, 2002), the temporal relationship between risk factors (Kuh et al., 2003) and to identify
critical periods during the life span where interventions can have the greatest impact for
modifying disease risk (Launer, 2005). Based on the description of life course epidemiology, it is
clear that the motivation for applying a life course perspective to epidemiological research is the
relationship between early life events and health outcomes later in life. This aspect of the life
course is not different than the life span framework and if life course epidemiology were only
interested in examining the relationship between early life exposures and later life outcomes then
it would be more appropriate to use the term life span epidemiology. However, the use of the
term life course is justified for two reasons. First is the emphasis by life course epidemiology that
generations are linked by common genetic and social factors and that these commonalities may
influence health. Second, life course epidemiology recognizes the dynamic nature of sociocultural factors and that secular changes in specific risk factors influence the overall health of a
population.
Life Course as a Conceptual Lens for Alzheimer’s Disease Research
There is strong empirical evidence that the biological cascade of events that may
ultimately lead to AD is initiated many years or even decades before cognitive decline is
observed. This, along with the identification of several midlife risk factors for poor cognition and
AD later in life, have contributed to the growing interest in a life course approach to study AD
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(Launer, 2005; Whalley, Dick, & McNeill, 2006). However, AD research has been focused on
examining biopsychosocial characteristics during midlife and there has been limited research that
has examined characteristics earlier in the life span. Midlife is a critical period for preventing AD
because the pathological changes to the brain associated with AD are unlikely to have occurred,
but it is necessary to consider the factors that influence health outcomes during midlife when
utilizing a life course perspective to study AD.
Many of the midlife risk factors that have been associated with AD can be linked with
living in a disadvantaged environment. Children who grow up in poverty are more likely to
engage in poor health behaviors (van de Mheen, Stronks, Looman, & Mackenbach, 1998), be
diagnosed with a chronic disease (Kittleson et al., 2006; van de Mheen et al., 1998), and have
lower educational attainment (Lawlor et al., 2005) as adults compared to children who grew up in
families of moderate or high socioeconomic status. When examined using a life course
perspective, several pathways that link childhood socioeconomic status (SES) with adult health
can be identified (S. Cohen, Janicki-Deverts, Chen, & Matthews, 2010). An example is the
influence that SES has on the physical environment and how this may modify psychological and
physical development. A child born into a family of low SES may live in an overcrowded home
that is in a neighborhood with poor air and water quality and limited access to education. These
disadvantages may cause a child to have developmental delays in language and reading due to
limited educational opportunities, consume a poor diet because of limited access to healthy foods,
and not engage in physical activity because their neighborhood is to dangerous to play outside.
Collectively, these disadvantages increase the risk for poor health as an adult and ultimately
increase the risk for poor cognitive functioning during old age if the person maintains their
current behavior. Compare this to a child who grows up in a family of moderate or high SES who
may live in a stable home in a neighborhood with good air and water quality and access to quality
educational opportunities. These advantages early in life would allow for a child to excel in
school from an early age and engage in positive health behaviors by modeling the behaviors of
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their parents. Collectively, these advantages decrease the risk for poor health as an adult and may
ultimately decrease the likelihood of having poor cognitive functioning later in life if the person
maintains their current behaviors.
The challenge of identifying potential AD risk factors prior to midlife is there are not
longitudinal studies that have sufficiently examined the physical, behavioral and social
characteristics of participants beginning in childhood through old age. An alternative approach
would be to have participants recall what their physical environment was like as a child and how
their environment influenced their psychological and physical development. This approach is not
realistic because of the difficulty of accurately recalling childhood experiences, especially among
older adults who may be cognitively impaired. The FHS provides a unique opportunity to
conduct life course research on AD because of the multi-generational design of the study. As
previously described, the life course principle of linked lives states that people live their lives
interdependently. Therefore, examining the social and behavioral characteristics of participants
of the Original Cohort can provide broad insight into what the physical environment may have
been like for participants of the FHS Offspring Cohort during childhood. The influences that
parental socioeconomic status, health behaviors and health characteristics have on the health
characteristics of subsequent generations can then be examined by linking data between the
Original and Offspring Cohorts. Since a large proportion of the Offspring Cohort was over 60
years of age upon receiving a neuropsychological battery, the influence that parental
characteristics have on the cognitive functioning among children who have progressed to old age
can be examined. The findings from this research have the potential to provide empirical
evidence that cognitive functioning during old age is influenced by parental characteristics.
The majority of life course research has focused on the relationship between early life
experiences and circumstances and later life outcomes, but it is important to not discount the
influence that the anticipation of future events has on behavior and decision-making in the
present. There is ongoing research that is examining how perceptions of future risk for AD
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influences present behaviors. The Risk Evaluation and Education for Alzheimer’s disease
(REVEAL) Study is an ongoing study in which healthy adults are informed of their APOE
genotype and are provided with a numerical risk assessment for AD based on their gender, age,
family history and APOE genotype (Roberts et al., 2005). The findings from the REVEAL Study
indicate that adults who learn they carry one or more copies of the APOE e4 allele are more likely
to start engaging in health behaviors that may reduce their risk for AD later in life, such as
changes to diet, exercise and medication or vitamin use, compared to adults who learned that they
did not carry an APOE e4 allele. This research exemplifies how anticipated future events can
influence present behavior.
Engaging a Life Course Approach to the Dissertation Research
The principles of the life course perspective can be utilized to create novel research
questions based on the findings generated by the dissertation research. One of the most important
principles of the life course perspective is that the timing in which an event or experience occurs
may have a significant impact on a person’s life course. Aims two and three of the dissertation
research modeled the trajectories of cholesterol according to chronological age, but an alternative
approach would be to model the trajectories of cholesterol in relation to the age in which AD was
diagnosed and determine if the trajectories of cholesterol differ before and after a diagnosis of
AD has been given. In this approach, the age in which a person was diagnosed with AD is
subtracted from their age during each observation period. The age in which a person was
diagnosed with AD would be zero and the time (in years) prior to AD diagnosis would be
negative and the time after diagnosis would be positive. This approach takes into account the
variability in age at which subjects are diagnosed with AD by setting the time of diagnosis to
zero. This method may provide insight to whether a distinct change in the trajectory of
cholesterol occurs a certain number of years before a subject is diagnosed with AD. A limitation
of this approach is that subjects who do not develop AD would be excluded from the analysis and
therefore the trajectories of cholesterol for AD subjects could not be compared to a control group.
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AD risk may also be modified according to the age at which a person is able to begin
controlling high cholesterol. The findings from aim two indicate that men who do not develop
AD have higher total cholesterol during midlife, but exhibit a decline in total cholesterol at a
younger age compared to men who go on to develop AD. This suggests that the age at which a
person is able to reduce their cholesterol influences their risk of developing AD. If the reduction
in cholesterol is due to changes in diet, exercise or from using cholesterol-lowering medications,
then this can provide insight into when interventions that target high cholesterol may have the
most lasting effects for cognitive functioning later in life.
The above examples demonstrate that the concepts of the life course perspective are
useful tools for conceptualizing future research. These two examples, however, would still be
categorized as life span research because neither example took into account the socio-cultural
context of the life span, which is necessary for a life course study. A life course study of the
relationship between cholesterol and AD would need to include data that incorporates the social
and cultural factors that influence cholesterol levels and cognitive functioning. These factors may
include government mandates on displaying nutritional information on restaurant menus,
regulations on the amount of trans-fats in food, or changes in Food and Drug Administration
guidelines for cholesterol medications. These social changes influence the behavior of
individuals and may contribute to secular changes in cholesterol levels and AD incidence and
prevalence as a result of overall improved vascular health at the population level. A challenge to
a life course study on the relationship between cholesterol and AD is this research requires
individual level (e.g. age, cholesterol, cognitive function) and population level (e.g. income
inequality, unemployment rate, access to medical care) data that have been collected
simultaneously. Merging population and individual level data can create appropriate data sets to
examine the influence that social and cultural factors may have on the relationship between
cholesterol and cognitive functioning during old age. This area of research could advance the
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current understanding of AD from a public policy perspective by examining how social and
cultural characteristics influence the cognitive and vascular health of older adults.
Conclusion
Much of the public’s perception of research is driven by how results are presented by
large media outlets. Popular news sources, such as the New York Times and Time Magazine, have
columns dedicated to summarizing current research on potentially significant discoveries in
regards to diagnosing and treating various diseases, and things people can incorporate into their
daily routines to decrease their risk for developing a certain disease or condition. While
disseminating current research to the general public via large media outlets is important for
keeping people informed, it is easy to become confused or misled when results that seemingly
conflict with prior research are presented. Therefore, it is important to always consider how the
public may perceive findings from research and how results fit with the public’s perception of
health and aging. This is particularly relevant to this dissertation research because there is a
strong perception among the general public that cholesterol is detrimental to health because of the
established relationship between high cholesterol and heart disease. This makes it necessary to
critique the dissertation research, and other epidemiological studies that have examined the
relationship between cholesterol and AD, within the context of the public’s perception towards
cholesterol, health, and aging.
This dissertation research presents limited evidence that older adults diagnosed with AD
maintain higher cholesterol from midlife to late life compared to older adults without dementia,
and that lower cholesterol during midlife is associated with higher cognition during old age.
These findings generally support the public health narrative that cholesterol is detrimental to
health and that controlling cholesterol through dietary changes, exercise, and cholesterol lowering
medications may decrease the risk for adverse health outcomes during old age. An informed
member of the general public may counter with the argument that they have read reports that
suggest older adults diagnosed with AD have lower cholesterol compared to older adults without
154

dementia and a drop in cholesterol is a risk factor for AD. This may lead a person to make the
conclusion that maintaining higher levels of cholesterol protects against AD and may be hesitant
to lower their cholesterol. This conflict can be resolved by providing contextual information on
the aging process and the normative and pathological changes that occur with advancing age.
Aging is characterized by normative declines in physiological and cognitive domains that,
collectively, contribute to a prolonged and progressive decline in functioning and quality of life.
As a person approaches death, however, these declines accelerate in what has been described as a
terminal drop or terminal decline (Gerstorf et al., 2010; Siegler, 1975). A plausible explanation
for the observed relationship between low cholesterol and AD is that AD or symptomatic
treatments for disease symptoms exacerbate this terminal decline by negatively affecting systems
involved in cholesterol homeostasis, such as liver function (Giambattistelli et al., 2012; Squitti et
al., 2007), cholesterol metabolism (Kolsch et al., 2010; Kolsch et al., 2004), and appetite (Ikeda,
Brown, Holland, Fukuhara, & Hodges, 2002). Therefore, older adults who exhibit an unintended
drop in cholesterol may be at a greater risk for AD compared to older adults who intentionally
lowered their cholesterol through dietary changes, physical exercise, or with cholesterol lowering
medications.
This dissertation research focused on the relationships between longitudinal trajectories
of cholesterol, AD and cognitive functioning later in life. This research also explored the utility
of creating summary scores of cognitive functioning that were based on cognitive performance on
individual subtests of a neuropsychological battery to differentiate between subjects with normal
cognition, cognitive impairment and dementia. The results from the dissertation research indicate
that a summary score that provides equal weight to subtests of a neuropsychological battery is
better able to differentiate between subjects that have been classified as having normal cognition,
ILMTB, MDITB, and dementia. There were subtle differences in the longitudinal trajectories of
total cholesterol, HDL cholesterol and total/HDL ratio from midlife to late life according to AD
status. The potential significance of these differences should be interpreted with caution, as they
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may not be clinically meaningful. There was not strong visual evidence for a relationship
between subject-specific trajectories of total cholesterol from midlife to late life and cognition
later in life, but older adults in the highest quartile for cognitive functioning had slightly lower
total cholesterol at approximately 55 years of age.
The results of the dissertation research brought to light important research questions on
the relationship between longitudinal trajectories of cholesterol, AD and cognitive functioning
later in life. Future research should utilize a life course perspective to determine if the timing in
which a decline in cholesterol occurs is associated with AD and cognitive functioning later in life.
Furthermore, a life course perspective may also be able to provide insight into if perceptions of
the future risk of AD and poor cognitive functioning influences present health behaviors.
Studying the relationship between cholesterol, AD and cognitive functioning may generate
evidence that can be applied to develop targeted interventions to improve the overall health of
adults across the life span.
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